Autogestão na reabilitação de pacientes com doença pulmonar obstrutiva crónica: o papel da telemonitorização e atividade física by Cruz, Joana Patrícia dos Santos
  
 
 
 
Universidade de Aveiro 
2016 
 Departamento de Ciências Médicas 
JOANA PATRÍCIA DOS 
SANTOS CRUZ 
 
AUTOGESTÃO NA REABILITAÇÃO DE PACIENTES 
COM DOENÇA PULMONAR OBSTRUTIVA 
CRÓNICA: O PAPEL DA TELEMONITORIZAÇÃO E 
ATIVIDADE FÍSICA 
 
SELF-MANAGEMENT IN THE REHABILITATION OF 
PATIENTS WITH CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE: THE ROLE OF 
TELEMONITORING AND PHYSICAL ACTIVITY 
 
 
  
 
  
 
 
 
Universidade de Aveiro 
2016  
Departamento de Ciências Médicas 
JOANA PATRÍCIA DOS 
SANTOS CRUZ 
AUTOGESTÃO NA REABILITAÇÃO DE PACIENTES 
COM DOENÇA PULMONAR OBSTRUTIVA CRÓNICA: 
O PAPEL DA TELEMONITORIZAÇÃO E ATIVIDADE 
FÍSICA 
 
SELF-MANAGEMENT IN THE REHABILITATION OF 
PATIENTS WITH CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE: THE ROLE OF 
TELEMONITORING AND PHYSICAL ACTIVITY 
 
 
 
 Tese apresentada à Universidade de Aveiro para cumprimento dos requisitos 
necessários à obtenção do grau de Doutor em Ciências e Tecnologias da 
Saúde, realizada sob a orientação científica da Doutora Alda Sofia Pires de 
Dias Marques, Professora Adjunta na Escola Superior de Saúde da 
Universidade de Aveiro, e coorientação da Doutora Dina Brooks, Professora 
Catedrática no Departamento de Fisioterapia da Universidade de Toronto. 
  Apoio financeiro da Fundação para a 
Ciência e Tecnologia do Ministério da 
Ciência, Tecnologia e Ensino Superior, 
e do Fundo Social Europeu, no âmbito 
do POPH-QREN – Formação 
Avançada – Tipologia 4.1. (Referência 
SFRH/BD/81328/2011). 
 
 
 
  
 
  
 
 
  
  
 
 
 
Dedico este trabalho ao meu pai 
 
 
 
  
 
  
 
 
  
 
 
 
 
 
 
o júri   
 
presidente Prof. Doutor Joaquim Manuel Vieira 
Professor Catedrático do Departamento de Engenharia Cerâmica e do Vidro da Universidade de 
Aveiro 
  
 Prof. Doutora Maria Cristina de Brito Eusébio Bárbara Prista Caetano 
Professora Associada com Agregação Convidada da Faculdade de Medicina da Universidade de 
Lisboa 
  
 Prof. Doutor Paulo Alexandre Silva Armada da Silva 
Professor Auxiliar da Faculdade de Motricidade Humana da Universidade de Lisboa 
  
 Prof. Doutor Rui Alberto Fernandes Antunes Viana 
Professor Auxiliar da Faculdade de Ciências da Saúde da Universidade Fernando Pessoa 
  
 Prof. Doutora Alda Sofia Pires de Dias Marques 
Professora Adjunta da Escola Superior de Saúde da Universidade de Aveiro 
  
 Prof. Doutora Paula Maria Gonçalves Pinto 
Professora Auxiliar Convidada da Faculdade de Medicina da Universidade de Lisboa 
  
 
  
 
 
  
 
  
 
 
  
  
 
agradecimentos 
 
A realização deste trabalho não teria sido possível sem o apoio, incentivo e 
colaboração de várias pessoas, às quais expresso aqui o meu sincero 
agradecimento.   
Agradeço aos participantes e instituições envolvidas nesta investigação o 
tempo e disponibilidade dispensados. Sem eles, este trabalho não teria sido 
possível. 
Agradeço à minha orientadora, Professora Doutora Alda Marques, por me ter 
acompanhado nesta difícil jornada (mesmo antes de ela começar). Admiro-lhe 
a competência, a perseverança e a resiliência, pois ajudaram-me a chegar até 
aqui. Obrigada pela sua disponibilidade e paciência, pelas interessantes 
discussões que tivemos, pelos momentos de descontração e, sobretudo, pela 
amizade que construímos. Foi um privilégio poder trabalhar consigo. 
Agradeço à minha coorientadora, Professora Doutora Dina Brooks, pelos 
conselhos e ideias partilhadas ao longo deste percurso. Foi importante para 
mim ter o reconhecimento de alguém com tão extensa contribuição nesta área. 
Agradeço à Dr.ª Lurdes a paciência, carinho e disponibilidade que demonstrou 
desde o início. O seu apoio foi (e continua a ser) fundamental para a equipa de 
investigação da qual faço parte. 
Agradeço às colegas (mas sobretudo, amigas) Anita, Cristina, Aninha, Giovana 
Tânia e Marlene, que estiveram comigo em vários momentos e que partilharam 
os meus anseios, dificuldades, expectativas e alegrias que fui vivenciando ao 
longo destes quatro anos. Sem vocês esta jornada não teria sido tão 
agradável! Um especial agradecimento à Cristina por termos trabalhado juntas 
neste desafio, pelas discussões maioritariamente saudáveis que tivemos e 
pela sua enorme energia que me foi contagiando durante este processo. 
Agradeço ao Nuno, o meu grande companheiro nesta e em outras jornadas. 
Obrigado por acreditares em mim, por enriqueceres o meu trabalho com os 
teus comentários, pelas discussões científicas que tivemos e, acima de tudo, 
por estares ao meu lado neste percurso por vezes sinuoso. O teu incentivo, 
apoio e encorajamento foram fundamentais para a realização deste trabalho. 
Agradeço à minha filha Carolina por me ajudar a ‘colocar o trabalho no seu 
lugar’ e por me dar ânimo e energia para concluir esta etapa. A defesa da tese 
não teria um gosto tão especial se ela não existisse. 
Agradeço à restante família, em especial aos meus pais, porque não teria 
conseguido chegar até aqui se não tivesse tido tão bons exemplos de vida. 
Obrigado por me ajudarem a ser quem sou hoje. 
Por fim, agradeço a todos os meus amigos em geral pelo apoio que me 
proporcionaram e por compreenderem as minhas ausências ocasionais para 
trabalhar no doutoramento. 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Life gives us the opportunities, 
we make them happen... 
  
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
  
palavras-chave 
 
Doença Pulmonar Obstrutiva Crónica, gestão da doença, atividade física, 
rehabilitação, auto-monitorização, tele-saúde, marcha. 
resumo 
 
 
A autogestão tem sido reconhecida como parte fundamental da gestão da 
Doença Pulmonar Obstrutiva Crónica (DPOC). No entanto, a evidência deste 
tipo de intervenções é ainda limitada. Esta Tese tem como objetivo 
compreender se as intervenções de autogestão podem ajudar os pacientes 
com DPOC a gerir melhor a sua doença e se têm um impacto significativo na 
sua saúde. Especificamente, esta Tese pretendeu: (i) aprofundar o papel da 
telemonitorização no domicílio para reduzir a frequência de exacerbações e a 
utilização de cuidados de saúde por parte dos pacientes com DPOC, bem 
como melhorar os resultados relacionados com a saúde; e (ii) investigar o 
impacto de uma intervenção comportamental para a promoção da atividade 
física (AF) em pacientes com DPOC (Walk2Bactive) durante e após um 
programa de reabilitação respiratória (RR). Foram realizados cinco estudos. 
Duas revisões sistemáticas (Capítulo 3) responderam ao primeiro objetivo 
desta Tese, sistematizando o conhecimento acerca da telemonitorização no 
domicílio no que diz respeito à sua eficácia, metodologias, adesão e satisfação 
de pacientes com DPOC. Os resultados revelaram que ainda não existe uma 
indicação clara de que a telemonitorização no domicílio produz melhorias nos 
resultados de saúde e na redução da utilização de cuidados de saúde em 
pacientes com DPOC. O número reduzido de participantes e a tecnologia 
utilizada em alguns estudos pode ter influenciado estes resultados. Assim, 
existe a necessidade de mais investigação nesta área antes de a 
telemonitorização poder ser incorporada na prática clínica. O segundo objetivo 
desta Tese foi alcançado através de três estudos originais. O primeiro estudo 
(Capítulo 4) avaliou a precisão dos monitores de AF (pedómetro Yamax 
PW/EX-510, acelerómetro GT3X+) utilizados no estudo piloto (Capítulo 5) e 
estudo principal (Capítulo 6). Os resultados principais sugerem que a 
intervenção comportamental para a promoção da AF pode ajudar os pacientes 
com DPOC a alcançar um estilo de vida mais ativo. No entanto, não produz 
melhorias nos resultados relacionados com a saúde. É necessário realizar 
investigação mais robusta nesta área para corroborar estes resultados e 
avaliar os efeitos da intervenção a curto e longo prazo. Em suma, o papel da 
autogestão na DPOC através da telemonitorização no domicílio e de uma 
intervenção comportamental para a promoção da AF ainda não é totalmente 
compreendido. Esta Tese contribuiu para avançar o conhecimento nesta área 
e apresenta recomendações importantes para pesquisas futuras. 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
keywords 
 
Chronic Obstructive Pulmonary Disease, disease management, physical 
activity, rehabilitation, self-monitoring, telehealth, walking. 
abstract 
 
Self-management has been acknowledged as a critical part of Chronic 
Obstructive Pulmonary Disease (COPD) management. However, evidence to 
support this type of intervention is still limited. This Thesis focuses on 
understanding whether self-management interventions can support patients 
with COPD to manage their disease and impact significantly on their health. 
Specifically, it aimed to: (i) gain more insight on the role of home telemonitoring 
to reduce the frequency of COPD exacerbations and healthcare utilisation and 
improve health-related outcomes; and (ii) investigate the impact of a physical 
activity (PA)-focused behaviour intervention combined with pulmonary 
rehabilitation (PR) on patients with COPD. Five studies were conducted. Two 
systematic reviews (Chapter 3) addressed the first aim of this Thesis by 
updating the body of evidence on home telemonitoring in COPD regarding its 
effectiveness, methodologies, patients’ adherence and satisfaction. Findings 
showed that there is still no clear indication that home telemonitoring improves 
health-related outcomes and reduces healthcare utilisation in COPD. A number 
of limitations, such as the small sample sizes and the telemonitoring 
technology, may have accounted for these results. Therefore, further work 
needs to be conducted before home telemonitoring can be incorporated into 
clinical practice. The second aim of this Thesis was addressed with three 
original studies. One study (Chapter 4) assessed the step-count accuracy of 
activity monitors (Yamax PW/EX-510 pedometer, GT3X+ accelerometer) which 
supported the feasibility study (Chapter 5) and the main study (Chapter 6). The 
main findings suggest that a PA-focused behavioural intervention combined 
with PR can be used to support patients with COPD in achieving a more active 
lifestyle. Nevertheless, it did not produce further improvements in health-related 
outcomes. More robust research is warranted to support these findings and 
assess the short- and long-term impact of this intervention in COPD. In 
conclusion, the role of patient self-management through home telemonitoring 
and a PA-focused behavioural intervention is not fully understood. This Thesis 
contributes for advancing the knowledge in this area and provides important 
recommendations for future research. 
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Introduction  
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory disease that 
affects 210 million people worldwide (World Health Organization [WHO], 2008). According 
to the WHO estimates, 3 million people died of COPD in 2012 (WHO, 2015) and it is 
projected to be the third leading cause of death in 2030 (WHO, 2008). Due to its high 
morbidity, mortality and associated costs, COPD is a major public health problem and a 
current societal challenge.  
The disease is characterised by “persistent airflow limitation that is usually progressive 
and associated with an enhanced chronic inflammatory response in the airways and the 
lung to noxious particles or gases” (Global Strategy for the Diagnosis Management and 
Prevention of COPD [GOLD], 2016). The disease seems initially confined to the lungs, 
however, patients with COPD become progressively physically limited mainly due to an 
increase in symptoms (e.g., dyspnoea, fatigue) (Lahaije et al., 2010), leading to functional 
impairment and long-term disability, seriously affecting patients’ quality of life (Reardon et 
al., 2006). Exacerbations and comorbidities further contribute to the individual progression 
of the disease and functional performance decline (GOLD, 2016). 
A recent guideline has emphasised the role of patient self-management as a critical part 
of COPD management (Spruit et al., 2013). Self-management interventions consist of 
patient training and support to help them acquire and practice the skills necessary to 
improve day-to-day control of their disease, carry out disease-specific therapeutic 
regimens and guide behaviour change (Effing et al., 2012). There is large variability in the 
nature of self-management interventions depending on its purposes and outcomes 
(Harrison et al., 2015, Zwerink et al., 2014). Typically, these interventions aim to reduce 
the frequency of exacerbations and/or their severity through early recognition and 
appropriate treatment (Nici and ZuWallack, 2015). One promising intervention is the use 
of information and communication technologies to monitor patients’ clinical status while 
they are at home, also referred to as home monitoring via telemedicine or home 
telemonitoring (Bolton et al., 2010, Kaptein et al., 2014). Home telemonitoring aims to 
empower patients to self-manage their disease by asking them to record symptoms and/or 
physiological signs on a regular basis and transmit them to a healthcare service, so that 
early signs of health deterioration can be detected and treatment can be delivered in a 
timely manner (Bolton et al., 2010, McKinstry, 2013). As a result, home telemonitoring 
may lead to improved clinical outcomes, reduced face-to-face contact with healthcare 
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services and thus less costly interventions. However, evidence supporting this type of 
intervention is still limited. 
Another critical component of self-management is the increase of patients’ physical 
activity (PA) levels (Effing et al., 2012). Patients with COPD are markedly inactive in daily 
life when compared to healthy subjects (Vorrink et al., 2011) and these low levels of PA 
have been associated with adverse outcomes, including increased risk of exacerbations 
(Moy et al., 2013), hospital admissions and mortality (Garcia-Aymerich et al., 2006, 
Waschki et al., 2011). Thus, improving PA levels has become a major topic of COPD 
research (Spruit et al., 2013). Pulmonary rehabilitation (PR) is the cornerstone of COPD 
management with well-documented effects on exercise capacity (McCarthy et al., 2015). 
As a self-management approach, PR would seem the ideal intervention to promote PA 
behaviours in patients with COPD (Spruit et al., 2013). However, previous studies 
assessing the impact of PR on PA levels have shown that an increase in exercise 
capacity does not necessarily translate into significant improvements in patients’ PA 
(Egan et al., 2012, Mador et al., 2011, Pitta et al., 2008). Therefore, interventions coupling 
PR with other self-management approaches that empower lifestyle modification are 
needed to increase patients’ PA levels. 
This Thesis focuses on understanding whether self-management interventions can 
support patients with COPD in their disease management and impact significantly on their 
health. Specifically, it aimed to: i) gain more insight on the role of home telemonitoring as 
a self-management intervention to reduce the frequency of COPD exacerbations and 
healthcare utilisation and improve health-related outcomes; and ii) investigate the impact 
of a PA-focused behaviour intervention combined with PR on PA levels and health status 
of patients with COPD. 
The work developed to accomplish these aims is presented in eight chapters. Chapter 1 
(Introduction) briefly outlines the impact of COPD at a global level and identifies the 
research problems addressed in this Thesis. In Chapter 2 (Background), an overview of 
the main challenges in COPD management is presented along with a description of the 
research problems. Chapter 3 includes two systematic reviews which provide an update of 
knowledge regarding home telemonitoring in COPD. The first systematic review (Study 1) 
assesses the effectiveness of home telemonitoring in reducing healthcare utilisation and 
improving health-related outcomes of patients with COPD. The second systematic review 
(Study 2) provides a comprehensive description of the methodologies of home 
telemonitoring interventions in COPD and summarises the findings related to patients’ 
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adherence and satisfaction with the use of telemonitoring systems. Chapters 4, 5 and 6 
compile the original studies developed within the scope of this Thesis. Chapter 4 includes 
the validation of the technological devices that supported the studies presented in 
Chapters 5 and 6 regarding step-count accuracy. The study presented in Chapter 5 
explores the feasibility of providing feedback on PA levels to patients with COPD during 
PR. Chapter 6 builds further on the observations of Chapter 5 and assesses the impact of 
a PA-focused behavioural intervention combined with PR in COPD. The main findings of 
the studies presented in Chapters 3-6 are integrated and discussed in Chapter 7. Finally, 
Chapter 8 presents the main conclusions and recommendations for future research and 
clinical practice. Figure 1 provides a schematic diagram of the rationale for the structure of 
this Thesis. 
 
 
Figure 1. Schematic diagram of the rationale for the structure of the Thesis. 
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Background 
This chapter provides a definition of Chronic Obstructive Pulmonary Disease (COPD) and 
its global burden, describes the impact of exacerbations on disease progression and 
outcomes, and highlights the importance of promoting an active lifestyle in patients with 
COPD. Then, an overview of the literature regarding self-management interventions in 
COPD is presented along with a description of the research problems. 
 
COPD definition and global burden 
COPD represents an important public health challenge that is both preventable and 
treatable (Global Strategy for the Diagnosis Management and Prevention of COPD 
[GOLD], 2016). This chronic respiratory disease affects 210 million people worldwide 
(World Health Organization [WHO], 2008) and results in a social and economic burden 
that is both substantial and increasing due to continued exposure to COPD risk factors 
and the aging of population (Buist et al., 2007). In Portugal, it is estimated that nearly 
800.000 people aged 40 years or older suffer from COPD (de Araújo, 2015). The latest 
WHO estimates (2015) refer that more than 3 million people died of COPD in 2012, which 
is equal to 6% of all deaths in that year. In 2030, COPD is projected to be the third leading 
cause of death following ischaemic heart disease and stroke (WHO, 2008) and the 
seventh leading cause of disability-adjusted life years (DALYs) lost (Mathers and Loncar, 
2006). 
The disease is characterised by “persistent airflow limitation that is usually progressive 
and associated with an enhanced chronic inflammatory response in the airways and the 
lung to noxious particles or gases” (GOLD, 2016). Its clinical presentation is very 
heterogeneous, although the most common symptoms of COPD are dyspnoea, cough 
and sputum production that can be variable from day-to-day and often throughout the day 
(Kessler et al., 2011). Additionally, the natural course of COPD includes frequent and 
recurrent exacerbations and the presence of comorbidities that further contribute to the 
individual progression of the disease and deterioration of patients’ health status. Many 
people suffer from COPD for years and die prematurely from it or its complications 
(GOLD, 2016). 
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Impact of exacerbations on disease progression and outcomes 
An exacerbation of COPD is defined as an acute episode characterised by a worsening of 
the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads 
to a change in medication (GOLD, 2016). The frequency of exacerbations varies greatly 
between patients (Aaron et al., 2012) and contributes to a faster rate of decline in lung 
function (Donaldson et al., 2002). These acute episodes have important functional 
consequences, such as a global impairment of the function of respiratory and peripheral 
skeletal muscles (Martinez-Llorens et al., 2004), and a reduction in physical activity (PA) 
levels (Pitta et al., 2006) and health-related quality of life (HRQOL) (Bourbeau et al., 
2007). Furthermore, previous studies have found that exacerbations have a negative 
impact on patient prognosis (Soler-Cataluña et al., 2005) and are responsible for 
unscheduled healthcare utilisation and increased direct costs (O'Reilly et al., 2007). It has 
been found that patients with frequent exacerbations requiring hospitalisation had the 
highest mortality rate with a risk of death 4.3 times higher (95%CI 2.62–7.02) than those 
requiring no hospital management (Soler-Cataluña et al., 2005). Furthermore, patients 
who tended not to seek treatment at exacerbation had poorer HRQOL and were more 
likely to be hospitalised than those who routinely reported their exacerbations for 
treatment (Wilkinson et al., 2004). These findings emphasise the need for interventions 
that enable early detection and prompt treatment of exacerbations to reduce the burden of 
COPD. 
 
Physical (in)activity in COPD: impact and recommendations 
Although COPD is primarily a disease of the respiratory system, it also has significant 
extrapulmonary (systemic) manifestations, including skeletal muscle wasting and 
dysfunction (Decramer et al., 2005). The pulmonary and peripheral abnormalities lead to 
an increase in the ventilatory requirements during exercise, resulting in exercise-induced 
symptoms such as dyspnoea and fatigue (Panagiotou et al., 2013, Stendardi et al., 2005). 
These symptoms make exercise an unpleasant experience which many patients try to 
avoid, leading to an inactive lifestyle (Lahaije et al., 2010). Muscle deconditioning and 
reduced PA further contribute to a worsening of the patients’ physical condition and to 
increased symptoms, yielding a downward spiral of symptom-induced inactivity (Reardon 
et al., 2006). In the long-term, this spiral may contribute to a decline in patients’ functional 
status and impaired HRQOL (Reardon et al., 2006). Thus, improving PA levels has 
become a major topic of COPD research (Watz et al., 2014). 
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Physical activity is defined as any bodily movement produced by skeletal muscles that 
substantially increases energy expenditure (Caspersen et al., 1985). Physical activity and 
exercise are often used interchangeably, however, these terms are not synonymous. 
Exercise is a subcategory of PA which is planned, structured and repetitive and aims to 
improve and/or maintain physical fitness. Physical activity also includes domestic and 
occupational tasks, as well as basic everyday tasks required for independent living 
(Caspersen et al., 1985). The intensity of PA is commonly classiﬁed as light, moderate or 
vigorous, depending on the energy expenditure associated with it. Other parameters, such 
as the number of daily steps, may also be considered when assessing PA (Garber et al., 
2011). A previous systematic review concluded that patients with COPD have a 
significantly reduced duration and intensity of daily PA when compared to healthy subjects 
(Vorrink et al., 2011). Furthermore, a large number of patients with COPD do not reach 
the international recommendations (Troosters et al., 2010, Watz et al., 2009), i.e., a 
minimum of 30 min/day of moderate intensity activities, 20 min/day of vigorous intensity 
activities or a combination of both; 7000-10,000 steps/day (Garber et al., 2011). Low 
levels of PA have been associated with adverse outcomes, including increased risk of 
exacerbations (Moy et al., 2013), hospital admissions and mortality (Garcia-Aymerich et 
al., 2006, Waschki et al., 2011). Other studies have shown that PA is correlated with lung 
function, exercise capacity and HRQOL (Watz et al., 2014). These findings suggest that 
regular PA may have important health-related benefits in patients with COPD. 
Since PA is a modifiable factor with potential to improve COPD prognosis, the latest 
GOLD guidelines (2016) have underlined the importance of promoting regular PA in 
COPD management. However, there is still little COPD-specific evidence to support this 
recommendation (GOLD, 2016). The American Thoracic Society and the European 
Respiratory Society defined PR as a comprehensive self-management intervention which 
includes (but is not limited to) exercise training, education and behaviour change, with the 
purpose of improving patients’ physical and psychological condition and promoting long-
term adherence to health-enhancing behaviours (Spruit et al., 2013). Hence, it would 
seem the ideal intervention to promote PA behaviours in patients with COPD. However, 
previous studies have shown that an increase in exercise capacity after PR does not 
necessarily translate into significant improvements in patients’ PA levels (Egan et al., 
2012, Mador et al., 2011, Pitta et al., 2008). One possible explanation for these findings is 
that PR programmes lack an effective behavioural component that targets changes in PA 
beyond those related to the structured exercise component of PR (Hill et al., 2015). 
Therefore, interventions coupling PR with PA-focused approaches may have the potential 
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to promote behaviour change and empower lifestyle modification in patients with COPD. 
This is a promising area for future research. 
 
Self-management in COPD 
Patient self-management has been proposed as a critical part of COPD management 
(Effing et al., 2012, Spruit et al., 2013). Although there is still no ‘gold standard’ definition 
of self-management, it refers to the patients’ ability to manage and cope with their 
symptoms, treatment, physical and psychosocial consequences and lifestyle changes 
inherent in living with a chronic disease (Barlow et al., 2002). A WHO policy brief (Coulter 
et al., 2008) has emphasised the role of patients’ self-management in promoting the long-
term sustainability of many health systems. The overall goal of self-management is to 
develop in patients an improved sense of self-efficacy, i.e. the patients’ belief regarding 
whether or not they feel they can successfully implement particular behaviours in order to 
produce certain outcomes (Bandura, 1977). 
In COPD, self-management interventions involve helping patients to acquire and practice 
the skills necessary to improve day-to-day control of their disease, carry out disease-
specific therapeutic regimens and guide behaviour change (Effing et al., 2012). Evidence 
regarding its effectiveness is still unclear. A recent systematic review found that self-
management interventions resulted in a lower probability of hospitalisations and significant 
effects on dyspnoea and HRQOL of patients with stable COPD (Zwerink et al., 2014). 
Though, these findings were not observed in self-management interventions delivered to 
patients following an acute exacerbation (Harrison et al., 2015). The large variability in the 
nature and outcomes of self-management interventions may explain this lack of evidence 
(Harrison et al., 2015, Zwerink et al., 2014). Typically, these interventions aim to reduce 
the frequency of exacerbations and/or their severity through early recognition and 
appropriate treatment (Nici and ZuWallack, 2015). In recent years, there has also been a 
growing interest in developing self-management interventions aimed to promote behaviour 
change with regard to patients’ PA (Effing et al., 2012). 
 
Self-management for early recognition and treatment of exacerbations 
Researchers and policy makers have been seeking cost-effective strategies to support 
patients in the early recognition and treatment of exacerbations. One promising 
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intervention is the use of information and communication technologies to monitor patients’ 
clinical status while they are at home, also referred to as home monitoring via 
telemedicine or home telemonitoring (Bolton et al., 2010, Kaptein et al., 2014). Home 
telemonitoring is one of the components of telehealth, which has been acknowledged as a 
key intervention in future integrated care (WHO, 2010). It is defined as the provision of 
care at a distance and may also include the use of telephonic/mobile services and tele-
consultations.  
Home telemonitoring aims to empower patients to self-manage their disease while they 
are at home by asking them to record daily symptoms and/or physiological signs on a 
regular basis and transmit them to a healthcare service, so that early signs of health 
deterioration can be detected and treatment can be delivered in a timely manner (Bolton 
et al., 2010, McKinstry, 2013). Therefore, this type of intervention has the potential to 
support patient self-management by increasing day-to-day care responsibilities of patients 
(and families) and minimising unnecessary face-to-face contact with the healthcare 
services. This may lead to improved clinical outcomes and less costly interventions 
(McKinstry, 2013). Nevertheless, evidence to support this type of intervention in COPD is 
limited. Previous systematic reviews on the topic have included other telehealth 
approaches (e.g., telephone support, teleconsultations) (Bolton et al., 2010, Kamei et al., 
2013, McLean et al., 2011, Polisena et al., 2010), rendering the interpretation of the 
impact of home telemonitoring alone. Therefore, Study 1 of Chapter 3 contributed for the 
development of knowledge in this area by systematically reviewing the effectiveness of 
home telemonitoring to reduce healthcare utilisation and improve health-related outcomes 
in patients with COPD. 
Making the case for investment in home telemonitoring interventions requires not only 
knowledge of the existing evidence, but also of how the interventions are delivered. 
Different forms of implementing telemonitoring applications have emerged over the years 
as a result of the continuous technological advances and efforts to improve COPD self-
management. However, previous reviews (Bartoli et al., 2009, Bolton et al., 2010, Kamei 
et al., 2013, McLean et al., 2011, Polisena et al., 2010) have provided little or no attention 
to home telemonitoring methodologies or to the technology employed. Moreover, optimal 
interventions require patients’ adherence (WHO, 2003), but there is still limited information 
about adherence to and satisfaction with home telemonitoring in COPD. Therefore, Study 
2 of Chapter 3 addresses these issues by presenting a systematic review of the 
methodologies used in home telemonitoring in COPD and patients’ adherence and 
satisfaction with the use of telemonitoring systems. This review may be a useful resource 
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for researchers, clinicians and policy makers as it points out important aspects regarding 
the integration of technology in COPD management and provides recommendations for 
future interventions. 
 
Self-management to increase physical activity 
In the last decade, several PA-focused interventions complementary to PR have been 
developed hoping to increase the PA levels of patients with COPD (Wilson et al., 2014). 
Those including self-monitoring using activity monitors and behavioural counselling 
provided promising results (Altenburg et al., 2015, de Blok et al., 2006) and, thus, may 
have the potential to produce significant changes in patients’ PA levels (Watz et al., 2014). 
A small randomised controlled trial conducted by de Block et al. (2006) compared a 
combined intervention of PR and a lifestyle PA counselling with feedback from a 
pedometer (experimental group) with PR alone (control group). The pedometer served as 
a reminder for patients to be physically active by providing them feedback on daily steps 
taken. Each intervention lasted 9 weeks. No significant differences were found between 
the experimental and control groups in pre- and post-test steps (de Blok et al., 2006). 
However, when the same intervention was implemented in a 3-month period, the 
experimental group presented significant improvements in the number of daily steps when 
compared to the control group, albeit the improvement was small (547 steps/day in the 
experimental group and -211 steps/day in the control group) (Altenburg et al., 2015). 
Furthermore, no significant between-group differences were found in exercise capacity 
and HRQOL, which questions the hypothesis that a more active lifestyle could translate 
into improved health-related measures. 
Methodological weaknesses, such as the type of pedometer used and patients’ 
experiences with the equipment, may explain in part these results. In both studies, a 
pedometer with a spring-suspended horizontal lever arm mechanism (Yamax Digi-Walker 
SW-200) was used to provide patients with feedback and assess the impact of the 
intervention. Previous research on the accuracy of spring lever arm pedometers (Crouter 
et al., 2005, Crouter et al., 2003, Le Masurier et al., 2004, Melanson et al., 2004) and, 
specifically, of the Yamax Digi-Walker SW-200 (Crouter et al., 2005, Le Masurier et al., 
2004, Melanson et al., 2004), has found that this type of pedometers significantly 
underestimates the number of steps at slow walking speeds (i.e., 3.24–5.64 Km/h). 
Therefore, they may not be appropriate to assess PA levels in slow walking populations, 
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such as in patients with COPD (Ilgin et al., 2011). Pedometers with a piezoelectric 
technology have been developed to overcome this problem; however, its accuracy has 
been scarcely investigated when worn at different walking speeds and body parts, and 
users’ preferences regarding wearing location have been poorly explored despite its 
importance to improve user’s acceptance.  
In addition to pedometers, the use of triaxial accelerometers (e.g., GT3X+) to objectively 
monitor and assess PA has increased in recent years. Accelerometers are often preferred 
in research and clinical settings because, in addition to step counts, they provide 
information on the frequency, duration and intensity of PA (Garber et al., 2011, Strath et 
al., 2013). Accelerometers have shown good validity results regarding activity counts and 
energy expenditure (Santos-Lozano et al., 2013, Van Remoortel et al., 2012); however, 
their step-count accuracy has not been extensively investigated. Assessment of 
accelerometer step-count accuracy along with pedometer accuracy is fundamental to 
enable comparisons among studies using different activity monitors. Chapter 4 provides a 
contribution to this field by: (1) assessing step-count accuracy of a piezoeletric pedometer 
(Yamax Power-Walker EX-510), when worn at different body parts, and a triaxial 
accelerometer (GT3X+); (2) comparing device accuracy; and (3) identifying user’s 
preferred location(s) to wear the pedometer. The activity monitors evaluated in this 
Chapter were further used in the studies presented in Chapters 5 and 6. 
Patients’ compliance with PA monitoring and their experience with the activity monitors 
may also have accounted for the results found by de Block et al. (2006) and Altenburg et 
al. (2015). Although de Block et al. (2006) have assessed patients’ compliance of 
recording daily step counts in the dairies, they did not explore patients’ experience of 
using the activity monitors to self-manage their PA levels. This aspect is a key element to 
ensure the feasibility of interventions involving activity monitoring and feedback. 
Nevertheless, it has received little attention in the literature (Troosters, 2009). In order to 
improve the knowledge in this important field of research, Chapter 5 explored the 
feasibility of providing feedback on PA levels of patients with COPD during PR. Chapter 6 
builds further on the observations of Chapter 5 and assessed the impact of a PA-focused 
behavioural intervention combined with PR in COPD, using a randomised controlled 
design. 
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Abstract 
Objectives: To provide a systematic review of the effectiveness of home telemonitoring to 
reduce healthcare utilisation and improve health-related outcomes of patients with COPD. 
Methods: An electronic literature search in Medline, Embase, B-on and Web of Science 
was conducted from June to August 2012 and updated until July 2013, using the following 
keywords: [tele(-)monitoring or tele(-)health or tele(-)homecare or tele(-)care or tele-home 
health or home monitoring] and [Chronic Obstructive Pulmonary Disease or COPD]. 
Randomised and non-randomised controlled trials evaluating home telemonitoring 
interventions in COPD were included. A meta-analysis using risk ratio (RR) and 
standardised mean difference (SMD) was conducted for healthcare utilisation 
(hospitalisations, length of stay, emergency department visits) and associated costs, and 
health-related outcomes (mortality, exacerbations and health-related quality of life 
(HRQOL)). 
Results: Nine articles were included. Significant differences were found for hospitalisation 
rates (RR=0.72; 95%CI=0.53–0.98; p=0.034); however, no differences in the other 
healthcare utilisation outcomes were observed. There was a trend to reduced healthcare 
costs in the telemonitoring group. In two studies, this intervention was associated with a 
reduced number of exacerbations (p<0.05) and a significant increase in HRQOL (SMD=-
0.53; 95%CI=-0.97– -0.09; p=0.019). 
Discussion and Conclusions: Home telemonitoring appears to have a positive effect in 
reducing respiratory exacerbations and hospitalisations and improving quality of life. 
However, the evidence of its benefits is still limited and further research is needed to 
assess the effectiveness of home telemonitoring in COPD management, as there are still 
few studies in this area. 
 
Keywords: COPD; healthcare utilisation; quality of life; telemedicine; telemonitoring. 
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Review Criteria 
Medline, Embase, B-on and Web of Science databases were searched (from June to 
August 2012, updated until July 2013) for randomised and non-randomised controlled 
trials evaluating the impact of home telemonitoring interventions on healthcare utilisation 
and health-related outcomes of patients with COPD. Meta-analyses were performed, 
when appropriate. 
 
Message for the Clinic 
Home telemonitoring is an innovative approach which enables the management of 
patients’ health condition at home, by exchanging health-related information with 
healthcare professionals. Studies included in this review provided limited evidence for the 
effectiveness of home telemonitoring in COPD on healthcare utilisation and health-related 
outcomes. To advocate the use of home telemonitoring as a patient management 
approach and to incorporate it into practice, further work needs to be conducted. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a progressive disease which accounts 
for a great economic and social burden (World Health Organization [WHO], 2008). In the 
United States, COPD was considered the 2nd cause of disability-adjusted life-years 
(DALYs) and the 5th cause of mortality in 2010 (Murray and Lopez, 2013). The disease 
trajectory is characterised by increasing symptoms (e.g., dyspnoea, fatigue) and a 
progressive decline in health status, punctuated by acute respiratory exacerbations 
(Global Strategy for the Diagnosis Management and Prevention of COPD [GOLD], 2013). 
Previous studies have shown that COPD exacerbations have a negative impact on patient 
prognosis (Soler-Cataluña et al., 2005) and are responsible for the greatest proportion of 
the total direct costs attributable to COPD (O'Reilly et al., 2007). Therefore, interventions 
to manage exacerbations at an early stage are urgently needed to reduce morbidity and 
mortality of COPD population, thereby reducing healthcare utilisation and associated 
costs. 
In recent years, researchers and policy makers have been seeking cost-effective 
strategies for delivering sustainable care in COPD. One promising approach is the use of 
information and communication technologies to monitor patients’ health status while they 
are at home, also referred to as home telemonitoring (Bolton et al., 2010). Home 
telemonitoring allows healthcare providers to review patients’ clinical data (e.g., oxygen 
saturation, heart rate) more regularly and, thus, health deterioration can be quickly 
detected and addressed. This may lead to improved clinical outcomes, greater patient 
self-management and less costly interventions (McKinstry, 2013). 
While the interest in telemonitoring interventions to manage patients at home is 
increasing, the evidence to support its effectiveness is still limited (McKinstry, 2013). 
Previous systematic reviews failed to demonstrate the benefit of home telemonitoring in 
COPD (Bolton et al., 2010, Kamei et al., 2013, McLean et al., 2011, Polisena et al., 2010). 
However, these reviews evaluated studies using home telemonitoring and a different 
telehealth approach, such as telephone support (McLean et al., 2011, Polisena et al., 
2010) or teleconsultations with occasional monitoring of patients’ clinical data (Bolton et 
al., 2010, Kamei et al., 2013, Polisena et al., 2010), rendering the interpretation of the 
impact of telemonitoring alone. Therefore, the question of whether home telemonitoring 
achieves its purpose, i.e., if it reduces healthcare utilisation and costs by effectively 
detecting and responding to COPD exacerbations in a timely manner, remains 
unanswered. This systematic review aimed to assess the effectiveness of home 
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telemonitoring to reduce healthcare utilisation and improve health-related outcomes of 
patients with COPD. 
 
Methods 
Information sources and search strategy 
An electronic literature search was performed from June to August of 2012 in Medline, 
Embase, B-on Online Knowledge Library and Web of Science databases. Search terms 
were based on a combination of the following keywords: [tele(-)monitoring or tele(-)health 
or tele(-)homecare or tele(-)care or tele-home health or home monitoring] and [Chronic 
Obstructive Pulmonary Disease or COPD]. Additional studies were searched within the 
reference list of the included articles, review articles on the topic (Bolton et al., 2010, 
Jaana et al., 2009, Kamei et al., 2013, McLean et al., 2011, Paré et al., 2007, Polisena et 
al., 2010) and weekly automatic updates retrieved from the databases until July 2013. 
 
Eligibility criteria and study selection 
This systematic review was reported according to preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) guidelines (Moher et al., 2009). Eligible studies 
were randomised (RCT) and non-randomised controlled trials (NRCT) involving patients 
with COPD and comparing a home telemonitoring intervention (experimental group – 
HTMG) to usual care (control group – CG). Patients in the HTMG had to periodically 
record clinical data (e.g., oxygen saturation, heart rate, symptoms) in their homes and 
transmit the data on a regular basis (i.e., ≥5days/week) using information and 
communication technologies, for further assessment by a healthcare team. The outcomes 
of interest were healthcare utilisation (i.e., hospitalisations, length of hospital stay, 
emergency department visits) and associated costs, mortality rates, respiratory 
exacerbations and health-related quality of life (HRQOL), collected during or immediately 
after the intervention.  
Studies were excluded if they: i) included patients with diseases other than COPD; ii) 
included only regular telephone calls, video-consultation or teleconference interventions 
with infrequent transmission of clinical data; iii) involved downloading the data during 
healthcare visits or just at the end of the study; iv) provided telemonitoring in other places 
than patients’ home; v) did not include a group without home telemonitoring (i.e., a CG); 
vi) did not collect the outcomes of interest during or immediately after the intervention. 
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Studies with a different design (e.g., one group pretest-posttest, observational or case 
studies), review papers, abstracts, papers on conference proceedings, editorials, 
commentaries to articles and study protocols were excluded. Papers without abstracts or 
written in languages other than English, Portuguese and Spanish were also excluded.  
Initial screening of articles was based on type of publication and relevance for the scope 
of the review, according to their title and abstract. Then, the full-text of potentially relevant 
articles was screened for content to decide its inclusion. Studies with multiple publications 
were identified to avoid duplicate reports.  
 
Data collection 
One reviewer (JC) extracted the data from the included studies and a second reviewer 
(AM) checked the extracted data. Disagreements were resolved by consensus. If 
consensus could not be reached, a third reviewer (DB) was consulted. A structured data 
extraction was performed, focusing on: study design, country where the study was 
conducted, sample size, type of intervention (HTMG) and comparator (CG), telemonitoring 
duration, outcome measures and results. 
 
Quality assessment 
The quality of the studies was independently assessed by two raters (JC and AM) using a 
modified version of the scoring system developed to evaluate telemedicine research by 
Hailey and co-workers (2011), summarised in Polisena et al. (2010). It consists of 5 levels, 
from A (high quality) to E (poor quality), based on study design and performance. Inter-
rater agreement was assessed using Cohen’s kappa coefficient, considering the cut-off 
points (Landis and Koch, 1977): slight agreement (≤0.20), fair agreement (0.21–0.40), 
moderate agreement (0.41–0.60), substantial agreement (0.61–0.80) and almost perfect 
agreement (≥0.81). Disagreements between raters were resolved by consensus.  
 
Synthesis of results 
Meta-analyses were conducted to evaluate the effects of home telemonitoring in 
healthcare utilisation and associated costs, mortality rates, respiratory exacerbations and 
HRQOL. In case of missing data, the corresponding authors were contacted via e-mail to 
provide more information. Five authors (De San Miguel et al., 2013, Koff et al., 2009, 
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Lewis et al., 2010b, Paré et al., 2006, Pedone et al., 2013) were contacted; however, only 
one replied. Effect sizes were calculated with the risk ratio (RR) for dichotomous variables 
and the standardised mean difference (SMD) for continuous variables. The 95% 
confidence intervals (95%CI) and significance tests were also computed (statistical 
significance: p<0.05). Effect size data were synthesised into forest plots and a fixed-
models effect was used in the absence of substantial heterogeneity across studies. 
Heterogeneity was measured using the I2 test, which represents the percentage of the 
variation in effect sizes that is due to heterogeneity rather than sampling error (Higgins et 
al., 2003). When substantial heterogeneity was found (I2≥50%) (Deeks et al., 2008), a 
random-effects model was applied. If appropriate, subgroup analyses for study design, 
COPD severity and telemonitoring duration were also conducted to explore reasons for 
heterogeneity. Publication bias was assessed by visual inspection of funnel plots and 
Egger’s regression intercept test if more than 5 studies were included in the meta-analysis 
(Sterne et al., 2005). Quantitative analyses were performed using Comprehensive Meta-
Analysis software v2.0 (Biostat, Englewood, New Jersey). 
 
Results 
Study selection 
The literature search identified 455 records. After duplicates removed, 130 records were 
screened for content through title and abstract. From these, 114 were excluded. The full-
text of 16 articles was then assessed for eligibility and 11 articles were excluded (Figure 
1). Five articles were identified as relevant from the automatic updates of the databases 
and the reference lists and were included in the review. One study had 2 publications 
reporting healthcare utilisation (Lewis et al., 2010b) and health-related outcomes (Lewis et 
al., 2010a), thus both articles were considered. In total, 10 articles on 9 studies were 
included, all published in English: 7 RCTs (Antoniades et al., 2012, Chau et al., 2012, De 
San Miguel et al., 2013, Jódar-Sánchez et al., 2013, Koff et al., 2009, Lewis et al., 2010a, 
Lewis et al., 2010b, Pedone et al., 2013) and 2 NRCTs (Paré et al., 2006, Trappenburg et 
al., 2008). 
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Figure 1. Flow diagram for study selection. 
 
Quality assessment 
Two articles were rated as A (high quality) (Chau et al., 2012, Lewis et al., 2010b), 7 as B 
(good quality) (Antoniades et al., 2012, Koff et al., 2009, Lewis et al., 2010a, Paré et al., 
2006, Trappenburg et al., 2008, Jódar-Sánchez et al., 2013, Pedone et al., 2013) and 1 as 
C (fair to good quality) (De San Miguel et al., 2013). Two articles rated as good quality 
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were in the borderline to be considered as high quality (Antoniades et al., 2012, Lewis et 
al., 2010a). Cohen’s kappa coefficient revealed substantial agreement between raters 
(κ=0.63; p=0.036). 
 
Study characteristics 
Five studies were published from 2011 to the present (Antoniades et al., 2012, Chau et 
al., 2012, De San Miguel et al., 2013, Jódar-Sánchez et al., 2013, Pedone et al., 2013). 
Table 1 provides an overview of the characteristics of each study.  
COPD severity was an inclusion criterion in all studies. Patients had to present moderate 
to severe COPD (n=4) (Antoniades et al., 2012, Chau et al., 2012, Lewis et al., 2010a, 
Lewis et al., 2010b, Pedone et al., 2013), severe COPD (n=2) (Paré et al., 2006), severe 
to very severe COPD (n=5) (Jódar-Sánchez et al., 2013, Koff et al., 2009, Trappenburg et 
al., 2008) and/or receive oxygen therapy (n=1) (De San Miguel et al., 2013, Jódar-
Sánchez et al., 2013). Samples included varied from 30 (Paré et al., 2006) to 165 
(Trappenburg et al., 2008), mostly older people (mean age ≥65 years old).  
Telemonitoring data were generally transmitted to a monitoring centre on a daily basis, 
during 2 (Chau et al., 2012) to 12 (Antoniades et al., 2012) months. Patients’ compliance 
with data transmission was assessed in 5 studies (Antoniades et al., 2012, Chau et al., 
2012, Jódar-Sánchez et al., 2013, Lewis et al., 2010b, Pedone et al., 2013) and ranged 
from 40% (Antoniades et al., 2012) to 98% (Chau et al., 2012), depending on the clinical 
measurement. In all studies, patient’s readings outside pre-determined values triggered 
an immediate action from the healthcare team monitoring the data. Usual care included 
the same healthcare component provided to the HTMG, but without telemonitoring (Table 
1). 
 
Synthesis of results 
An overview of the outcomes assessed in each study is provided in Table 2. 
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Table 1. Main characteristics of the studies. 
First author 
(year) 
Study 
design 
Country Participants Telemonitoring 
duration 
Home telemonitoring 
(experimental group) 
Usual care  
(experimental and 
control groups) 
Antoniades (2012) RCT Australia 44 patients with moderate to severe 
COPD and with ≥1 
hospitalisations/year:  
HTMG (n=22) and CG (n=22).  
12 months Transmission of data about spirometry 
parameters, weight, temperature, 
blood pressure, oxygen saturation, 
electrocardiogram, sputum colour and 
volume, symptoms and medication 
usage, on a daily basis (on weekdays).  
Clinical management 
according to Australian 
and New Zealand 
guidelines with 
provision of outreach 
nursing, a written 
action plan and 
availability of 
pulmonary 
rehabilitation (chronic 
disease management 
programme). 
Chau (2012) RCT Hong Kong 53 older people with moderate to 
severe COPD and with ≥1 
hospitalisations/year:  
HTMG (n=30) and CG (n=23). 
2 months (mean 
duration 54.36 
days) 
Measurements of oxygen saturation, 
heart rate and respiration rate 3 times 
a day (on weekdays). The technology 
provided patients with a medication 
and pursed-lips breathing reminder 
with a feedback function. 
In-home nurse visits to 
offer education on self-
care and symptom 
management 
techniques. 
De San Miguel 
(2013) 
RCT Australia 71 patients with COPD treated with 
long-term oxygen therapy:  
HTMG (n=36) and CG (n=35). 
6 months Daily transmission of blood pressure, 
heart rate, oxygen saturation, weight, 
temperature and of data related to 
patients’ general state of health. 
Patients also received an educational 
book about COPD. 
Educational book 
about COPD. 
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(table 1 – continued) 
First author 
(year) 
Study 
design 
Country Participants Telemonitoring 
duration 
Home telemonitoring 
(experimental group) 
Usual care  
(experimental and 
control groups) 
Jódar-Sánchez, 
(2013) 
RCT Spain 45 patients with clinically stable 
COPD and chronic respiratory 
failure, receiving long-term oxygen 
therapy and with ≥1 
hospitalisations/year:  
HTMG (n=24) and CG (n=21). 
4 months Daily measurement (on weekdays) of 
blood pressure, heart rate and oxygen 
saturation and spirometry 2 days per 
week, 20 minutes after taking 
prescribed inhaled therapy, seated and 
rested, and while on oxygen therapy. 
Conventional medical 
care. 
Koff (2009) RCT United 
States of 
America 
40 patients with severe to very 
severe COPD (GOLD 3 and GOLD 
4):  
HTMG (n=20) and CG (n=20). 
3 months Transmission of data about symptoms, 
oxygen saturation, spirometry 
parameters and steps in six-minute 
walking distance, on a daily basis (on 
weekdays), plus disease-specific and 
self-management education and 
interaction with study coordinators 
through the telemonitoring system 
(proactive integrated care programme). 
Usual access to 
healthcare providers.  
Lewis (2010a, 
2010b) 
RCT United 
Kingdom 
40 patients with moderate to severe 
COPD after undertaken pulmonary 
rehabilitation:  
HTMG (n=20) and CG (n=20). 
6 months Data transmission twice a day 
regarding the condition of patients’ 
chest over the preceding day/night, 
oral temperature, heart rate and 
oxygen saturation. 
Standard care. 
Paré (2006) NRCT Canada 30 patients with severe COPD that 
required frequent home visits:  
HTMG (n=20) and CG (n=10). 
6 months Daily transmission of peak flow rate, 
symptoms and medication taken. 
Traditional system of 
in-home visits (CG 
only). 
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(table 1 – continued) 
First author 
(year) 
Study 
design 
Country Participants Telemonitoring 
duration 
Home telemonitoring 
(experimental group) 
Usual care  
(experimental and 
control groups) 
Pedone (2013) RCT Italy 99 older people with moderate to 
severe COPD (GOLD 2 and GOLD 
3):  
HTMG (n=50) and CG (n=49). 
9 months Data transmission 5 times a day, 
every 3 hours, of oxygen saturation, 
heart rate, respiratory rate, physical 
activity and body temperature. 
 
Standard care. 
Trappenburg 
(2008) 
NRCT Netherland
s 
165 patients with severe to very 
severe COPD (GOLD 3 and GOLD 
4) with ≥1 hospitalisations/6 months: 
HTMG (n=101) and CG (n=64). 
6 months Daily transmission of data about 
symptoms, medication compliance and 
knowledge, with immediate feedback 
from the system. 
Usual access to 
healthcare providers. 
COPD – chronic obstructive pulmonary disease; CG – control group; HTMG – home telemonitoring group; GOLD - Global Initiative for Chronic Obstructive 
Lung Disease; NRCT - non-randomised controlled trial; RCT – randomised controlled trial. 
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Table 2. Types of outcomes measured in the home telemonitoring and control groups. 
 Hospitalisations 
Length of 
hospital 
stay 
Emergency 
department visits 
Healthcare 
costs 
Mortality 
Quality of 
life 
Respiratory 
exacerbations 
Other 
outcomes* 
First author 
(year) 
Rate Mean Mean Rate Mean Mean Rate Mean Rate Mean  
Antoniades 
(2012) 
 ● ●    ● ●    
Chau (2012) ●  ● ●    ●   ● 
De San Miguel 
(2013) 
● ● ● ● ● ●  ●   ● 
Jódar-Sánchez, 
(2013) 
● ● ● ● ●  ● ●   ● 
Koff (2009) ●   ●  ●  ●    
Lewis (2010a, 
2010b) 
● ● ●  ●  ● ●   ● 
Paré (2006) ● ● ●   ●     ● 
Pedone (2013) ●  ●      ●   
Trappenburg 
(2008) 
● ● ●  ●  ● ●  ● ● 
*Other outcomes: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio (Chau et al., 2012), type and quantity of prescribed 
medication (Trappenburg et al., 2008), six-minute walking distance (Antoniades et al., 2012), anxiety and depression symptoms (Lewis et al., 2010a), primary care 
contacts (chest and non-chest) (Lewis et al., 2010b), specialised consultations (Jódar-Sánchez et al., 2013), healthcare team phone calls and home visits (De San 
Miguel et al., 2013, Jódar-Sánchez et al., 2013, Koff et al., 2009, Lewis et al., 2010b, Paré et al., 2006), mortality (Jódar-Sánchez et al., 2013, Lewis et al., 2010b) and 
costs related to telemonitoring equipment and healthcare resources (Paré et al., 2006). 
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Hospitalisation rates 
Six RCTs (Chau et al., 2012, De San Miguel et al., 2013, Jódar-Sánchez et al., 2013, Koff 
et al., 2009, Lewis et al., 2010a, Pedone et al., 2013) and 2 NRCTs (Paré et al., 2006, 
Trappenburg et al., 2008) including 486 patients reported hospitalisation rates in both 
groups. Patients receiving home telemonitoring had a significantly lower risk of 
hospitalisation than those receiving usual care (RR=0.72; 95%CI=0.53–0.98; Z=-2.12; 
p=0.034; Figure 2; I2=4.73%). Publication bias was not evident either from visual 
inspection of the funnel plot (data not shown) and the Egger’s regression intercept test 
(intercept=-0.21; 95%CI=-2.46–2.03; p=0.824). 
 
Figure 2. Risk ratio of hospitalisation in the home telemonitoring and control groups (fixed-effects model). 
 
Mean number of hospitalisations 
Seven studies reported the mean number of hospitalisations per patient (Antoniades et 
al., 2012, De San Miguel et al., 2013, Jódar-Sánchez et al., 2013, Koff et al., 2009, Lewis 
et al., 2010a, Paré et al., 2006, Trappenburg et al., 2008). Three studies were excluded 
from quantitative analysis due to missing data (De San Miguel et al., 2013, Koff et al., 
2009, Paré et al., 2006). Therefore, 4 studies including 244 patients with COPD were 
included (Antoniades et al., 2012, Jódar-Sánchez et al., 2013, Lewis et al., 2010a, 
Trappenburg et al., 2008). There were no significant differences between groups (SMD=-
0.06; 95%CI=-0.32–0.19; Z=-0.50; p=0.617; I2=16.42%). 
 
Length of hospital stay 
Eight studies providing information about hospitalisations also reported the mean length of 
hospital stay (in days) (Antoniades et al., 2012, Chau et al., 2012, De San Miguel et al., 
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2013, Jódar-Sánchez et al., 2013, Lewis et al., 2010b, Paré et al., 2006, Pedone et al., 
2013, Trappenburg et al., 2008). Four studies were excluded from the quantitative 
analysis due to missing or non-comparable data (De San Miguel et al., 2013, Lewis et al., 
2010b, Paré et al., 2006, Pedone et al., 2013). Four studies with 244 patients with COPD 
were included (Antoniades et al., 2012, Chau et al., 2012, Jódar-Sánchez et al., 2013, 
Trappenburg et al., 2008). The length of hospital stay was not different between groups 
(SMD=0.06; 95%CI=-0.19–0.31; Z=0.48; p=0.635; I2=0%). 
 
Emergency department visit rates 
Only 4 studies with 194 patients, all RCTs, reported emergency department visit rates 
(Chau et al., 2012, De San Miguel et al., 2013, Jódar-Sánchez et al., 2013, Koff et al., 
2009). There was no evidence of a significant effect of home telemonitoring on emergency 
department visit rates (RR=0.68; 95%CI=0.38–1.18; Z=-1.34; p=0.179; I2=22.53%).  
 
Mean number of emergency department visits 
Five studies reported the mean number of emergency department visits (De San Miguel et 
al., 2013, Jódar-Sánchez et al., 2013, Koff et al., 2009, Lewis et al., 2010b, Trappenburg 
et al., 2008). Three studies were excluded from the quantitative analysis due to non-
comparable data (De San Miguel et al., 2013, Lewis et al., 2010b, Koff et al., 2009). Two 
studies, 1 RCT (Jódar-Sánchez et al., 2013) and 1 NRCT (Trappenburg et al., 2008), 
comparing home telemonitoring to usual care for 4-6 months in 160 patients with severe 
to very severe COPD were included. The number of emergency department visits was not 
significantly different between groups (SMD=0.20; 95%CI=-0.49–0.88; Z=0.56; p=0.576). 
There was substantial heterogeneity across studies (I2=74.81%) (Deeks et al., 2008), 
therefore, a random-effects model was applied and a subgroup analysis of study designs 
was conducted.  
The NRCT (Trappenburg et al., 2008) reported a significantly lower mean number of 
emergency department visits in the HTMG (SMD=0.51; 95%CI=0.14–0.88; Z=2.70; 
p=0.007). This positive trend was not observed in the RCT (Jódar-Sánchez et al., 2013) 
(SMD=-0.19; 95%CI=-0.78–0.39; Z=-0.65; p=0.515).  
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Healthcare-related costs 
Three studies assessed the costs related to healthcare services (De San Miguel et al., 
2013, Koff et al., 2009, Paré et al., 2006). De San Miguel et al. (2013) reported total cost 
savings of 112,439US dollars (USD) in the HTMG. Koff et al. (2009) suggested that home 
telemonitoring reduced healthcare-related costs (mean change=-1,401USD; 95%CI=-
6,566–3,764USD) when compared to usual care (mean change=1,709USD; 95%CI=-
4,349–7,768USD); however, the difference was not significant (p=0.21). Paré et al. (2006) 
found that telemonitoring yielded a reduction in hospitalisation costs (29,686USD) and a 
total cost reduction of 6,750USD when compared to usual care, including the costs 
associated with the implementation of each intervention (e.g., home visits or technology).  
 
Mortality rates 
Four studies with 294 patients presented mortality rates (Antoniades et al., 2012, Jódar-
Sánchez et al., 2013, Lewis et al., 2010b, Trappenburg et al., 2008). Two of them reported 
non-COPD related reasons for death (Antoniades et al., 2012, Lewis et al., 2010b). 
Mortality rates were not different between groups (RR=1.43; 95%CI=0.40–5.03; Z=0.55; 
p=0.582; I2=0%). 
 
Respiratory exacerbations 
One RCT (Pedone et al., 2013) and 1 NRCT (Trappenburg et al., 2008) including 214 
patients assessed the number of respiratory exacerbations during the intervention in both 
groups. These studies found that the CG had a higher incidence of respiratory events 
(HTMG:9/50; CG:15/49; p=0.152) (Pedone et al., 2013) and mean number of 
exacerbations (HTMG=0.65±1.4; CG=1.01±1.4; p=0.004) (Trappenburg et al., 2008). 
Two studies reported the number of exacerbations detected by the telemonitoring system 
in the HTMG (Jódar-Sánchez et al., 2013, Koff et al., 2009). In Jódar-Sánchez et al. 
(2013) the device provided 40 alerts and in Koff et al. (2009) it detected 9 exacerbations. 
A worsening of peripheral oxygen saturation was the most frequent altered clinical finding 
in the detection of a respiratory exacerbation (Koff et al., 2009, Pedone et al., 2013). 
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Health-related quality of life 
Seven studies evaluated patients’ HRQOL before/after the intervention, using either 
disease-specific (Chronic Respiratory Disease Questionnaire (Antoniades et al., 2012), 
Chronic Respiratory Questionnaire (Chau et al., 2012, De San Miguel et al., 2013), St. 
George’s Respiratory Questionnaire (SGRQ) (Jódar-Sánchez et al., 2013, Koff et al., 
2009, Lewis et al., 2010a), Clinical COPD Questionnaire (Trappenburg et al., 2008)) or 
general (EURO-QOL-5D Questionnaire (Jódar-Sánchez et al., 2013, Lewis et al., 2010a), 
Medical Outcome Study Short-Form 36 Questionnaire (Antoniades et al., 2012)) quality of 
life measurement instruments. Overall, no significant differences were found between 
groups. Pooling was not appropriate because the instruments measure different domains 
of HRQOL (Glaab et al., 2010). Only two RCTs presenting the mean change (i.e., 
posttest-pretest) of total and sub-dimension scores of the SGRQ were pooled (Jódar-
Sánchez et al., 2013, Koff et al., 2009). In SGRQ, lower scores represent better quality of 
life (Jones, 2005). A statistically significant change was found in the SGRQ total score 
(SMD=-0.53; 95%CI=-0.97– -0.09; Z=-2.35; p=0.019; I2=17.74%) suggesting that patients 
receiving home telemonitoring had a greater HRQOL after the intervention (Figure 3). This 
trend was not confirmed for SGRQ sub-dimensions (p>0.05; I2=0.00%). 
In terms of clinical significance (i.e., mean change ≥4units) (Jones, 2005), both groups 
exhibited a clinically important change in SGRQ total score in Jódar-Sánchez et al. (2013) 
(HTMG=10.9; CG=4.5); however, only the HTMG achieved this clinical change in Koff et 
al. (2009). 
 
Figure 3. Mean change in quality of life of the home telemonitoring and control groups using the St. George’s 
Respiratory Questionnaire total and sub-dimension (activity, impact and symptoms) scores (fixed-effects 
model). Std diff in means: standardised mean difference. 
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Discussion 
This systematic review assessed the effectiveness of home telemonitoring in COPD. Nine 
studies were included, five of them published from 2011 to the present which emphasises 
the novelty of this type of intervention. Most studies were RCTs of good quality; however, 
some of them had relatively small samples. Findings suggest that, although home 
telemonitoring appears to have a positive effect in detecting and reducing respiratory 
exacerbations and improving HRQOL, there is still no clear indication that it reduces 
healthcare utilisation and associated costs as only hospitalisation risk was reduced in the 
HTMG. One NRCT (Trappenburg et al., 2008) also showed a significantly lower number of 
emergency department visits in the HTMG. However, this result should be interpreted with 
caution because of the inherent risk of bias associated with this study design. 
Furthermore, this positive trend was not observed in a RCT with a similar target-
population and telemonitoring duration (Jódar-Sánchez et al., 2013). 
Healthcare utilisation was similar in both groups, with the exception of hospitalisation 
rates. Some reasons may have contributed to these findings. Firstly, it was not always 
clear whether healthcare utilisation reported in some studies was related to respiratory 
exacerbations (Dinesen et al., 2012, Jódar-Sánchez et al., 2013, Paré et al., 2006, 
Trappenburg et al., 2008). Therefore, it is unclear if COPD-related healthcare utilisation 
was actually reduced. Secondly, the levels of patients’ compliance with telemonitoring 
may also explain some of the results. As reported earlier, compliance with data 
transmission ranged from 40% (Antoniades et al., 2012) to 98% (Chau et al., 2012). This 
lower compliance found in some studies might have contributed to the failure in detecting 
health deterioration. Hence, the purpose of home telemonitoring, i.e., the continuous 
monitoring of patients’ clinical data to early detect and address health deterioration, may 
not have been reached due to a lack of patients’ compliance.  
The two studies reporting the occurrence of respiratory exacerbations in both groups 
found that the CG had a higher number of exacerbations during the intervention, when 
compared to the HTMG (Pedone et al., 2013, Trappenburg et al., 2008). Two additional 
studies reported that the telemonitoring system was able to detect respiratory 
exacerbations (Jódar-Sánchez et al., 2013, Koff et al., 2009). These findings support the 
hypothesis that telemonitoring can be a potential way of detecting and managing COPD 
exacerbations in a timely manner. Advancements in physiological sensors and in 
information and communication technologies may, therefore, offer opportunities for 
providing healthcare management tools, enabling extended independent living at home for 
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individuals with COPD. However, there is still a lack of clarity about which parameters 
should be used to detect exacerbations (McKinstry, 2013). The worsening of peripheral 
oxygen saturation was the most frequent altered clinical finding in the detection of 
respiratory exacerbations (Koff et al., 2009, Pedone et al., 2013). A previous exploratory 
research supports these results (Hurst et al., 2010). According to Hurst and co-workers 
(2010), a composite measure that combines oxygen saturation and heart rate may be 
useful to identify an exacerbation onset. In this review, only four studies collected both 
measurements (Chau et al., 2012, Jódar-Sánchez et al., 2013, Lewis et al., 2010a, Lewis 
et al., 2010b, Pedone et al., 2013). 
Studies reporting healthcare-related costs revealed a positive trend towards 
telemonitoring interventions, suggesting that home telemonitoring may, therefore, have 
the ability to produce savings in COPD management (Jaana et al., 2009). This trend may 
be in part related to the decreased hospitalisation rates found in the present study. 
According to previous research, hospitalisations represent more than one-half of the total 
direct costs attributable to COPD (Miller et al., 2005), mostly due to respiratory 
exacerbations (Toy et al., 2010). However, the small number of studies providing 
healthcare-related cost information and the differences in the estimation of this outcome 
(e.g., in the study of De San Miguel et al. (2013), hospital visit costs were based on length 
of stay rather than number of hospitalisations) limit the interpretation of the findings. 
Further work still needs to be conducted on this topic to draw final conclusions. 
Findings on patients’ HRQOL were inconsistent. In most studies, no significant changes 
after the intervention were found. Nevertheless, they used different measurement 
instruments which made difficult to perform comparisons. When two studies using the 
same questionnaire were pooled (Jódar-Sánchez et al., 2013, Koff et al., 2009), significant 
changes were found in favour of the HTMG. These studies also demonstrated a clinically 
important change in the HTMG and one found a clinical change also in the CG (Jódar-
Sánchez et al., 2013). Hence, the ability of home telemonitoring to demonstrate an 
improvement in HRQOL beyond to that achieved with usual care remains a challenge. 
 
Limitations 
One limitation of this review concerns the exclusion of six studies written in languages 
other than English, Portuguese and Spanish, since they could be relevant for the scope of 
the review. The fact that some studies could not be integrated in the quantitative analysis 
due to missing or non-comparable data is another limitation. Thus, it is unknown if any of 
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these studies could have influenced the outcomes in the telemonitoring group. Lastly, in 
most cases, the number of studies included in the meta-analysis was insufficient (n<5) 
(Sterne et al., 2005) to measure the potential of publication bias. 
 
Implications for research and practice 
The value of home telemonitoring to reduce healthcare utilisation and improve health-
related outcomes is not yet well defined. Therefore, to advocate the use of this 
intervention as a patient management approach and to incorporate it into practice, further 
work needs to be conducted. In addition, variations in compliance rates suggest that 
telemonitoring regimens may not be appropriate for all patients. Further research is 
needed to identify the types of patients most likely to benefit from these interventions. 
Future studies should also consider: i) including a composite measure of oxygen 
saturation and heart rate to early detect exacerbations; ii) using similar HRQOL 
measurement instruments to enable comparisons across studies; iii) reporting healthcare 
utilisation data in a format that can be further pooled into meta-analysis.  
 
Conclusion 
The findings provide limited evidence of the effectiveness of home telemonitoring to 
reduce healthcare utilisation and improve health-related outcomes in patients with COPD. 
Although this intervention appears to have a positive effect in reducing respiratory 
exacerbations and hospitalisations and improving HRQOL, there is still no clear indication 
that it reduces healthcare utilisation and associated costs. Further research is needed to 
assess the effectiveness of home telemonitoring in COPD management, as there are still 
few studies in this area. 
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Abstract 
Aim: This systematic review aimed to provide a comprehensive description of the 
methodologies used in home telemonitoring interventions for Chronic Obstructive 
Pulmonary Disease (COPD) and to explore patients’ adherence and satisfaction with the 
use of telemonitoring systems.  
Methods: A literature search was performed from June to August and updated until 
December of 2012 on Medline, Embase, Web of Science and B-on databases using the 
following keywords: [tele(-)monitoring, tele(-)health, tele(-)homecare, tele(-)care, tele-
home health or home monitoring] and [Chronic Obstructive Pulmonary Disease or COPD]. 
References of all articles were also reviewed. 
Results: Seventeen articles were included, 12 of them published from 2010 to the 
present. The methodologies were similar in the training provided to patients and in the 
data collection and transmission processes. However, differences in the type of 
technology used, telemonitoring duration and provision of prompts/feedback, were found. 
Patients were generally satisfied and found the systems useful to help them manage their 
disease and improve healthcare provision. Nevertheless, they reported some difficulties in 
their use, which in some studies were related to lower compliance rates.  
Conclusions: Telemonitoring interventions are a relatively new field in COPD research. 
Findings suggest that these interventions, although promising, present some usability 
problems that need to be considered in future research. These adjustments are essential 
before the widespreading of telemonitoring. 
 
Keywords: adherence; chronic obstructive pulmonary disease; e-health; remote 
monitoring; satisfaction level; telemedicine. 
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Research Highlights 
▪ Telemonitoring interventions should to be adjusted to their target population; 
▪ Assessment of patients’ acceptance of telemonitoring technology should be 
considered prior to its implementation; 
▪ Future research should consider the inclusion of easy-to-use technology and more 
training sessions; 
▪ Frequency of data collection/transmission should be flexible to improve adherence; 
▪ Changes in patients’ self-management behavior should be explored in future studies. 
 
Summary Points 
What is already known on the topic: 
▪ The number of patients with COPD being managed at home is increasing to reduce 
health-related costs while trying to increase patients’ comfort; 
▪ Home telemonitoring is an innovative approach which facilitates patients’ 
management at home, by exchanging information between patients and their 
healthcare professionals; 
▪ There are systematic reviews available on the topic of home telemonitoring in 
respiratory patients and, specifically, in patients with COPD. However, they lack 
information about telemonitoring methodologies and patients’ adherence. 
What has this study added to our knowledge: 
▪ Home telemonitoring interventions, although promising, still need to be adjusted to 
ensure their suitability to the target population. Assessment of patients’ needs, 
characteristics and acceptance of the technology may facilitate patients’ adherence 
to telemonitoring regimens; 
▪ Future home telemonitoring interventions for COPD should consider the inclusion 
of easy-to-use technology and more training sessions to facilitate patients’ 
education on the use of the technologies, and they should be flexible in frequency 
of data collection and transmission to improve adherence; 
▪ The impact of telemonitoring interventions on patients’ self-management behavior 
and satisfaction should also be explored, as well as their associations with patient 
outcomes and healthcare utilization. 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent disease worldwide 
(World Health Organization [WHO], 2008). As the disease progresses, patients become 
more susceptible to respiratory exacerbations which cause frequent hospital admissions 
and readmissions and, thus, have a considerable impact on patients’ quality of life and 
healthcare costs (Casas et al., 2006, Global Strategy for the Diagnosis Management and 
Prevention of COPD [GOLD], 2013). This poses COPD as a public health problem of 
increasing concern to healthcare systems worldwide (Nici et al., 2006). A number of 
interventions have been developed to help patients self-manage their disease and 
improve their quality of life, therefore reducing pressures on healthcare resources. Recent 
studies have shown that the number of patients with COPD being managed at home is 
increasing to reduce health-related costs while trying to increase patients’ comfort (Bolton 
et al., 2010). 
Home telemonitoring is a relatively new approach (dating back to the early 1990s) which 
facilitates patients’ management at home (Paré et al., 2007). It is defined as the use of 
telecommunication technologies to transmit data on patients’ health status (e.g., oxygen 
saturation, vital signs) from home to a healthcare center (Jaana et al., 2009, Paré et al., 
2007). By systematically monitoring patients’ health condition, home telemonitoring can be 
used for a timely assessment of an acute exacerbation or as a mechanism to generate 
alarms to the patients and/or healthcare professionals when clinical changes that may 
constitute a risk to the patient occur (McKinstry, 2013). This approach aims to empower 
patients to manage their disease (e.g., by recognizing the early signs of exacerbations), 
improve patient-professional interactions and prevent unplanned hospital admissions 
(McKinstry, 2013, Paget et al., 2010). 
Five systematic reviews are available on the topic of home telemonitoring in respiratory 
patients (Jaana et al., 2009) and, specifically, in patients with COPD (Bartoli et al., 2009, 
Bolton et al., 2010, McLean et al., 2011, Polisena et al., 2010). However, they focus on 
clinical outcomes (e.g., quality of life) (Polisena et al., 2010, Jaana et al., 2009, McLean et 
al., 2011), reduction in healthcare service utilization (Bolton et al., 2010, Jaana et al., 
2009, McLean et al., 2011, Polisena et al., 2010), feasibility and use (Jaana et al., 2009), 
and on economic (Bolton et al., 2010, Jaana et al., 2009) and organizational (Bartoli et al., 
2009) impacts of telemonitoring. None of these studies provides a comprehensive 
description of the telemonitoring methodologies, which is essential to enhance the design 
of future telemonitoring interventions and facilitate comparisons between studies. 
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Furthermore, optimal interventions require patients’ adherence (WHO, 2003), but there is 
still limited information about adherence to telemonitoring in COPD research. Previous 
studies on telemonitoring in different health conditions have suggested that adherence is 
related to patients’ satisfaction with the telemonitoring regimens (Kraai et al., 2011, 
Rahimpour et al., 2008, Sanders et al., 2012), so satisfaction should be considered when 
assessing patients’ adherence. Thus, this systematic review aimed to: (1) provide a 
comprehensive description of the methodologies used in home telemonitoring for COPD; 
and (2) describe the current state of literature on patients’ adherence and satisfaction with 
the use of telemonitoring systems. 
 
Methods 
Information sources and search strategy 
A literature search was performed from June to August of 2012 in the medical databases 
Medline (1948-2012) and Embase (1974-2012) and wide-ranging scientific databases 
Web of Science (1970-2012) and B-on Online Knowledge Library (1999-2012). These 
databases were included to ensure that all relevant articles were retained. Search terms 
were based on a combination of the following keywords: [tele(-)monitoring or tele(-)health 
or tele(-)homecare or tele(-)care or tele-home health or home monitoring] and [Chronic 
Obstructive Pulmonary Disease or COPD]. Search was customized for each database 
according to their filtering specificities. Additional searches for relevant studies were 
performed within the bibliography of the selected articles and weekly automatic updates 
retrieved from the databases until December of 2012. 
 
Eligibility criteria and study selection 
This systematic review is structured according to Preferred Reporting Items for Systematic 
Reviews and Meta-Analyzes (PRISMA) guidelines (Liberati et al., 2009; Moher et al., 
2009). Eligible studies included adult people with a diagnosis of COPD whose health 
condition was telemonitored at home. Home telemonitoring was defined according to the 
following criteria (Jaana et al., 2009, Paré et al., 2007): i) patients or their caregivers had 
to periodically record patients’ clinical data (e.g., physiological signs or symptoms) at 
home; ii) these data had to be transmitted using telecommunication technologies from 
patients’ home to a monitoring center. Studies were excluded if they: i) included patients 
with diseases other than COPD (i.e., the intervention was not specific to COPD 
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population); ii) included only regular telephone calls, video-consultation or teleconference 
interventions without telemonitoring clinical data; iii) involved downloading the data during 
healthcare visits or at the end of the study; iv) were limited to a technical description of the 
technology employed; vi) provided telemonitoring in other places than patients’ home. 
Studies without information on patients’ adherence and satisfaction were still retained in 
the review to enable a full description of the methodologies used in home telemonitoring 
(the first aim of the paper). In this review, the term adherence followed the definition 
proposed by the WHO (2003) and consisted of the extent to which the patient's behavior 
corresponds to the recommendations provided by the monitoring center regarding the use 
of the telemonitoring technology. The studies considered for review were randomized 
controlled trials (RCTs) and quasi-experimental studies; observational studies which did 
not include a telemonitoring intervention and case studies were excluded. Non-original 
articles (e.g., review papers, editorials, commentaries to articles, study protocols) and 
abstracts of communications or meetings were not considered suitable and, therefore, 
were excluded from this review although their reference list was reviewed closely. Papers 
without abstracts or written in languages other than English, Portuguese and Spanish 
were also excluded.  
Study selection followed the stages recommended by the guidelines for conducting 
systematic reviews (Centre for Reviews and Dissemination, 2009). Initial screening of 
articles was based on type of publication and relevance for the scope of the review 
according to their title, abstract and keywords. Then, the full-text of potentially relevant 
articles was screened for content to decide its inclusion in the review. Studies with 
multiple publications were identified to avoid duplicate reports.  
 
Data collection process 
One reviewer extracted the data from the included studies and a second reviewer 
checked the extracted data. Disagreements were resolved by discussion between the two 
reviewers. Data were extracted in a structured table-format (developed prior to data 
collection) according to the following topics: first author’s last name and year of 
publication, study design, country where the study was conducted, participants, type(s) of 
intervention(s), telemonitoring methodology, patients’ adherence and satisfaction. The 
telemonitoring methodology data were synthesized in sub-categories: i) telemonitoring 
duration; ii) type of technology; iii) patients’ training to use the system; iv) data collection 
and transmission; v) use of prompts, reminders and/or feedback and detection of health 
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deterioration. Patients’ adherence was obtained by accessing dropout and compliance 
rates of patients who participated in the telemonitoring interventions. When available, 
reasons for non-adherence were also collected. Meta-analyzes could not be performed 
due to the nature of the data collected (description of methodologies) and lack of 
comparable outcomes to measure patients’ adherence and satisfaction. Instead, a 
narrative synthesis was employed to synthesize the findings (Popay et al., 2006). 
 
Quality assessment 
Quality of studies was formally assessed according to the guidelines for conducting 
systematic reviews (Centre for Reviews and Dissemination, 2009), using a modified 
version of the scoring system developed by Hailey et al. (2011) to evaluate telemedicine 
research. This modified version was summarized in a recent systematic review on COPD 
(Polisena et al., 2010) and consists of 5 levels, from grade A (high quality) to E (poor 
quality), taking into consideration the study design and performance. For study design, 
scores were assigned to 4 types of study: large RCTs (≥50 subjects in each arm), small 
RCTs, prospective non-randomized studies and retrospective studies. For study 
performance, five areas of interest were considered: patient selection, 
description/specification of the intervention, specification and analysis of study, patient 
disposal and outcomes reported.  
The quality of studies was independently assessed by two reviewers and inter-rater 
agreement calculated using the Cohen’s kappa coefficient. The kappa values can be 
interpreted as (Landis and Koch, 1977): slight agreement (≤0.20), fair agreement (0.21–
0.40), moderate agreement (0.41–0.60), substantial agreement (0.61–0.80) and almost 
perfect agreement (≥0.81). Disagreements between reviewers were resolved by 
consensus. 
 
Results 
Study selection 
The database search identified 455 records. After duplicates removal, 130 records were 
screened for relevant content. During title, abstract and keyword screening, 109 articles 
were excluded due to the following reasons: non-original articles (n=55), case studies 
(n=3), no abstract provided (n=6), inclusion of non-COPD patients (n=17), absence of 
telemonitoring interventions (n=22) and other languages rather than English, Portuguese 
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or Spanish (n=6). The full-text of the 21 potentially relevant articles was assessed and 8 
articles were excluded. Reasons for exclusion included: no telemonitoring information 
(n=4), laboratory testing of the system (n=2), participants with diseases other than COPD 
(n=1) and provision of teleconsultations alone (n=1). Automatic updates from the 
databases and search for relevant articles within the bibliography of selected articles 
retrieved 4 articles, which were also included (Figure 1). From the articles included in the 
analysis, eight were identified as referring to the same studies: 2 articles per study in 2 
studies (Kim et al., 2012a, Kim et al., 2012b, Lewis et al., 2010a, Lewis et al., 2010b) and 
4 articles pertaining to a single study (Dinesen et al., 2012, Haesum et al., 2012, Jensen 
et al., 2012a, Jensen et al., 2012b). In total, 17 articles on 12 studies were included, all 
published in English. 
 
 
 
Figure 1. Flow diagram for study selection according to the preferred reporting items for systematic reviews 
and meta-analyzes (PRISMA) guidelines. 
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Study characteristics 
Study characteristics are presented in Table 1. Most studies were randomized controlled 
trials (n=5), followed by uncontrolled before-and-after studies (n=4) and non-randomized 
controlled trials (n=3). Sample sizes varied from 20 to 165 patients with COPD, mostly 
older people. Ten studies included specifically patients in advanced stages of the disease. 
Most studies recruited patients during/following hospital admission or those receiving 
specialized care at the hospital or at home. 
In 6 studies, the intervention consisted of telemonitoring clinical data plus other health 
care components such as: in-home nurse visits (n=1), virtual visits/consultations or regular 
telephone calls from the healthcare team (n=5) or provision of education (n=5). 
 
Quality assessment 
Quality levels differed across articles: 4 were rated A (high quality) (Chau et al., 2012, 
Dinesen et al., 2012, Haesum et al., 2012, Lewis et al., 2010b), 7 were rated B (good 
quality) (Antoniades et al., 2012, Koff et al., 2009, Lewis et al., 2010a, Paré et al., 2006, 
Ure et al., 2012, Trappenburg et al., 2008, Sund et al., 2009), 5 were rated C (fair to good 
quality) (Jensen et al., 2012a, Jensen et al., 2012b, Kim et al., 2012b, Kim et al., 2012a, 
Sicotte et al., 2011) and 1 was rated E (poor quality) (Dale et al., 2003). The articles rated 
as A and 3 articles rated as B (Antoniades et al., 2012, Koff et al., 2009, Lewis et al., 
2010a) were referring to randomized controlled trials. Cohen’s kappa coefficient revealed 
substantial agreement between raters (Ƙ=0.78, p=0.001) for study quality levels. 
 
Description of telemonitoring methodology 
Telemonitoring duration  
The length of the telemonitoring period ranged from 2 to 12 months (Table 1). While 8 
studies defined a specific period for telemonitoring, 2 reported that the duration was 
defined according to patients’ needs. 
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Table 1. Main characteristics and description of the technology used in the studies. 
First author 
(year) 
Study 
design 
Country Participants Type(s) of intervention(s) or 
comparator(s) 
Telemonitoring 
duration 
Description of technology 
Antoniades 
(2012)  
RCT Australia 44 patients with moderate to 
severe COPD and with ≥1 
hospital admissions/year 
randomized in 2 groups: IG 
(n=22) and CG (n=22). 
IG: home telemonitoring; 
CG: usual care. 
12 months Laptop computer with peripherals: blood 
pressure cuff and stethoscope, pulse 
oximeter, pneumotachograph, 
electrocardiogram touch plate and 
thermometer.  
Chau (2012)  RCT Hong Kong 53 older people with moderate to 
very severe COPD randomized in 
2 groups: IG (n=30) and CG 
(n=23). 
IG: home telemonitoring plus in-
home nurse visits with provision of 
education. 
CG: in-home nurse visits with 
provision of education. 
2 months (mean 
duration 54.36 
days) 
Mobile phone with a touch-screen monitor 
and peripheral devices: oximeter and 
respiratory rate sensor.  
Dale (2003)  UBA United 
Kingdom 
55 patients with COPD. Home telemonitoring plus additional 
telephone questions. 
3 months Oximeter and home weight scale. 
Dinesen (2012), 
Haesum (2012), 
Jensen (2012a), 
Jensen (2012b)  
RCT Denmark 111 patients with severe or very 
severe COPD randomized in 2 
groups: IG (n=60) and CG (n=51). 
IG: home telemonitoring plus in-
home exercises plus a monthly 
video meeting. 
CG: in-home exercises. 
4 months Telemonitor device. Other devices (not 
connected to the main device): weight 
scale, blood pressure monitor, oximeter, 
spirometer and step counter (in Dinesen 
(2012) and Haesum (2012)). 
Kim (2012a), 
(2012b)  
Non-
equivalent 
multiple-
group 
UBA 
Korea 144 patients with COPD randomly 
allocated in 3 groups: IG1 (n=78), 
IG2 (n=36) and IG3 (n=30). 
IG1: home telemonitoring; 
IG2: home telemonitoring plus 
education plus mobile phone 
service; 
IG3: home telemonitoring plus 
education plus video phone 
teleconsultation. 
6 months Integrated platform with peripherals: 
spirometer, oximeter and electronic 
stethoscope. 
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(table 1 – continued) 
First author 
(year) 
Study 
design 
Country Participants Type(s) of intervention(s) or 
comparator(s) 
Telemonitoring 
duration 
Description of technology 
Koff (2009)  RCT United 
States of 
America 
40 patients with COPD grades 3 
and 4 according to the GOLD 
criteria. 
IG: home telemonitoring plus 
education plus usual care. 
CG: usual care. 
3 months Health Buddy® device. Other devices (not 
connected to the main device): oximeter, 
pedometer and mini-spirometer. 
Lewis (2010a), 
(2010b)  
RCT United 
Kingdom 
40 patients with moderate to 
severe COPD randomized in 2 
groups after undertaken 
pulmonary rehabilitation: IG 
(n=20) and CG (n=20). 
IG: home telemonitoring during 26 
weeks and usual care in the 
following 26 weeks. 
CG: usual care for 52 weeks. 
6 months Hand-held telemonitor (Docobo® Health 
HUB) to display questions and a 
peripheral oximeter. A manual 
thermometer was also provided. 
Paré (2006)  NRCT Canada 30 patients with severe COPD 
assigned in 2 groups: IG (n=20) 
and CG (n=10). 
IG: home telemonitoring; 
CG: usual home care. 
6 months Web phone with a touch-screen monitor 
and a modem. 
Sicotte (2011)  NRCT Canada 46 patients with severe COPD 
assigned in 2 groups: IG (n=23) 
and CG (n=23). 
IG: home telemonitoring; 
CG: usual home care. 
Mean±SD of 
146.7±72.3 days 
Web phone with a touch-screen monitor. 
Sund (2009)  UBA United 
Kingdom 
20 patients with moderate to 
severe COPD. 
Home telemonitoring.  6 months Mobile phone with a touch-screen and a 
peripheral spirometer. 2 software 
packages to enter data about symptoms 
and spirometry. 
Trappenburg 
(2008)  
NRCT Netherlands 165 patients with moderate to 
severe COPD: IG (n=101) and 
CG (n=64). 
IG: home telemonitoring plus 
education plus usual care; 
CG: usual care. 
6 months Health Buddy® device with 4 large 
buttons to present questions and 
education. 
Ure (2012)  UBA  27 patients with moderate to 
severe COPD. 
Home telemonitoring. 2 months Touch-screen computer and peripherals: 
Bluetooth-linked oximeter and spirometer. 
UBA - Uncontrolled before-and-after study; NRCT - non-randomized controlled trial; RCT – Randomized controlled trial; NA – no available information; COPD – 
chronic obstructive pulmonary disease; IG – intervention group; CG – control group; SD – standard deviation.  
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Technology 
The telemonitoring systems were different across studies (Table 1). Some studies 
provided detailed information about them, including the peripheral devices that could be 
connected to a main device, such as: oximeters (n=5), spirometers (n=3), blood pressure 
monitors (n=1), thermometers (n=1), electrocardiographs (n=1), respiratory rate sensors 
(n=1) and/or electronic stethoscopes (n=1). The main device was frequently a mobile/web 
phone with an integrated touch-screen (n=4) or a touch-screen computer (n=1) that 
allowed patients to record data collected via the peripheral devices and/or to answer 
questions about their symptoms and disease management. Two studies used the same 
main device, which also provided patients with information about the disease and/or 
educational questions to answer regularly. 
 
Patients’ training 
Training to use the telemonitoring systems was described in 9 studies (Table 2). Four 
studies reported that patients were trained in their homes during the initial home visit by a 
nurse working in the telemonitoring project. Patients had to demonstrate the use of the 
system in 3 studies and they received information about the normal clinical parameters in 
only 1 study. In 2 studies, ongoing support could be given according to patients’ needs. 
 
Data collection and transmission 
Table 3 summarizes the clinical data collected through the telemonitoring systems. The 
most common parameters collected were symptoms (n=9), oxygen saturation (n=8), 
spirometric parameters (n=6), medication (n=6), heart rate (n=5), temperature (n=3) and 
weight (n=3). 
Data collection process was similar across studies. Answers to symptoms and self-
management questions (e.g., changes in medication, patient knowledge about COPD) 
were performed manually using touch-screen monitors. Regarding clinical data, it was not 
always clear if the information had to be inserted manually or if the process was automatic 
(i.e., the peripheral devices enabled automatic data transfer to the main device). Four 
studies required data collection at a specific time of the day and in 2 studies the data were 
collected more than once per day (Table 3). 
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Table 2. Patients’ training and specificities of data transmission and management. 
First author 
(year) 
Training to use the 
system 
Reminders, prompts 
and/or feedback 
Data transmission  Data management Detection of health 
deterioration 
Antoniades (2012)  In the initial home visit. 
Ongoing in-home support 
available, if required.  
On-screen prompts to 
complete the 
measurements and 
questionnaire. 
Via a telephone line to a 
central server. 
A nurse monitored the data 
on weekdays.  
 
Significant changes triggered 
a contact to a 
physician/nurse or to the 
patient for further 
assessment. 
Chau (2012)  In the initial home visit, 
provided by a nurse, with 
return demonstration.  
Medication and pursed-lips 
breathing reminders with a 
feedback function. 
Via a radio service to an 
online network platform on 
a base station.  
A nurse monitored the data. Immediate action taken 
when changes in clinical 
data occurred (not specified). 
Dale (2003) In the initial home visit, 
provided by a nurse. 
NA Via a telephone line to a 
clinical response center. 
 
A nurse monitored the data 
on a daily basis.  
Clinical changes could lead 
to further assessment or 
treatment. A physician could 
be contacted for decision-
making. 
Dinesen (2012), 
Haesum (2012), 
Jensen (2012a), 
Jensen (2012b)  
In the initial home visit, with 
advice on how to exercise. 
NA Through a secure line using 
wireless to a healthcare 
center/hospital and stored 
in patient’s database. 
Healthcare professionals 
monitored the data. 
Healthcare professionals 
could give advice (not 
specified). 
Kim (2012a), 
(2012b)  
At the hospital, with return 
demonstration, and then at 
home. Ongoing in-home 
support available, if 
required. 
NA Via a cable modem or 
digital subscriber lines. 
NA NA 
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(table 2 – continued) 
First author 
(year) 
Training to use the 
system 
Reminders, prompts 
and/or feedback 
Data transmission  Data management Detection of health 
deterioration 
Koff (2009)  In the initial home visit, 
provided by a nurse, with 
education about the normal 
clinical parameters. 
Advice to contact the 
coordinator when classified 
as red flags. 
Via a telephone line to the 
databank, each night.  
The coordinator monitored 
the data in the following 
morning of data 
transmission. 
Patients automatically 
stratified into 3 color-coded 
groups and contacted if 
persistent red/yellow flags 
appeared. A red flag or a 
patient call led to the contact 
of the primary care 
physician. 
Lewis (2010a), 
(2010b)  
In the initial home visit (~1h 
per patient).  
NA Via a free-phone landline to 
a central server, at 02h00 
daily. Transmission failures 
were followed by a call or a 
message on the screen 
after 7 days (2010a) or 24h 
(2010b). 
Healthcare professionals 
monitored the data. 
Detection of health 
deterioration triggered an 
automatic email message to 
healthcare professionals, 
who called the patient (on 
weekdays). 
Paré (2006)  In the initial home visit, 
provided by a nurse. 
Alerts and advice when 
readings fell outside pre-set 
values. 
Over the internet. A nurse monitored the data 
on a daily basis. 
Data outside pre-set values 
triggered an automatic alert 
to patients and the nurse, 
who contacted the patient or 
the physician for decision-
making.  
Sicotte (2011)  NA Alerts and advice when 
readings fell outside pre-
defined values. 
Over the internet, in real 
time. 
NA Data outside pre-set values 
triggered automatic alerts to 
a surveillance center and a 
nurse called the patient. 
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(table 2 – continued) 
First author 
(year) 
Training to use the 
system 
Reminders, prompts 
and/or feedback 
Data transmission  Data management Detection of health 
deterioration 
Sund (2009)  In the initial home visit, with 
an information sheet and 
return demonstration. A 
helpline was available. 
Prompts to attach the 
spirometer to the main 
device. 
To research center, in real 
time. Transmission failures 
for 2 days were followed by 
a call. 
Data monitored by the 
research team, based on 
daily time-score plots about 
symptoms and FEV1. 
Exacerbations automatically 
detected by a red line on the 
time-plots. Patients were 
called to start treatment with 
pre-provided medications. 
Trappenburg 
(2008)  
NA Each answer received 
immediate feedback from 
the device: praise or 
encouragement to try 
again. 
Via a telephone line to 
Health Hero’s data center. 
Respiratory nurses 
monitored the data on 
weekdays.  
Data automatically stratified 
and color-coded. Nurses 
received alerts and 
contacted the patient and/or 
notified a pulmonary 
physician (if needed). 
Ure (2012)  NA NA Via a secure broadband 
link to a call center. 
Transmission failures were 
followed by a call. 
Staff monitored the data. Staff contacted the patient or 
physician on weekdays 
according to an algorithm. 
Patients received an action 
plan and emergency supply 
of medication to commence 
as soon as an exacerbation 
was recognized. Physicians 
provided clinical care at 
weekends. 
NA – no available information; FEV1 – Forced expiratory volume in 1 second.  
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Table 3. Type and frequency of data collection. 
First author 
(year) 
Symptoms Oxygen 
saturation 
Spirometry Heart rate Temperature Weight Blood 
pressure 
Respiratory 
rate 
Medication Other 
reports* 
Frequency 
Antoniades (2012)  ● ● ●  ● ● ●  ●  Daily, at the 
same time 
Chau (2012)   ●  ●    ●   3 times/day on 
weekdays 
Dale (2003)   ●  ●  ●     Daily 
Dinesen (2012), 
Haesum (2012), 
Jensen (2012a), 
Jensen (2012b)  
● ● ● ●  ● ●    According to 
prescription 
Kim (2012a), 
(2012b)  
● ●  ●       Daily 
Koff (2009)  ● ● ●      ● ● Daily morning 
on weekdays 
Lewis (2010a), 
(2010b)  
● ●  ● ●    ●  2 times/day, at 
a specific period 
Paré (2006)  ●  ●      ●  Daily 
Sicotte (2011)  NA NA NA NA NA NA NA NA NA NA Daily 
Sund (2009)  ●  ●      ● ● Daily evening 
Trappenburg 
(2008)  
●        ● ● Daily 
Ure (2012)  ● ● ●  ●      Daily 
NA – no available information. *Other reports: lung and heart sounds (Kim et al., 2012), electrocardiogram data (Antoniades et al., 2012), number of steps in the 6-minute 
walking test (Koff et al., 2009) and questions regarding patients’ knowledge about COPD (Koff et al., 2009, Trappenburg et al., 2008).  
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Data were transmitted on a daily basis in almost all studies. This process was usually 
performed via telephone line to a secure server, either on real time (n=2) or at a specific 
time of the day (n=2). Data were received in a healthcare center, call center or 
manufacturer center. There, healthcare professionals could monitor the data, generally on 
a daily basis (Table 2). In 6 studies, the information transmitted was automatically 
analyzed and alerts were sent to healthcare professionals and/or researchers when 
readings fell outside pre-established parameters. When data were not transmitted on 
consecutive days, patients were contacted via telephone call (n=3) or via message in the 
monitor screen (n=1). 
 
Reminders, feedback and detection of health deterioration 
Three studies provided reminders or prompts via the telemonitoring system to patients 
(Table 2). Prompts consisted of step-by-step instructions to help patients complete the 
measurements and/or questions or instructions to attach a peripheral to the main device. 
One study provided patients with a medication and pursed-lip breathing reminder. 
Two types of automatic feedback could be given by the systems: feedback about blank 
and/or correct/incorrect answers (n=1) or alerts when readings fell outside pre-established 
parameters (n=3). When deterioration of health condition was detected, patients could 
contact the healthcare professionals (n=1) or be contacted via telephone calls (n=9). 
Patients’ answers about their health condition could determine the next action to be taken 
(Table 2): contact of a physician to make a decision about treatment (n=4) or providing 
patients with an action plan and an emergency supply of medication to commence as 
soon as an exacerbation was recognized (n=2). 
 
Patients’ adherence and satisfaction 
Compliance and dropout rates 
Since these data were intended to inform about the adherence of patients to 
telemonitoring regimens, information about the control groups (if it existed) was not 
included. 
All studies provided information on patient dropouts. From these, only 3 provided 
information on dropouts before intervention (Chau et al., 2012, Kim et al., 2012, Lewis et 
al., 2010). Reasons for withdrawal included (Chau et al., 2012): worsening of patient’s 
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physical condition, financial-related reasons (patients did not have enough money to 
attend the follow-up and to afford the additional cost of recharging the batteries of the 
device every other day), refusal to use the belt for measuring respiratory rate in cold 
weather, the device was too difficult to carry around at work or the frequency of 
telemonitoring was too demanding (i.e., 3 times/day on weekdays). 
Five of the studies which provided dropout information during the intervention period had 
a high number of dropouts (≥20%) and/or low compliance rates (≤80%) (Antoniades et al., 
2012, Chau et al., 2012, Kim et al., 2012, Sund et al., 2009, Trappenburg et al., 2008), 
while 5 reported low dropout rates (Dinesen et al., 2012, Koff et al., 2009, Paré et al., 
2006, Sicotte et al., 2011, Ure et al., 2012). The frequency of data transmission was 
related to lower compliance rates in one study. Chau et al. (2012) found that patients’ 
compliance rates were high when data were transmitted once per day (98% for oxygen 
saturation and 83% for respiratory rate), but they decreased when the frequency was the 
recommended 3 times a day (79% and 60%, respectively).  
Overall, dropout reasons were related to usability problems (n=2) (Kim et al., 2012, Sund 
et al., 2009) and technical problems with the system or the telephone line (n=3) (Koff et 
al., 2009, Sund et al., 2009, Ure et al., 2012). Other reasons not related to the 
telemonitoring system itself included the occurrence of respiratory exacerbations or illness 
(n=3) (Chau et al., 2012, Dinesen et al., 2012, Kim et al., 2012), relocation (n=2) 
(Antoniades et al., 2012, Trappenburg et al., 2008) and patients’ death (n=4) (Antoniades 
et al., 2012, Lewis et al., 2010, Sicotte et al., 2011, Trappenburg et al., 2008). 
 
Patients’ satisfaction 
Nine studies assessed patient satisfaction with the telemonitoring system (Table 4). 
Studies used quantitative scales/questionnaires (n=5), qualitative interviews (n=1) or both 
(n=2). Only one study did not provide information about how these data were collected. 
Patient satisfaction assessments were conducted face-to-face or through telephone calls. 
Most quantitative data were collected using non-validated scales and none of the studies 
used the same questionnaire. Thus, a meta-analysis could not be performed.  
Overall, patients found the technology easy to learn and/or use (n=7) and useful (n=5). 
Most patients reported that the system improved self-management of their health 
condition, as they: had a better understanding of their disease, symptoms and ways to 
control them; were more involved in their health care; and recognized earlier the signs of 
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exacerbations. In the patients’ perspective, the system also improved the care received 
from healthcare professionals. Patients felt a sense of security and reassurance when 
using the system because they knew their health condition was being monitored and they 
would be contacted if deterioration occurred (n=5). Furthermore, patients reported that the 
system helped them to improve communication with healthcare professionals and 
facilitated the access to professional advice (n=3). Levels of satisfaction were reduced 
regarding the medication prompt (n=2); patients did not find it useful because they already 
took their medication correctly. 
In some studies, open-ended questions provided additional information about the 
difficulties felt by patients when using the systems (n=3). Patients reported the following 
difficulties regarding the device itself: the display screen was too small and words too 
small to read; the touch-screen was difficult to use due to deficits in sensation and poor 
fine motor control; push buttons were too small to manipulate and the button to initiate an 
emergency call too sensitive or the volume was difficult to adjust. In one study, patients 
mentioned that the mobile phone was far too technologically advanced for them and they 
did not know how to operate when unexpected characters were displayed. As a result, 
some patients needed help from their caregiver to transmit the data. Difficulties such as 
determining the precise area to apply the device or using the belt of the respiratory rate 
sensor due to dyspnea or discomfort were also described in 2 studies. 
Some concerns with the system functioning were reported: the batteries of peripheral 
devices were of short-lived duration and needed a long time to charge, power supply 
connection was small and confusing (n=1) and the background noise of the computer fan 
caused some problems in smaller living situations (n=1). Other concerns included the 
uncertainty of data transmission (n=3) and the limited portability of the device (n=1). 
Suggestions to improve the system were given in two studies and consisted of adding a 
blood pressure monitor, ensuring the transmission of clinical data and giving real time 
feedback. 
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Table 4. Patients’ satisfaction with the telemonitoring system. 
First author (year) Measures of patients’ satisfaction Results of patients’ satisfaction 
Antoniades (2012)  Non-validated questionnaire related to: ease of use of 
the system; adequacy of technical support; system 
usefulness for disease management; overall 
satisfaction. 
- Easy-to-use system (94%);  
- Good technical support (100%); 
- Useful to manage the disease (82%);  
- Overall satisfaction (88%). 
Chau (2012)  Quantitative data: Self-developed satisfaction 
questionnaire (1-5 Lickert scale, 5 being the highest 
level of satisfaction) related to: ease of use; level of 
confidence in using the system; acceptability; 
usefulness; satisfaction with nurse support. 
 
 
 
Qualitative data: Open-ended comments. 
 
 
Quantitative data (% or mean±SD): 
- Overall satisfaction (91%); 
- Adequate explanation (86.3%) and understanding (3.50±1.10); 
- Usage difficulties (2.45±0.80); 
- Mediation reminders (60%); 
- Automated healthcare advice (50%) and nurse support (100%) reassuring; 
- Useful to manage the disease (54.5%); 
- Recommend to others (3.14±089). 
Qualitative data: 
- Facilitated timely care and access to professionals to help decide on the best action; 
- Reminders about medication not helpful because patients remembered to take it. 
Difficulties found: 
- Action taken when unexpected characters were displayed (n=5); 
- Instability of data transmission; 
- Small display screen, words, push buttons and power supply; 
- Use of the touch screen, due to decreased sensation and fine motor control; 
- Emergency call button too sensitive; 
- Need of help from caregiver to transmit the data; 
- Use of the belt of respiratory rate sensor (dyspnea, cold water in the winter); 
- Short-lived duration batteries with long time needed to charge. 
Suggestions: add a blood pressure monitor. 
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(table 4 – continued) 
First author (year) Measures of patients’ satisfaction Results of patients’ satisfaction 
 
Dale (2003)  
Satisfaction questionnaire approved by the local 
research and medical ethics committee. 
- Easy-to-use equipment; 
- Health condition well managed; 
- Monitoring service reassuring (no quantitative data reported). 
Kim (2012)  Quantitative data: Tool developed by the research 
team to measure attitude toward the system (4-point 
Lickert scale questions, from “strongly agree” to 
“strongly disagree”): user satisfaction; intention to use 
in the future; preferred cost. 
  
Qualitative data: Open-ended questionnaire. 
Quantitative data: Most patients were “satisfied” or “very satisfied” with the systems. “Agree” or 
“strongly agree” options were higher for the topics: 
- Physical aspect (n=136); 
- Ease to use (n=129); 
- Treatment improvement (n=140) and communication with physician (n=139); 
- Recommendation to others (n=128). 
Qualitative data:  
Difficulties found: 
- Selection of the precise area to apply the device; 
- Incorrectly connection of the device or error of the server; 
- Learning to use the video phone and adjusting the volume; 
- Limited portability of the device. 
Suggestions: Ensure data transmission, give real-time feedback and include blood pressure 
monitors. 
Koff (2009)  Questionnaire about satisfaction with individual pieces 
of the equipment (1-10 Lickert scale: 10 being the 
highest level of satisfaction). 
Satisfaction was very high for all equipments (mean scores 9.6 to 8.5), except for the 
pedometer (4.5), which was not accurate for some patients with gait impairments. 
Lewis (2010a)  NA Most patients found it “helpful” or “very helpful” (88%); 1 patient “neither agreed nor disagreed” 
that it was useful; 1 patient found it “inconvenient”. 
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(table 4 – continued) 
First author (year) Measures of patients’ satisfaction Results of patients’ satisfaction 
Paré (2006)  Questionnaire about satisfaction completed by 
telephone (4-point Lickert scale: 4 being the highest 
level of satisfaction) and related to: ease of use; 
technical support; usefulness. 
Results (mean±SD): 
- Easy-to-use web phone (3.47±1.18); 
- Training (3.76±0.75) and vocabulary used (3.65±0.86); 
- Problems solved within 24h (3.57±1.09); 
- Sense of security (3.35±1.22); 
- Useful for the adoption of new practices to stabilize health condition (3.65±0.86). 
Sicotte (2011)  Validated scale of patient satisfaction (5-point Lickert 
scale: 5 being the highest level of satisfaction). 
Validated scale of the benefits of telemonitoring (5-
point Lickert scale, 1=very little to 5=very good). 
Overall satisfaction (mean±SD, 4.6±0.8): 
- Information quality (4.6±0.5), usefulness (4.2±1.4), presentation (4.9±0.4) and understanding 
(4.6±0.7); 
- Data confidentiality and security (4.4±1.0); 
- Ease of use (4.8±0.4) and learning (4.4±0.9); 
- Frequency of use (4.9±0.3); 
- Technical performance (4.2±0.8); 
Perceived benefits (mean±SD): 
- Reassurance (4.2±1.2); 
- More quickly detection of health deterioration (3.6±1.3) and action when it occurred (4.1±1.3); 
- Medication taken as prescribed (2.5±1.7). 
Ure (2012)  Face-to-face interviews about acceptability of the 
system, specifically: installation; training; use; disease 
management; benefits about care, health 
management, recognition of symptoms and feelings; 
concerns; confidentiality; communication with 
healthcare professionals; recommended changes. 
Most patients found the system easy to use and useful: 
- Earlier recognition of exacerbations; 
- Facilitated access to professional advice; 
- Confidence to respond to health deterioration; 
- Reassurance. 
Difficulties found: 
- Background noise of the computer fan caused problems in smaller living situations; 
- Uncertainty of data transmission. 
NA – No available information; SD – standard deviation.  
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Discussion 
This systematic literature review provided a comprehensive description of the 
methodologies of home telemonitoring interventions in COPD and summarized the 
findings related to patients’ adherence and satisfaction with the use of telemonitoring 
systems. The majority of the articles were published from 2010 to the present, suggesting 
that telemonitoring interventions are a relatively new field in COPD research. Protocols of 
the telemonitoring studies were similar in several aspects such as the training provided to 
patients and the process of data collection and transmission. Studies diverged on the type 
of technology used, telemonitoring duration, and on the provision of prompts, reminders 
and/or feedback. Training was usually provided in the initial home visit. However, this 
training may not have been enough to allow easy use of the systems, as many difficulties 
were encountered. 
With respect to data collection, most studies lacked information about whether data had to 
be inserted manually or if the process was automatic, hindering study replication. 
Furthermore, some of these studies required data collection/transmission at a specific 
time of the day or more than once a day. These options were related to lower compliance 
rates in one study (Chau et al., 2012). The results suggest that the moment and frequency 
of data collection/transmission should be flexible to meet patients’ preferences and 
specific needs. However, the optimal frequency of data collection/transmission has not yet 
been defined in the literature. 
Information on the type of technology used was lacking in some studies. Generally, a 
main device was connected to one or more peripheral devices. Most studies did not 
provide systems with options for adjusting them to each patient, making the use of those 
systems difficult. Some patients identified difficulties in manipulating the devices and in 
viewing the information provided on screen (Chau et al., 2012). According to the review by 
Botsis and Hartvigsen (2008), telemonitoring systems should fulfill the following criteria: i) 
be easy to use; ii) operate without interruptions; and iii) provide security and confidentiality 
of data collected. These criteria were not fully addressed in the included studies, since 
patients were not always comfortable about using the technology to monitor their health 
condition. Furthermore, the difficulties felt by patients may have been a contributor to the 
high dropouts found in some studies, as suggested by Sanders and co-workers in their 
study exploring the factors related to the non-adherence to telemonitoring interventions 
(Sanders et al., 2012). To overcome these difficulties, it has been suggested that patients 
should receive training over a period of several days to help them learn to use the new 
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technology and, therefore, optimize its use (Demiris et al., 2001). As the success of a 
telemonitoring system depends on how well it serves the needs of the target population 
(Demiris et al., 2001), assessment of patients’ acceptance of the system may also be 
useful to avoid dropouts and ensure patients’ compliance. According to the American 
Telemedicine Association (Krupinski et al., 2006), evaluating and tailoring technology 
systems to specific user populations may contribute significantly to reduce technophobia 
among potential users. 
Despite the usability problems, most patients reported that the system provided them with 
a better understanding of their disease and helped them to recognize the earlier signs of 
an exacerbation. These findings support the belief that telemonitoring may improve self-
management of the disease (Fairbrother et al., 2012). According to Bourbeau et al. 
(2004), self-management refers to the various tasks that a person carries out for 
management of their condition, in order to control their disease and improve their well-
being. By helping patients to be aware of their symptoms and act in case of 
exacerbations, home telemonitoring may have facilitated patients’ self-management. 
Furthermore, patients felt secure and reassured when using the system, because they 
knew that they would be contacted if deterioration occurred. The worsening of symptoms 
associated with COPD exacerbations is usually present for days before hospital 
admissions (Kim et al., 2012). Thus, home telemonitoring may be a valuable tool to detect 
these changes sooner and allow an earlier intervention to reduce the severity of 
exacerbations. This is particularly important since exacerbations contribute to the 
deterioration of patients’ clinical status (GOLD, 2013). 
The results of this review showed that patients were overall satisfied with the 
telemonitoring systems. This is an encouraging finding, since one of the aims of home 
telemonitoring is to explore the potential of the monitoring services to provide a continuum 
of care and, therefore, patients’ satisfaction must be high for successful innovations to 
achieve a significant change in practice patterns. However, this positive impact may be 
questionable and even overestimated, since the included studies used poorly constructed 
instruments. According to previous literature (Bolton et al., 2010), the concept of patient 
satisfaction is still not well defined and validated instruments are lacking.  
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Limitations 
The present study has several limitations that need to be acknowledged. First, the study 
was restricted to English, Portuguese and Spanish languages. Although six records 
written in other languages were excluded, they could be relevant for the scope of the 
review. Second, this review included studies which were not specific for patients with 
COPD but had a sub-group of patients with this disease, and/or studies with different 
interventions (telemonitoring alone versus telemonitoring plus other health care 
components). This may have contributed to the differences found between studies. 
Nevertheless, this was deemed necessary to gather all information about the 
methodologies used in home telemonitoring for COPD. Finally, patients’ satisfaction was 
explored regardless of clinical outcomes and healthcare utilization. Thus, it was not 
possible to assume that more satisfied patients were those with improved outcomes and 
reduced healthcare utilization.  
 
Recommendations for future telemonitoring interventions 
This review points out important methodological aspects that should be considered by 
researchers and healthcare professionals when developing home telemonitoring 
interventions for patients with COPD, and it provides recommendations for future 
interventions: 
▪ The inclusion of more training sessions may facilitate patients’ education on the use 
of the systems;  
▪ Assessment of patients’ needs, characteristics and acceptance of the telemonitoring 
technology should be considered prior to its implementation, as it may help adjusting 
the intervention to the target population; 
▪ Studies should consider the inclusion of easy-to-use technology for patients with 
COPD, including those with disabilities;  
▪ The frequency of data collection and transmission should be flexible to improve 
adherence to telemonitoring interventions. As the optimal frequency of data 
collection/transmission has not been set yet, future research should also explore this 
topic; 
▪ The potential of telemonitoring interventions to change patients’ self-management 
behavior, as well as its associations with patient outcomes and healthcare utilization, 
should be explored to improve the evidence on this topic; 
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▪ Patients’ satisfaction with the use of systems should be further explored using more 
robust and validated instruments. Alternatively, a thorough qualitative analysis can be 
conducted to enable an in-depth understanding of patients’ satisfaction and the use of 
that information to improve future technology designs. 
 
Conclusion 
Home telemonitoring interventions are a relatively new field in COPD research. Findings 
suggest that these interventions, although promising, still need to be adjusted to ensure 
their suitability to the target population. This study provides important recommendations 
for future telemonitoring interventions, such as the inclusion of additional training sessions 
to facilitate patients’ education on the use of the systems and the assessment of patients’ 
characteristics and acceptance of the technology prior to its implementation. These 
adjustments are essential before the widespreading of telemonitoring can occur. Future 
research should also investigate the impact of these interventions on patients’ self-
management behavior and satisfaction, and explore their associations with patient 
outcomes and healthcare utilization. 
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Abstract 
Background: This study aimed to: assess step-count accuracy of a piezoeletric 
pedometer (Yamax PW/EX-510), when worn at different body parts, and a triaxial 
accelerometer (GT3X+); compare device accuracy; and identify the preferred location(s) 
to wear a pedometer.  
Methods: Sixty-three healthy adults (45.8±20.6 years old) wore 7 pedometers (neck, 
lateral right and left of the waist, front right and left of the waist, front pockets of the 
trousers) and 1 accelerometer (over the right hip), while walking 120m at slow, self-
preferred/normal and fast paces. Steps were recorded. Participants identified their 
preferred location(s) to wear the pedometer. Absolute percent error (APE) and Bland and 
Altman (BA) method were used to assess device accuracy (criterion measure: manual 
counts) and BA method for device comparisons.  
Results: Pedometer APE was below 3% at normal and fast paces despite wearing 
location, but higher at slow pace (4.5–9.1%). Pedometers were more accurate at the front 
waist and inside the pockets. Accelerometer APE was higher than pedometer APE 
(P<0.05); nevertheless, limits of agreement between devices were relatively small. 
Preferred wearing locations were inside the front right (n=25) and left (n=20) pockets of 
the trousers.  
Conclusion: Yamax PW/EX-510 pedometers may be preferable than GT3X+ 
accelerometers to count steps, as they provide more accurate results. These pedometers 
should be worn at the front right or left positions of the waist or inside the front pockets of 
the trousers.  
 
Key words: actigraphy; dimensional measurement accuracy; exercise; walking. 
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Introduction 
Regular physical activity (PA) is associated with important health benefits (Warburton et 
al., 2006) and may prevent the development and progression of chronic diseases (e.g., 
cardiovascular disease, chronic obstructive pulmonary disease [COPD] (Esteban et al., 
2010, Warburton et al., 2006)). Thus, improving PA levels of healthy and chronic disease 
populations has become a public health priority (World Health Organization [WHO], 2010). 
Since walking is the most common type of exercise (Hootman et al., 2001), international 
PA recommendations using step-count goals have been developed (Garber et al., 2011, 
Tudor-Locke and Bassett, 2004). One simple strategy to monitor these goals is the use of 
pedometers (Bravata et al., 2007). Pedometers are simple and inexpensive motion 
devices that count steps taken and present them on real time, providing immediate 
feedback to the user. They have been used as a motivational tool to improve PA 
behaviours and in PA screening and assessment of interventions (Bravata et al., 2007, 
Tudor-Locke and Bassett, 2004). 
Numerous studies have evaluated the accuracy of diverse pedometers in measuring steps 
(Crouter et al., 2005, Crouter et al., 2003, Le Masurier et al., 2004, Melanson et al., 2004) 
and they concluded that accuracy was lower at slower speeds, particularly in pedometers 
using a spring-suspended horizontal lever arm mechanism (Crouter et al., 2005, 
Melanson et al., 2004). As these pedometers had to be worn in a vertical position on a 
belt/waistband, body composition and pedometer tilt could influence pedometer accuracy 
(Crouter et al., 2005). To overcome this problem, pedometers with a piezoelectric 
technology (e.g., Yamax PW/EX-510) were developed. These pedometers may be used in 
non-traditional wearing locations, e.g. inside the pockets or around the neck. 
Nevertheless, there are still few studies exploring the impact of wearing positions on 
accuracy of piezoelectric pedometers (De Cocker et al., 2012, Hasson et al., 2009, 
Holbrook et al., 2009). Furthermore, pedometers may have low acceptance when 
attached to certain body parts or clothing (de Bruin et al., 2008) or when used in certain 
situations (e.g., when wearing a dress) (Gardner and Campagna, 2011). This issue has 
been scarcely explored in previous validation studies, despite its importance to improve 
user acceptance (de Bruin et al., 2008). 
In addition to pedometers, the use of triaxial accelerometers (e.g., GT3X+) to objectively 
assess PA has increased in recent years (Trost and O'Neil, 2014). Triaxial accelerometers 
are motion devices that measure acceleration in 3 planes during body movement (Strath 
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et al., 2013). Many accelerometers have also a step-count function, though most of them 
do not provide feedback (Bassett and John, 2010). Hence, they are intended to measure 
PA rather than to motivate individuals to exercise. Accelerometers are often preferred in 
research and clinical settings because they provide more information than pedometers, 
e.g. frequency, duration and intensity of PA (Strath et al., 2013). They have shown good 
validity with regard to activity counts and energy expenditure in healthy and chronic 
disease populations (Santos-Lozano et al., 2013, Van Remoortel et al., 2012); however, 
their step-count accuracy has not been extensively investigated, with most studies being 
conducted in the last 5 years (Barreira et al., 2013a, Barreira et al., 2013b, Connolly et al., 
2011, Van Remoortel et al., 2012, Webber et al., 2014, Tudor-Locke et al., 2015). 
Assessment of accelerometer step-count accuracy along with pedometer accuracy is 
fundamental to enable comparisons among studies using different motion devices. 
This study aimed to: (1) assess step-count accuracy of a piezoeletric pedometer (Yamax 
PW/EX-510), when worn at different body parts, and a triaxial accelerometer (GT3X+); (2) 
compare device accuracy; and (3) identify user’s preferred location(s) to wear a 
pedometer. 
 
Methods 
Design 
This prospective cross-sectional study was conducted as part of a larger study 
(www.clinicaltrials.gov, NCT02122614). Ethical approval was obtained from the Central 
Regional Health Administration (2011-02-28), Hospital Centre (34428) and National Data 
Protection Committee (9250/2012, 2012-11-06). 
 
Participants 
Sixty-three healthy adults volunteered to participate in the study. They were included if the 
following criteria were met: (1) ≥18 years old; (2) able to walk independently without a 
walking aid; and (3) able to understand the purpose and procedures of the study. 
Participants were excluded if they presented severe cardiovascular, neurological, 
respiratory, musculoskeletal or psychiatric disorders or severe visual/hearing impairment. 
Written informed consent was obtained according to the Declaration of Helsinki. 
  
 
Chapter 4 
89 
 
 
 
Socio-demographic and anthropometric (height, weight) data were collected to 
characterise the sample. The performance of the Yamax PW/EX-510 pedometer (Yamasa 
Tokey Keiki Corporation, Tokyo, Japan) and the GT3X+ accelerometer (ActiGraph, 
Pensacola, FL) was then assessed. 
 
Instruments 
The Yamax PW/EX-510 is a lightweight pedometer with a triaxial sensor and a visual 
display to present on real time the estimated step counts, energy expenditure, fat burn, 
distance and activity time. For this study, only step counts were considered. This 
pedometer has an 11-step filter (i.e., if a person moves less than 11 steps and take about 
5s without moving, those steps are not counted) to recognise actual walking activity and a 
30-day and 30-week memory function that enables the user to recall steps. The user’s 
weight and stride length must be entered before using the pedometer. 
The GT3X+ accelerometer has also an embedded triaxial sensor that detects acceleration 
in 3 planes. After initialisation, the device collects and stores PA data which can be further 
downloaded and converted into time-stamped activity counts, step counts, energy 
expenditure and body postures, using specific software (Actilife – ActiGraph, Pensacola, 
FL). The accelerometer does not have a visual display to provide the user with real-time 
data. 
 
Procedures  
This study followed the international recommendations for pedometer testing (Strath et al., 
2013): (1) pedometers should be tested during walking at slow, moderate and fast paces; 
and (2) pedometer accuracy should be assessed by manually counting steps (criterion 
measure) over a 100- to 200-meter course and then comparing pedometer steps and 
manual counts. To perform the tests, participants were required to use trousers with front 
side pockets and flat shoes (except flip-flops). They were instructed to walk 120m in a 
straight 20-meter corridor while wearing 7 pedometers and 1 accelerometer. Pedometers 
were worn simultaneously at different body parts: 1 around the neck suspended from a 
lanyard; 2 attached with a belt clip at the lateral right and left (midaxillary line) sides of the 
waist and 2 attached at the front right and left (midclavicular line) sides; 2 in the front (right 
and left) pockets of the trousers. Universal belt clips were used to attach the pedometers 
at the waist. Before data collection, one researcher entered participant’s weight and stride 
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length in each pedometer. Stride length was measured by asking patients to walk 10 
steps in a straight corridor marked with a measuring tape and dividing the total distance 
per 10 (e.g., 6.0m/10 steps=0.60m). The accelerometer was worn on a waistband over the 
right hip, according to the manufacturer recommendations and the results from a recent 
study (Tudor-Locke et al., 2015). It was initialised before data collection (30Hz) using 
ActiLife v6.7.2. 
The test (i.e., walking 120m) was performed at 3 different paces in a random order: slow, 
self-preferred (normal) and fast pace. For slow pace, participants were asked to walk 
slowly as if they were taking a walk. For normal pace, participants were instructed to walk 
at their usual speed. For fast pace, they were asked to walk as if they were late to an 
appointment. Trials were repeated twice at two proximal occasions. All trials were 
recorded using video-recordings. One researcher counted every step taken during trials 
with a digital tally counter (criterion measure) and recorded trial duration using a 
stopwatch. At the end of each trial, the researcher registered step counts of each 
pedometer. Pedometers were then set to zero for the next trial. To ensure researcher 
blinding, manual counts were recorded before registering pedometer steps. Only in case 
of doubt the researcher signalled the trial of interest and reviewed the video-recording. As 
the accelerometer does not provide real time data, the researcher recorded the start time 
of each trial to allow its identification in the data downloaded. Data were downloaded in 1-
by-1s epochs using Actilife v6.7.2. 
After completing the tests, participants’ opinion about the most and least preferred 
locations to wear a pedometer was collected. They could choose up to 3 wearing 
locations (without order of preference). 
  
Statistical analysis 
Descriptive statistics were conducted to characterise the sample. The average walking 
speed (trial 1) was calculated for each pace using the equation 1:  
Speed (km/h)=0.120 (km)/time (h) (1) 
where 0.120km is the total distance walked and time is the duration of each trial.  
Accuracy of pedometers and accelerometer was analysed by comparing their estimated 
steps with manual counts (trial 1) and consistency of measurement error was assessed by 
comparing the results of the same device on trials 1 and 2. The absolute percent error 
(APE) was calculated for each device at each walking pace as follows (equation 2):  
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APE=(|device steps-observed steps|/observed steps)*100 (2) 
APE absolute value was used to avoid that positive and negative values cancelled each 
other out when calculating average APE. Values closer to zero indicated more accurate 
results and an APE below 3% has been considered acceptable (Crouter et al., 2003, 
Holbrook et al., 2009). 
Normality of data was assessed with the Kolmogorov-Smirnov test. Differences in 
accuracy of devices were analysed with a repeated measures analysis of variance 
(ANOVA), for each walking pace. If a significant difference was detected (P<0.05), post-
hoc analyses were conducted. Consistency of measurement error was assessed using 
paired samples t-tests. APE was used instead of step counts to account for individual 
variability (i.e., number of steps may vary among individuals even in a well-controlled 
environment). 
The Bland and Altman (BA) method (Bland and Altman, 1986) was used to assess 
agreement between estimated steps and manual counts (trial 1). Mean of the differences 
and tight agreement intervals around 0 suggested more accurate results. The BA method 
was also used to examine agreement between pedometer- and accelerometer-estimated 
steps. Positive values indicated that pedometer presented higher values than 
accelerometer. 
Data concerning participants’ most and least preferred locations to wear a pedometer 
were converted into frequencies. When participants identified more than 1 preferred 
location, all answers were considered.  
Statistical analyses were performed using SPSS v20.0 (IBM Corp., Armonk, NY) and 
GraphPad Prism v5.0 (GraphPad Inc., La Jolla, CA, USA). 
 
Results 
Participants 
Participants had a mean age of 45.8±20.6 years (range 20-86) and body mass index of 
25.2±4.3kg/m2, mostly female (n=42, 66.7%). The average speed performed in slow, 
normal and fast paces was 3.3±0.6km/h, 4.4±0.7km/h and 5.5±0.7km/h, respectively. The 
number of steps recorded manually and through pedometers and accelerometer is 
presented in Table I.  
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Table I. Number of steps collected manually and through the pedometers (worn at different body parts) and 
the accelerometer, at 3 walking paces. 
 Slow pace Normal pace Fast pace 
Manual count (steps) 215.0±23.8 189.2±22.2 172.2±20.2 
Pedometer (steps)    
Neck 196.6±37.1 185.4±19.6 168.8±18.1 
Lateral right 195.3±36.0 186.8±20.7 169.9±19.1 
Front right 201.5±32.3 186.8±20.6 170.1±18.7 
Right pocket 202.2±31.6 187.1±20.5 170.1±18.7 
Lateral left 200.6±34.5 186.2±21.1 169.4±18.6 
Front left 202.4±29.9 187.0±20.9 169.9±19.5 
Left pocket 206.8±20.7 186.9±19.7 170.5±19.9 
Accelerometer (steps) 175.5±38.7 179.1±16.9 164.5±15.3 
 
 
Device accuracy 
Absolute percent error 
Table II presents the APE of pedometers and accelerometer on trials 1 and 2. On trial 1, 
the mean APE of pedometers was below 3% at normal and fast paces, despite wearing 
location. The performance was poorer at slow pace (mean APE>4%). When comparing 
locations, accuracy was improved (i.e., mean and standard deviation were the smallest) 
for pedometers located at the front right and left of the waist, at all paces (Table II). 
Pedometers inside the pockets also showed a high performance, with the pedometer of 
the left pocket presenting the lowest APE at slow pace (4.5±7.7%). Despite that, 
differences among pedometer APE were only significant between pedometers worn 
around the neck and attached to the front left of the waist, the latter presenting a lower 
APE (1.9±2.1% vs. 1.2±1.4%, P=0.006). 
The accelerometer presented a high APE, ranging from 16.8±19.4% at slow pace to 
3.9±2.9% at fast pace. 
Regarding consistency of measurement error, no significant differences were found 
between APEs of pedometers (P>0.05), irrespective of wearing location. The same results 
were found for the accelerometer (P>0.05, Table II).  
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Table II. Absolute percent error (APE) of steps registered by the pedometers worn at different body parts and 
the accelerometer, at 3 walking paces (results from trials 1 and 2).  
 Slow pace Normal pace Fast pace 
 
APE (%) 
mean, SD 
APE (%) 
mean, SD 
APE (%) 
mean, SD 
 Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 
Pedometer       
Neck 9.0±17.2 8.8±18.1 1.9±2.1a 1.8±1.8 1.9±1.8 1.9±1.8 
Lateral right 9.1±16.5 7.0±13.7 1.6±1.5 1.9±2.5 1.5±1.5 1.8±2.3 
Front right 6.8±12.9 5.7±12.1 1.3±1.3 1.5±2.4 1.3±1.4 1.4±2.1 
Right pocket 6.3±12.7 5.7±14.7 1.2±1.7 1.6±3.4 1.8±1.9 1.4±1.8 
Lateral left 6.9±14.1 6.2±12.3 1.9±3.4 3.1±11.7 1.6±2.3 1.4±1.9 
Front left 5.8±11.0 5.3±12.1 1.2±1.4a 1.3±2.3 1.4±1.9 1.2±1.7 
Left pocket 4.5±7.7 3.4±9.1 1.7±2.9 1.8±2.3 1.7±1.9 1.7±2.3 
Accelerometer  16.8±19.4b 15.7±19.4 4.6±2.6b 4.6±3.1 3.9±2.9b 3.8±3.5 
aDifferences between APE of the pedometers were significant (P=0.006). bDifferences between the APE of all 
pedometers and the accelerometer on trial 1 were significant at slow pace (0.001<P<0.043), and at normal 
and fast paces (P<0.001). Abbreviations: APE, absolute percent error; SD, standard deviation. 
 
Bland and Altman method 
Table III presents the mean of the differences between manual counts and device-
estimated steps and the LoA. An excellent level of agreement was found for all 
pedometers at normal and fast paces, except for the pedometer around the neck which 
presented poorer agreement (i.e., higher mean difference and wider LoA). At slow pace, 
the mean difference between manual counts and pedometer-estimated steps was high 
(from -6.7 to -19.8 steps) and the LoA were wide, despite wearing location. Overall, better 
agreement results were found for pedometers located at the front right and left of the waist 
and inside the pockets.  
The accelerometer showed the highest mean of the differences and the widest LoA, at all 
walking paces (Table III). 
 
Table III. Mean of the differences between manually-counted and device-estimated steps and limits of 
agreement, at 3 walking paces. 
 Slow pace Normal pace Fast pace 
 
Meandiff 
(steps) 
LoA (steps) 
Meandiff 
(steps) 
LoA (steps) 
Meandiff 
(steps) 
LoA (steps) 
Pedometer       
Neck -18.5 -100.6 ‒ 63.7 -3.8 -13.2 ‒ 5.6 -3.4 -10.4 ‒ 3.6 
Lateral right -19.8 -94.9 ‒ 55.3 -2.3 -9.6 ‒ 5.0 -2.3 -8.3 ‒ 3.7 
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(table III – continued) 
 Slow pace Normal pace Fast pace 
 
Meandiff 
(steps) 
LoA (steps) 
Meandiff 
(steps) 
LoA (steps) 
Meandiff 
(steps) 
LoA (steps) 
Front right -13.5 -71.4 ‒ 44.4 -2.4 -8.1 ‒ 3.3 -2.1 -7.9 ‒ 3.7 
Right pocket -11.2 -69.3 ‒ 46.8 -1.1 -9.2 ‒ 6.9 -1.1 -10.3 ‒ 8.1 
Lateral left -14.4 -75.3 ‒ 46.4 -3.0 -16.4 ‒ 10.4 -2.9 -11.9 ‒ 6.2 
Front left -12.7 -61.9 ‒ 36.5 -2.2 -8.1 ‒ 3.7 -2.2 -9.6 ‒ 5.1 
Left pocket -6.7 -48.4 ‒ 35.0 -1.4 -15.6 ‒ 12.8 -1.6 -9.5 ‒ 6.3 
Accelerometer  -38.5 -137.4 ‒ 60.4 -9.1 -21.2 ‒ 3.1 -6.8 -19.1 ‒ 5.4 
 Abbreviations: Meandiff, mean of the differences (i.e., observed steps – device steps); LoA, limits of 
agreement. 
 
Comparison between devices 
When comparing the two devices, the accelerometer presented a significantly higher APE 
than pedometers, regardless of wearing location (0.001<P<0.043, Table II). The 
accelerometer recorded a lower number of steps than pedometers, with the mean of the 
differences ranging from 19.7 to 29.2 steps at slow, 5.7 to 7.7 steps at normal, and 3.5 to 
5.8 steps at fast pace (Table IV). Even though, the LoA were relatively small at normal 
and fast paces. 
 
Table IV. Mean of the differences between pedometer and accelerometer step counts and limits of 
agreement, at 3 walking paces.  
 Accelerometer 
 Slow pace Normal pace Fast pace 
 Meandiff 
(steps) 
LoA (steps) 
Meandiff 
(steps) 
LoA (steps) 
Meandiff 
(steps) 
LoA (steps) 
Pedometer       
Neck 21.6 -76.4 ‒ 119.5 5.7 -4.2 ‒ 15.5 3.5 -5.7 ‒ 12.7 
Lateral right 19.7 -60.7 ‒ 100.0 6.9 -4.6 ‒ 18.4 4.7 -7.0 ‒ 16.2 
Front right 26.6 -59.6 ‒ 112.7 6.8 -3.6 ‒ 17.2 4.9 -4.9 ‒ 14.7 
Right pocket 26.2 -50.8 ‒ 103.2 7.7 -4.0 ‒ 19.3 5.8 -7.4 ‒ 18.9 
Lateral left 26.3 -64.2 ‒ 116.8 6.2 -8.8 ‒ 21.1 4.1 -5.7 ‒ 13.8 
Front left 28.3 -63.1 ‒ 119.7 7.0 -3.6 ‒ 17.6 4.7 -5.2 ‒ 14.5 
Left pocket 29.2 -37.5 ‒ 95.9 7.4  -4.7 ‒ 19.4 5.4 -7.7 ‒ 18.5 
Abbreviations: Meandiff, mean of the differences (i.e., pedometer steps – accelerometer steps); LoA, limits of 
agreement.  
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Pedometer preferred locations 
According to participants’ opinion, the best locations to wear the pedometer were inside 
the right (n=25) and left (n=20) pockets of the trousers (Figure 1). The neck was reported 
both as one of the most (n=17) and least (n=15) preferred locations. Other least preferred 
locations were the lateral right and left positions of the waist (n=21 each) and the front 
right and left positions of the waist (n=16 each). 
 
Figure 1. Participants’ opinion about the most and least preferred locations to wear the pedometer 
(participants could choose more than 1 preferred location up to 3, without order of preference). 
 
Discussion 
Pedometers Yamax PW/EX-510 were highly accurate in quantifying steps at normal and 
fast walking paces, but less accurate at slow pace. Pedometers worn at the front right and 
left of the waist and inside the pockets of the trousers were the most accurate. The latter 
was also the most preferred location to wear the pedometer. The GT3X+ accelerometer 
underestimated the steps when compared to manually-counted and pedometer steps. 
Findings support the use of pedometers for measuring ambulatory activity using step 
counts. 
Accuracy of pedometers was low at slow pace, despite wearing location. Similar results 
have been described in validation studies using other piezoelectric pedometers (De 
Cocker et al., 2012, Holbrook et al., 2009), suggesting that caution should be taken when 
using this type of technology in slow walking populations (e.g., older adults (Prince et al., 
1997) and patients with neurological disorders (Busse et al., 2006)). Nevertheless, 
piezoelectric pedometers have shown lower measurement errors than those using a 
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spring-suspended lever arm mechanism, particularly at slower speeds (Crouter et al., 
2005, Melanson et al., 2004). Thus, pedometers with a piezoelectric mechanism should 
be preferred particularly when used by individuals who naturally ambulate at slower 
speeds. In controlled conditions, a 3% is frequently considered an acceptable 
measurement error (Crouter et al., 2003, Holbrook et al., 2009). Other studies have 
suggested that a maximum error of 5% (De Cocker et al., 2012, Vincent and Sidman, 
2003) or 10% (Crouter et al., 2003) can be accepted for slower speeds. In this study, the 
average measurement error of pedometers was approximately 4.5-9.1%, thus they may 
be considered fairly accurate. 
Pedometers were more accurate when worn at the front right and left of the waist and 
inside the pockets. These results were consistent among trials. Therefore, individuals 
should be provided with these two wearing options when using Yamax PW/EX-510 
pedometers. Since some individuals have reported difficulties in deciding where to use the 
pedometer in certain situations (e.g., when using clothing without pockets) (Gardner and 
Campagna, 2011), this finding may improve users’ acceptance of pedometers. 
Furthermore, pockets were identified as a preferred location to wear the pedometer, thus 
this option may enhance pedometer use in daily living. 
Pedometer worn around the neck was reported as both one of the most and least 
preferred locations. Although this is one of the manufacturers’ recommended positions, 
results suggest that it may not be advisable since it was one of the locations with lower 
accuracy and agreement results. Reasons for these findings are not clear, however, it is 
possible that lack or excess of movement of the upper body during walking may have 
produced over- or under-oscillation of the pedometer, leading to higher measurement 
error. Previous validation studies using other piezoelectric pedometer brand have shown 
opposite findings, with pedometers around the neck providing the most accurate results 
(De Cocker et al., 2012, Hasson et al., 2009). This finding reinforces the need to test 
different pedometer models before using them, as recommended in international 
guidelines (Strath et al., 2013). 
The GT3X+ accelerometer provided poorer accuracy and agreement results than 
pedometers, although differences between devices and LoA were relatively small at 
normal and fast paces. Previous research supports these findings. Studies conducted in 
specific populations (i.e., pregnant women, overweight and obese adults, older adults 
with/without walking aids) have shown that pedometers (either with a piezoelectric or a 
lever arm mechanism) present higher step-count accuracy results than the GT3X+ 
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(Barreira et al., 2013a, Barreira et al., 2013b, Connolly et al., 2011, Webber et al., 2014), 
particularly when walking at slower speeds (Connolly et al., 2011, Webber et al., 2014). 
Therefore, caution must be taken when comparing step counts of studies that have 
employed different types of motion devices, since their findings may differ. Likewise, the 
choice of the motion device should be based on a number of factors, including: 
(1) Need for PA feedback – since pedometers provide feedback to the user, they may be 
more appropriate in self-monitoring interventions (Strath et al., 2013, Trost and O'Neil, 
2014). Conversely, if individuals must be blinded, then accelerometers may be 
chosen as most of them do not provide this feedback function (Bassett and John, 
2010); 
(2) Type of outcomes – accelerometers capture the frequency, duration and intensity of 
human movement, providing a more detailed analysis of daily PA (Strath et al., 2013, 
Trost and O'Neil, 2014). Hence, they may be valuable in PA screening or assessment 
of PA interventions; 
(3) Cost – pedometers may be preferred to accelerometers in simple studies measuring 
only step counts, due to their lower cost (Strath et al., 2013) and high accuracy (as 
found in the present study). 
 
Strengths and limitations 
This study has several strengths that should be acknowledged. Overground walking was 
chosen instead of treadmill walking to reflect daily ambulatory activity. Nevertheless, it 
was not possible to control walking speed throughout the tests. Participants’ opinion about 
the most and least preferred locations to wear the pedometer was a novel and important 
finding, as it may influence people’s adherence in using pedometers on a daily basis. 
Finally, validation of Yamax PW/EX-510 pedometer was innovative, since previous 
studies validating piezoelectric pedometers have been mostly limited to Omron models 
(De Cocker et al., 2012, Hasson et al., 2009, Holbrook et al., 2009, Wallmann-Sperlich et 
al., 2015, Zhu and Lee, 2010). This pedometer has additional features that may be 
valuable in motivating individuals to be more physically active (e.g., 30-day and 30-week 
memory function). This should be further explored. 
This study had also several limitations. One limitation concerns to the fact that only step 
counts were considered. Since both devices are able to provide additional parameters, 
these should be validated in future research. The context of validation tests (i.e., 
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controlled conditions) was another limitation. Tests conducted under free-living conditions 
are warranted to fully capture the potential of motion devices to detect human activity. 
Lastly, all tests were performed in healthy adults which may limit the generalisability of 
findings. Nevertheless, previous validation studies conducted in healthy and chronic 
disease populations concluded that pedometer accuracy was similar between samples 
when walking at different speeds (Furlanetto et al., 2010, Turner et al., 2012). 
 
Conclusions 
Findings suggest that Yamax PW/EX-510 pedometers may be preferable than GT3X+ 
accelerometers to count steps, as they provide more accurate results. These pedometers 
should be worn at the front right or left positions of the waist or inside the front pockets of 
the trousers. The latter was considered the most preferred location to wear the 
pedometer. 
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Abstract 
Objectives: This study aimed to investigate whether providing feedback on physical 
activity (PA) levels to patients with Chronic Obstructive Pulmonary Disease (COPD) is 
feasible and enhances daily PA during pulmonary rehabilitation (PR). 
Methods: Patients with COPD participated in a 12-week PR program. Daily PA was 
measured using activity monitors on weeks 1, 7 and 12 and feedback was given in the 
following weeks, including: number of steps; time spent in sedentary, light and moderate-
to-vigorous intensity activities; time spent standing, sitting and lying. Compliance with PA 
monitoring was collected. Two focus groups were conducted to obtain patients’ 
perspectives on the use of activity monitors and feedback given. Differences in PA data 
were also assessed. 
Results: Sixteen patients (65.63±10.57 years; FEV1 70.31±22.74pp) completed the study. 
Eleven participants used the activity monitors during all monitoring days. Participants 
identified problems regarding the use of activity monitors and monitoring duration. Daily 
steps (p=0.026) and standing time (p=0.030) were improved from weeks 1–7, however, 
the former declined from weeks 7–12.  
Conclusions: Using feedback to improve PA during PR is feasible and results in 
improved daily steps and standing time on week 7. The subsequent decline suggests that 
additional strategies may be needed to stimulate/maintain PA improvements. Further 
research with more robust designs is needed to investigate the impact of feedback on 
patients’ daily PA. 
 
Keywords: Accelerometer; Chronic Obstructive Pulmonary Disease; Exercise; 
Monitoring; Physical activity; Rehabilitation. 
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Introduction 
Low levels of physical activity (PA) have been associated with increased healthcare 
utilization and reduced survival in patients with Chronic Obstructive Pulmonary Disease 
(COPD) (Garcia-Aymerich et al., 2006). Thus, improving PA levels has become one of the 
main goals of COPD research (Ng et al., 2012, Spruit et al., 2013). 
Pulmonary rehabilitation (PR) is an evidence-based intervention which includes exercise 
training, education and psychosocial support (Spruit et al., 2013). The exercise training 
component has been shown to improve exercise capacity and reduce dyspnea (Vestbo et 
al., 2013); however, its effects in increasing PA levels are limited (Ng et al., 2012). A 
recent study showed that although a 3-month PR program increased patients’ exercise 
capacity and quality of life, changes in daily PA were restricted to a marginal improvement 
in walking intensity (Pitta et al., 2008). The authors suggested that patients would likely 
require longer programs to increase their time spent actively (Pitta et al., 2008). 
Alternatively, PA levels may be enhanced by including behavior strategies in PR programs 
(Spruit et al., 2013). One strategy consists of increasing patients’ awareness of their 
actual PA levels (Troosters et al., 2010). In healthy adults, awareness of individual PA is a 
potential determinant of the intention to increase PA levels (Ronda et al., 2001). As 
patients with COPD tend to overestimate their PA levels (Pitta et al., 2005), making them 
aware of their actual levels may contribute to improve patients’ PA. For this purpose, 
activity monitors can be a valuable tool because they provide objective information about 
PA which can be then delivered to the patient. However, the effective contribution of 
activity monitors to increase PA levels of patients with COPD is still unclear, with the few 
existing studies showing conflicting results (de Blok et al., 2006, Hospes et al., 2009, 
Steele et al., 2008). Differences in the devices used, PA monitoring protocols and 
interventions may explain in part these discrepancies, but patients’ compliance with PA 
monitoring and their experience with the activity monitors may have contributed as well. 
These aspects are key elements to ensure feasibility of interventions involving PA 
monitoring and feedback; nevertheless, they have been understudied in COPD research 
(Troosters, 2009). Before the widespread utilization of this technology on a larger scale, 
its feasibility should be investigated. Therefore, this study aimed to investigate whether 
providing feedback on PA levels to patients with COPD, using activity monitors, is feasible 
and enhances patients’ daily PA during PR. 
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Methods 
Design 
This was a feasibility study with a mixed methods design. The study received full approval 
from the Institutional Ethics Committee. 
 
Participants  
Patients with COPD were recruited in two primary care centers of the central region of 
Portugal (Aveiro). General practitioners informed eligible patients about the study and 
asked their willingness to participate. Inclusion criteria were: (a) being 18 years old or 
older; (b) having a diagnosis of COPD according to the GOLD criteria (Vestbo et al., 
2013); and (c) presenting clinical stability for one month prior to the study (no hospital 
admissions or exacerbations). Patients were excluded if they: (a) presented severe 
psychiatric, neurologic or musculoskeletal conditions and/or unstable cardiovascular 
disease; or (b) were engaged in regular exercise before the study. Patients who agreed to 
participate were contacted by the researchers. Detailed information about the study was 
provided and written informed consent was obtained before data collection. 
 
Intervention 
The intervention was conducted between April and July and consisted of a 12-week PR 
program with exercise training (three times per week, 60 min/session) and 
psychoeducation (once per week, 90 min), plus the provision of feedback on PA levels to 
participants. Exercise training sessions included:  
▪ A warm-up period (5-10 min) with range-of-motion, stretching, low-intensity aerobic 
exercises and breathing techniques; 
▪ Endurance training (20 min walking) at 60-80% of the six-minute walk test (6MWT) 
average speed (Jenkins, 2007), with intensity adjusted to patient’s fatigue/dyspnea 
(4-6 in the Modified Borg Scale (Spruit et al., 2013)); 
▪ Strength training (15 min) including seven exercises (two sets, 10 repetitions/set) of 
the major upper and lower limbs muscle groups, at 50-85% of the 10 repetition 
maximum (10-RM) (Nici et al., 2006). Progression was based on the two-for-two rule  
(American College of Sports Medicine, 2009); 
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▪ Balance training (5 min) with static and dynamic exercises organized in progressive 
levels of difficulty (Chodzko-Zajko et al., 2009); 
▪ A cool-down period (10 min) similar to the warm-up. 
The psychoeducation component included educational and supportive modules regarding: 
information about COPD; breathing and energy conservation techniques; adoption of 
healthy lifestyles (exercise, nutrition, sleep habits); emotion-management strategies; and 
community resources. 
PA was monitored during the first (W1), seventh (W7) and 12th (W12) weeks of the PR 
program using the activity monitors GT3X+ (ActiGraph, Pensacola, FL) and feedback to 
participants was given in the following weeks. As these devices did not provide automatic 
feedback to participants, researchers analyzed the information collected and summarized 
it. Feedback was given by one of the health professionals conducting the PR program and 
lasted 15-20 minutes. Feedback about W1 and W7 was given at the end of the exercise 
training session of the following week (W2 and W8, respectively); feedback about W12 
was given in the week following program completion. Each participant received written 
(graphical) and verbal information about: (a) time spent standing, sitting and lying on each 
day of the week; (b) a weekly average of the number of daily steps and of time engaged in 
sedentary, light and moderate-to-vigorous intensity activities. On W1, participants were 
instructed to maintain their routine to establish a baseline of their activity levels and 
received verbal and written instructions on how to use the device. When receiving 
feedback of W1, participants were informed about the recommended values of PA for 
healthy people (≥150 min/week or ≥30 min/day of moderate intensity activities, ≥75 
min/week or ≥20 min/day of vigorous intensity activities or a combination of both, 
performed continuously or accumulated in bouts of at least 10 min; 7000-10,000 steps/day 
(Garber et al., 2011)). Although feedback was given in group, each participant received 
individualized recommendations to improve or maintain their PA levels regarding the time 
spent in moderate-to-vigorous intensity activities and number of steps per day, based on 
the results of the previous week. They also received general recommendations to improve 
daily PA and a leaflet with exercises similar to those of the exercise training component. 
Feedback of W7 and W12 was similar to W1. 
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Data collection 
Participants’ characteristics 
Socio-demographic data were collected before the intervention to characterize the 
sample. Lung function was assessed with a portable spirometer (MicroLab 3500, 
CareFusion, Kent) according to the guidelines (Miller et al., 2005). All participants took 
their usual prescribed medications before performing the lung function test. COPD grade 
and severity (ranging from group A - low risk, less symptoms - to group D - high risk, more 
symptoms) were determined in accordance with the GOLD criteria (Vestbo et al., 2013). 
Patients’ breathlessness was measured using the Modified Medical Research Council 
Dyspnea Scale (Doherty et al., 2006). Exercise capacity was assessed with the maximal 
distance walked on the 6MWT (Jenkins, 2007). Two tests were performed according to 
the American Thoracic Society guidelines (2002). The best performance was reported and 
related to the reference values (Troosters et al., 1999). 
  
Feasibility measures 
Patients’ compliance with the use of activity monitors (number of days wearing the device, 
time per day) and reasons for non-compliance were collected. In the week following the 
intervention, two focus groups were conducted in Portuguese to evaluate patients’ 
perspectives on the use of activity monitors and feedback given. Each focus group lasted 
approximately 30 minutes and was audio-recorded for further transcription and analysis.  
  
Physical activity 
Daily PA was assessed using the activity monitors GT3X+ (already validated in COPD 
population (Rabinovich et al., 2013, Van Remoortel et al., 2012)) on W1, W7 and W12 of 
the PR program. Participants were instructed to wear the device for seven consecutive 
days during waking hours (except when bathing or swimming) and informed about its 
correct positioning: at the waist on an elastic belt, at the anterior axillary line of the right 
hip. Data were then downloaded using Actilife version 6.7.2 (ActiGraph, Pensacola, FL). 
Since five or more days of measurement are required to reliably assess PA in COPD 
(Watz et al., 2009), patients with less than five days in one of the time points were 
excluded from PA analysis. A valid day was defined as at least 8 hours of wearing time 
(Demeyer et al., 2014). Daily PA was calculated using the algorithms incorporated in the 
software and included: (a) number of steps; (b) time spent in sedentary, light and 
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moderate-to-vigorous intensity activities; and (c) time spent standing, sitting and lying. 
Cut-points for PA intensity were defined as: sedentary (0-99 counts-per-minute [CPM]), 
light (100-1951 CPM) and moderate-to-vigorous intensity activities (1952-∞ CPM) 
(Freedson et al., 1998). Since an increase in exercise capacity might facilitate increases in 
PA (Zwerink et al., 2013), the 6MWT was also performed in the week following program 
completion to assess intervention-related differences. 
 
Data analysis 
Participants’ characteristics 
Descriptive statistics were used to characterize the sample. Baseline measurements of 
completers and dropouts were compared using independent t-tests for normally 
distributed data, Mann Whitney U-tests for ordinal/non-normally distributed data, and Chi-
square tests for categorical data. The normality of data was investigated with the Shapiro–
Wilk test. A similar analysis was conducted to compare baseline measurements of 
patients with complete and incomplete PA assessment (i.e., patients with seven PA 
monitoring days vs. those without seven monitoring days). 
 
Feasibility measures 
The number of monitoring days missed by patients and wearing time was calculated and 
reasons for non-compliance analyzed. Focus group analyzes were conducted by two 
independent researchers using the procedures suggested by Ulin (2005): (a) reading and 
rereading the transcripts; (b) identifying possible themes; (c) displaying the information 
relevant to each theme; (d) reducing the information to its essential points; and (e) 
identifying its core meaning. Any disagreements were resolved by consensus.  
  
Physical activity 
Differences in PA data among the three time points were assessed using a repeated-
measures analysis of variance (ANOVA) and pairwise comparisons were performed 
whenever statistical significance (p<0.05) was reached. Effect sizes (ES) were computed 
using the eta squared (ƞ2), interpreted as: 0.01 small, 0.06 medium and 0.14 large effect 
(Cohen, 1988). Observed power was also calculated. A paired t-test was used to assess 
differences in the six-minute walking distance (6MWD) of participants before and after the 
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intervention. Analyzes were conducted using SPSS version 20.0 (IBM Corp., Armonk, 
NY).  
 
Results 
Participants 
Twenty patients entered the study. However, four were lost due to non-COPD health-
related problems (n=2), changes in work schedule (n=1) and no reasons given (n=1). 
Sixteen participants completed the intervention. Their baseline characteristics are 
presented in Table 1. There were no significant differences between completers and 
dropouts (p>0.05).  
 
Table 1. Participants’ characteristics (n=16). 
Characteristics   
Age (years) 65.63±10.57 
Male 11 (68.8%) 
Educational level  
 Primary education 9 (56.2%) 
Secondary education 4 (25.0%) 
Higher education/University 3 (18.8%) 
Current occupation  
Employed 4 (25.0%) 
Retired 12 (75.0%) 
BMI (Kg/m2) 30.37±4.12 
FEV1% predicted 70.31±22.74 
COPD grade  
Mild 5 (31.2%) 
Moderate 8 (50.0%) 
Severe to very severe 3 (18.8%) 
GOLD classification  
A 7 (43.8%) 
B 6 (37.5%) 
C 1 (6.3%) 
D 2 (12.5%) 
mMRC 2 [22.75] 
6MWD (m) 466.50±81.56 
6MWD% predicted 74.95±8.59 
Note: The results are shown as mean±SD, n (%) or median [25th percentile  75th percentile]. BMI: body mass 
index; FEV1: forced expiratory volume in one second; GOLD: Global Initiative for Chronic Obstructive Lung 
Disease; mMRC: modified Medical Research Council Dyspnea Scale; 6MWD: six-minute walking distance. 
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Feasibility measures 
Eleven participants (68.8%) used the activity monitors during all monitoring days. Five 
participants missed one day (n=1, 6.3%), two days (n=1, 6.3%) or three days or more 
(n=3, 18.8%) of PA monitoring in at least one of the time points. Reasons included: the 
monitor was uncomfortable to wear in specific situations (n=1, 6.3%); failure to attend the 
last week of the program due to work-related issues (n=1, 6.3%); and forgetfulness (n=3, 
18.8%). No significant differences were found in the baseline characteristics of 
participants who had complete and incomplete PA assessments (p>0.05). Daily wearing 
time was similar over the weeks (W1=14.04±0.68h; W7=13.85±1.92h; W12=13.40±1.81h, 
p=0.348).  
Five participants (out of 16 who completed the study) did not attend the focus groups due 
to work-related issues (n=2), schedule constraints (n=2) and no reasons given (n=1). 
Focus group analyzes revealed that, whilst five participants (45.5%) reported no 
difficulties in using the activity monitors, six participants (54.5%) felt that the device was 
uncomfortable due to its placement and the pressure exerted by the elastic belt: 
 “It caused some pressure and sometimes the elastic belt felt like scratching (…) It was 
placed in a region where there is not much fat, there is mostly bone.” [P1] 
“I used the monitor underneath the clothes and, when I started to sweat, it felt like burning...” 
[P2] 
Suggestions to improve its use consisted of changing the elastic belt for another with a 
softer material (n=4, 36.4%), and changing the placement (e.g. attached to the thigh, 
chest or arm) (n=4, 36.4%) or the dimensions of the device, making it more flattened (n=2, 
18.2%).  
Regarding data collection, six participants (54.5%) mentioned that there were too many 
days of monitoring. The optimal duration for using the device would be three days (n=4, 
36.4%): 
“Sometimes it was even unnoticed, but at the end of the 3rd, 4th, 5th days it started to [bother 
me]. I would choose to use it only for 3 days, because this was the time that it did not really 
bother...” [P3] 
The feedback given to participants made them more conscious about their PA levels, as 
they found that it reflected the reality (n=8, 72.7%). Six participants (54.5%) reported that 
they had improved their active time because they were wearing the devices: 
“Using the device made me walk more!” [P4] 
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“I tried to get out of the car when I could to avoid being seated for so long.” [P3] 
Three participants (27.3%) referred that giving daily feedback (instead of a weekly 
average) would be important to allow comparisons between the activities performed on a 
given day and the results reported by the device: 
“We should use it during the day and download [the information] at the end of it. We would 
try to improve, ‘On this day I didn’t do anything… It was Tuesday… On Tuesday, I have no 
chance to improve…’ or ‘I will try to improve!'” [P5] 
 
Physical activity 
Table 2 presents daily PA levels of patients in the three time points. Significant differences 
with a large effect were found for number of daily steps (p=0.026, ƞ2=0.306). Participants 
increased their steps from W1 to W7 (p=0.050), followed by a decrease on W12 
(p=0.048). The mean time spent in moderate-to-vigorous intensity activities was above the 
30 min/day in the three time points, however, no significant differences were found 
(p=0.167). No changes were observed in time spent in light intensity and sedentary 
activities (p=0.685 and p=0.673). 
 
Table 2. Daily physical activity levels of participants on weeks 1, 7 and 12 of the intervention (n=13). 
 Week 1 Week 7 Week 12 p-value ƞ2 Observed 
power 
Daily steps  
(number) 
8,638.23±2,408.14 10,002.27±2,798.13 8,858.43±1,641.80 0.026*,a 0.306 0.692 
Moderate-to-
vigorous intensity 
activities (min) 
36.51±27.89 41.31±26.38 31.46±20.86 0.167 0.139 0.361 
Light intensity  
activities (min) 
344.52±86.76 335.27±94.25 344.44±79.42 0.685 0.031 0.105 
Sedentary  
activities (min) 
454.14±88.56 464.77±89.34 444.54±76.18 0.673 0.035 0.107 
Standing (min) 253.19±77.47 302.18±70.25 283.24±64.07 0.030*,b 0.254 0.668 
Sitting (min) 481.15±94.69 459.06±71.32 435.54±68.41 0.260 0.115 0.274 
Lying (min) 46.26±32.86 33.96±23.37 48.39±28.34 0.269 0.112 0.267 
Note: The results are shown as mean±SD. *Significant at p-value<0.05. aPairwise comparisons were in the 
borderline of statistical significance between weeks 1 and 7 (p=0.050) and significant between weeks 7 and 
12 (p=0.048). bPairwise comparisons were significant between weeks 1 and 7 (p=0.021). 
  
 
Chapter 5 
115 
 
 
 
Regarding body postures, differences were found for standing time (p=0.030, ƞ2=0.254). 
Specifically, improvements were observed between W1 and W7 (p=0.021), but not 
between W7 and W12 (p=0.130). No significant differences were found for time spent 
sitting (p=0.260) or lying (p=0.269). 
Regarding exercise capacity, participants’ 6MWD was significantly increased after the 
intervention (466.50±81.56m vs. 513.33±86.18m, p=0.001). 
 
Discussion 
This study demonstrated that using feedback to improve PA during PR is feasible and 
increases the number of daily steps and standing time in the short-term. Nevertheless, 
there are still some issues that should be further enhanced in to stimulate and/or maintain 
PA improvements. 
Overall, participants’ compliance was satisfactory and they reported a positive experience 
regarding the use of activity monitors. Still, some participants reported problems related to 
usability issues (monitor placement, pressure exerted by the elastic belt) and duration of 
PA monitoring. To date, a small number of studies has specifically addressed these 
issues; however, this may have important implications for compliance with activity 
monitoring (Trost et al., 2005) and should be carefully considered when planning a study. 
In addition, some participants occasionally forgot to wear the activity monitor. To 
overcome this problem, future studies should implement strategies to improve patients’ 
compliance, as it has been recommended in the literature (Trost et al., 2005). 
Participants reported that feedback made them more conscious about their PA levels and 
PA improvements were related to wearing the devices. This suggests that the aim of 
including feedback in PR was achieved, i.e., increasing patients’ awareness and 
motivating them to improve daily PA. Nevertheless, some participants mentioned that 
daily feedback would have facilitated comparisons between the activities performed on a 
given day and the results reported by the device. Activity monitors with an automatic daily 
feedback function may, therefore, be valuable to meet patients’ needs and expectations. 
Pedometers include this option, but their limited accuracy may prevent them from 
detecting PA changes in interventional studies (Ng et al., 2012). Future advances in 
sensing technologies may offer opportunities to improve PA monitoring and feedback in 
COPD research.  
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Participants improved their daily steps and standing time from W1 to W7; however, the 
former declined from W7 to W12. Nevertheless, a large effect was observed indicating a 
relevant change. These findings suggest that patients’ PA levels may already be 
increased on W7 of PR programs, if appropriate feedback is given. However, 
complementary strategies may be necessary to stimulate and/or maintain PA 
improvements, since a decline was observed on W12. In this study, a psychoeducation 
session focused on promoting exercise habits in participants was carried out on W6, 
which could have acted as an additional motivational tool to stimulate behavior change 
and, thus, improve participants’ PA on W7. Future research should explore the value of 
feedback and additional strategies (e.g. psychoeducation sessions about exercise habits) 
to stimulate patients’ behavior change into a more active lifestyle, as this is one of the 
current challenges in COPD research. 
 
Strengths and limitations 
The combination of quantitative and qualitative methods of data collection is a strength of 
the present study, as it enabled gathering the full experience of participants with the use 
of activity monitors and provided important information for the design of future 
technologies and interventions. 
The small sample size and lack of control group were limitations of the present study, 
which may have contributed to the insufficient power obtained in some comparisons. The 
absence of a control group may have acted as a confounding factor, since previous 
studies have shown that PR per se is able to promote increases in PA levels (Pitta et al., 
2008). Further studies with more robust designs are needed to investigate the value of 
providing feedback on PA levels to patients with COPD during PR. In addition, patients’ 
PA levels were collected on specific weeks of the PR program, which may compromise 
the comparisons with previous studies. However, this was deemed necessary to enable 
the provision of feedback on PA levels to participants as part of the intervention. 
Most participants were in mild and moderate COPD grades, which differ from other 
intervention studies with PA monitoring (Pitta et al., 2008, Steele et al., 2008, de Blok et 
al., 2006). Nevertheless, recent literature has acknowledged that PA is already reduced in 
early COPD grades (Troosters et al., 2010, Watz et al., 2009) and PR is now considered a 
standard of care for all patients, including those at earlier grades (Spruit et al., 2013).  
The fact that feedback was only given on specific time points may have limited 
participants’ PA improvements. In addition, it was not possible to determine if PA levels 
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were already increased before W7. Future studies should explore the impact of more 
regular feedback and monitoring on patients’ daily PA. Furthermore, since patients were 
on average sufficiently active on W1 (i.e., above the internationally recommended target 
of 7,000 steps per day) (Garber et al., 2011), future studies should explore whether 
patients who have a lower step performance at baseline are more motivated to change 
their daily steps during and after the intervention. 
The mean time spent in moderate-to-vigorous intensity activities was above the 30 
min/day in the three time points, which could suggest that patients have met the 
international recommendations (Garber et al., 2011). However, one recent study showed 
that the recommended time of moderate-to-vigorous intensity activities varies upon the 
selected PA analysis, i.e., bouts vs. non-bouts analysis (van Remoortel et al., 2013). In 
the study of van Remoortel at al. (2013), the commonly used bouts cut-point of 30 min/day 
was associated to a non-bouts cut-point of 80 min/day. Since the present study did not 
conduct a bouts analysis, it is possible that patients did not reach the international PA 
target for moderate-to-vigorous intensity activities. Future studies using bouts and non-
bouts analysis should be conducted in order to clarify whether patients with COPD meet 
the international recommendations.  
Despite the limitations, results from this study suggest that feedback on PA levels can be 
used to support patients in achieving a more active lifestyle, by helping them to self-
monitor their daily PA. The costs associated to the provision of feedback were relatively 
small and related to the purchase of activity monitors and the time needed by health 
professionals to deliver feedback to the participants (15-20 min). Therefore, this seems a 
feasible intervention to be implemented in various health care settings. Furthermore, as 
lower PA levels have been related to increased healthcare utilization, poorer quality of life 
and reduced survival of patients with COPD (Garcia-Aymerich et al., 2006, Waschki et al., 
2011, Watz et al., 2008), it is reasonable to believe that this type of intervention may lead 
to reduced COPD health-related costs. This should be investigated in future research. 
 
Conclusions 
Providing feedback on physical activity (PA) levels to patients with COPD is feasible and 
may enhance daily PA during pulmonary rehabilitation. However, additional strategies 
might be necessary to stimulate patients’ behavior change into a more active lifestyle, as 
this is one of the current challenges in COPD research. Patients’ experiences on the use 
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of activity monitors should also be assessed, as they provide valuable information to 
adjust PA technologies and interventions to the target population. Further research with 
more robust designs is needed to investigate the impact of feedback on patients’ daily PA. 
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Abstract 
Objectives: To investigate the impact of a physical activity (PA)-focused behavioural 
intervention during and after pulmonary rehabilitation (PR) on PA levels (primary aim), 
health-related outcomes and self-efficacy (secondary aims) of patients with COPD. 
Methods: 32 patients were randomly assigned to an experimental (EG) or control (CG) 
group. The EG received a PA-focused behavioural intervention during PR (three months) 
and follow-up support (three months). The CG received PR (three months). Daily PA was 
collected: number of steps; time spent in moderate-to-vigorous PA (MVPA), total PA and 
sedentary activities (SA). Secondary outcomes comprised exercise capacity, muscle 
strength, health-related quality of life (HRQOL) and self-efficacy. Measures were collected 
at baseline, three and six months. 
Results: Compared with the CG, the EG improved the number of steps (p=0.006) and 
time spent in MVPA (p=0.007), total PA (p=0.014) and SA (p=0.018) at three months. 
Differences were maintained after follow-up support (0.025≤p≤0.040), except for SA 
(p=0.781). Exercise capacity, muscle strength and HRQOL were increased at three and 
six months (p≤0.002) with no between-group differences (0.148≤p≤0.987). No changes 
were observed in self-efficacy (p=0.899). 
Conclusions: A PA-focused behavioural intervention during and after PR may improve 
patients’ PA levels. Further research is warranted to assess the sustainability of the 
findings. 
 
Clinical Trial Registration: ClinicalTrials.gov NCT02122614, URL: www.clinicaltrials.gov  
 
Keywords: Chronic Obstructive Pulmonary Disease; Daily activity; Exercise; Monitoring; 
Pedometer; Social Cognitive Theory. 
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Introduction 
Patients with Chronic Obstructive Pulmonary Disease (COPD) are markedly inactive 
during daily life (Pitta et al., 2005). Low physical activity (PA) levels have been associated 
with adverse outcomes, including hospitalisation and all-cause mortality (Waschki et al., 
2011, Garcia-Rio et al., 2012); therefore, increasing patients’ PA has become a desirable 
outcome (Spruit et al., 2013). 
Pulmonary rehabilitation (PR) is the cornerstone of COPD management with well-
documented effects on exercise capacity and health-related quality of life (HRQOL) (Nici 
et al., 2006). Hence, it would seem the ideal intervention to promote PA behaviours in 
patients with COPD (Spruit et al., 2013). However, previous studies assessing the impact 
of PR on PA levels have shown that an increase in exercise capacity does not 
necessarily translate into significant improvements in patients’ PA (Egan et al., 2012, 
Mador et al., 2011, Pitta et al., 2008). Alternative methods to produce PA behaviour 
change within PR are therefore needed. 
In the last decade, several PA-focused interventions complementary to PR have been 
developed (Wilson et al., 2014). Those including self-monitoring using activity monitors, 
behaviour change approaches and goal setting showed the most promising results 
(Altenburg et al., 2015, Cruz et al., 2014). However, to date, only a few randomised 
controlled trials have studied the effectiveness of these interventions along with PR in 
improving patients’ PA (Altenburg et al., 2015, de Blok et al., 2006, Steele et al., 2008). 
The aim of this randomised controlled trial was to investigate the impact of a PA-focused 
behavioural intervention during and after a PR programme on PA levels of patients with 
COPD. Secondary aims were to evaluate its effects on health-related outcomes and self-
efficacy. 
 
Methods 
Study Design 
This was a randomised controlled trial. Patients were randomly assigned to receive a PA-
focused behavioural intervention during and after PR (experimental group [EG]) or PR 
alone (control group [CG]), using a computer-generated schedule in random blocks of 
two. One researcher kept the allocation sequence in sealed opaque envelopes, drew the 
envelopes and scheduled patients. Patients knew about the existence of two groups but 
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not the differences between interventions. Ethical approval was obtained from the Central 
Regional Health Administration (2011-02-28), Hospital Centre (34428) and National Data 
Protection Committee (9250/2012). Written consent was obtained from each participant. 
The trial was registered at ClinicalTrials.gov (NCT02122614) and was reported according 
to CONSORT guidelines (Schulz et al., 2010). 
 
Participants 
Patients were recruited from three primary care centres and a district hospital. Patients 
were included if they were: 18 years or older; diagnosed with COPD according to the 
GOLD criteria (Global Strategy for the Diagnosis Management and Prevention of COPD 
[GOLD], 2015); clinically stable in the last month (i.e., no hospital admissions or 
exacerbations) and able to provide informed consent. Exclusion criteria consisted of the 
presence of severe neurologic, musculoskeletal or psychiatric disorders, unstable 
cardiovascular disease or severe visual impairment, and participation in PR in the 
previous six months or in regular strenuous exercise. 
 
Intervention 
Patients of both groups underwent 12 weeks (three months) of PR between April and July 
2014. Additionally, the EG received a PA-focused behavioural intervention (three plus 
three months). 
 
Pulmonary rehabilitation 
PR consisted of exercise training and psychosocial support and education sessions. 
Exercise training was held three times/week (60min/session) by physiotherapists with 
expertise in the field and comprised warm-up, aerobic training, resistance training, 
balance training, and cool-down (as described elsewhere (Cruz et al., 2014)). 
Psychosocial support and education sessions were conducted once a week (90min) by a 
multidisciplinary team. Topics included information about COPD, promotion of healthy 
lifestyles (PA, nutrition) and self-management strategies. PR programmes were 
conducted at different times to avoid group contamination. 
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PA-focused behavioural intervention 
The PA-focused behavioural intervention was implemented by one physiotherapist during 
the PR programme (three months) and continued for three months after its completion. It 
was specifically designed to achieve a sustained increase in patients’ PA levels and was 
based on the Social Cognitive Theory (SCT) (Bandura, 1986), which acknowledges the 
role of self-efficacy, goal setting and performance feedback as core elements of behaviour 
change. The present intervention incorporated these concepts by using the Health 
contract technique (Haber, 2010, Haber and Rhodes, 2004) and objective feedback 
provided by pedometers. The intervention is described in detail below. 
In the first psychosocial support and education session, participants in the EG were given 
a piezoelectric pedometer (Yamax Power Walker EX-510) and a log diary to record daily 
steps in order to establish their baseline steps. These pedometers have shown good 
accuracy results at slow (absolute percent error [APE] 4.5-9.1%), self-preferred/normal 
and fast (APE<3%) speeds, particularly when worn at the front right or left sides of the 
waist or inside the front pockets of the trousers (Cruz et al., 2015). In the following 
session, participants received a Health contract (Haber, 2010), i.e., a written agreement 
between each patient and the physiotherapist. The physiotherapist assisted patients in 
completing the Health contract: they had to formulate an individualised long-term step-
count goal to achieve by the end of the PR programme, based on their baseline steps and 
international PA recommendations (7000-10,000steps/day (Garber et al., 2011)), and 
identify potential facilitators (e.g., walking with family/friends, planning a daily schedule). 
Participants also received a calendar to register their short-term step-count goals and 
daily steps, which were self-monitored with the pedometer. Short-term goals were defined 
on a weekly basis and consisted of the previous short-term goal plus ~800 additional 
steps (if the goal of the previous week was met) (Moy et al., 2010) or the previous goal (if 
it was not met). The final aim was to achieve the long-term goal. In each psychosocial 
support and education session, the physiotherapist provided individual feedback on 
patients’ performance and helped them to define the next short-term goal (~20-
30min/session). In the last session, the long-term goal was reassessed. If achieved, 
participants were praised and asked to readjust it for the next 3 months. After PR, patients 
continued registering their steps in the calendar and received the physiotherapist’s 
support on a weekly (in the first month) and fortnightly (in the second and third months) 
basis by telephone calls. 
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Measures 
Participants’ characteristics were assessed at baseline. Outcome measures were 
collected at baseline, three months (i.e., post-PR) and six months (i.e., after the PA-
focused behavioural intervention). 
 
Participants’ characteristics 
Sociodemographic and anthropometric data were collected using a structured 
questionnaire and dyspnoea using the modified Medical Research Council dyspnoea 
scale (mMRC) (Doherty et al., 2006). Lung function was assessed with a portable 
spirometer (MicroLab 3500, CareFusion, Kent) (Miller et al., 2005) and GOLD grades and 
exacerbation risk groups were determined (GOLD, 2015). 
 
Primary outcome measure 
Daily PA levels were assessed using activity monitors GT3X+ (ActiGraph, Pensacola, FL), 
already validated in COPD (Rabinovich et al., 2013, Van Remoortel et al., 2012). 
Participants wore the device for four consecutive weekdays during waking hours (except 
when bathing or swimming) (Demeyer et al., 2014). Data were downloaded using Actilife 
v6.10.4 (ActiGraph, Pensacola, FL). A valid day was defined as ≥8h of wearing time 
(Demeyer et al., 2014). Daily PA included the time spent in moderate-to-vigorous PA 
(MVPA, 1952–∞ counts-per-minute [CPM]), total PA (100–∞CPM) (Freedson et al., 1998) 
and number of steps. Time spent in MVPA was calculated considering the total time 
(overall MVPA) and the internationally recommended duration of ≥30min of daily MVPA, 
either continuous or in blocks of ≥10min (recommended MVPA) (American College of 
Sports Medicine, 2014). Time spent in sedentary activities (SA, 0–99CPM) was also 
calculated (Freedson et al., 1998). 
 
Secondary outcome measures 
Secondary outcomes comprised exercise capacity (six-minute walk test) (American 
Thoracic Society, 2002), quadriceps muscle strength (1 repetition maximum) (American 
College of Sports Medicine, 2014), HRQOL (St. George’s Respiratory Questionnaire, 
SGRQ – 3 domains and global score) (Jones, 2005) and self-efficacy (Self-Efficacy Scale) 
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(Pais-Ribeiro, 1995). The questionnaires presented good internal consistency (SGRQ: 
0.695≤Cronbach’s α≤0.877; Self-Efficacy Scale: Cronbach’s α=0.696). 
 
Statistical analysis 
Sample size was estimated using the primary outcome measure based on a pilot study 
(Cruz et al., 2014). It was found that 12 patients with COPD would be required in each 
group to provide 80% power (=0.05) to detect significant between-group differences in 
MVPA (using the effect size eta squared, ƞ2=0.139). However, as PR programmes have a 
considerable dropout rate (~30%) (Fischer et al., 2009, Garrod et al., 2006), 16 patients 
per group were recruited. Power analyses were performed using G*Power v3.1.3 (Franz 
Faul, Kiel University, Germany). 
Baseline characteristics were compared between groups and between completers and 
dropouts with independent t-tests for normally distributed data, Mann Whitney U-tests for 
ordinal data and Chi-square tests for categorical data. For each outcome, a mixed-model 
analysis of variance (ANOVA) was used to determine the effects of time and time X group 
interaction considering a level of significance of 0.05. Effect sizes were computed using 
the partial eta squared (ƞ2partial), interpreted as: ƞ2partial≥0.01 small, ƞ2partial≥0.06 medium 
and ƞ2partial≥0.14 large effect (Cohen, 1988). Observed power was also calculated. If 
interaction was significant, a simple effects analysis was performed using independent t-
tests to assess between-group differences at each time point. Data were analysed using 
SPSS v20.0 (IBM, Armonk, NY) and GraphPad Prism v5.0 (GraphPad, La Jolla, CA). 
 
Results 
Participants 
Forty patients were screened (Figure 1); however, eight were excluded for not meeting the 
inclusion criteria (n=5) or declining to participate (n=3). Therefore, 32 patients were 
allocated to the EG (n=16) or CG (n=16). Participants (27 males) had a mean age of 
66.4±8.4 years and a FEV1 of 67.1±20.1% predicted. No significant between-group 
differences were found in baseline characteristics (0.121≤p≤0.855, Table 1). 
Twenty-six participants completed the intervention and posttest assessments and thus 
were included in the analysis. Baseline characteristics were not significantly different 
between completers and dropouts (0.143≤p≤0.817). 
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Figure 1. Flow diagram. 
 
Table 1. Characteristics of participants from both groups (n=32). 
 Experimental 
group (n=16) 
Control  
group (n=16) 
P 
Age, years 68.8±8.2 64.1±8.2 0.121 
Sex (male), n(%) 13 (81.2%) 14 (87.5%) 0.626 
Current occupation, n(%)    
Retired 14 (87.5) 11 (68.8) 0.303 
Employed 2 (12.5) 2 (12.5)  
Unemployed 0 3 (18.8)  
BMI, Kg/m2 29.3±3.6 29.6±6.3 0.855 
mMRC, M[IQR] 1.5 [1.0–2.0] 2.0 [1.0–2.5] 0.423 
FEV1, L 1.9±0.8 2.0±0.7 0.699 
FEV1, % predicted 65.5±21.1 68.4±19.7 0.697 
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(table 1 – continued) 
 Experimental 
group (n=16) 
Control  
group (n=16) 
P 
GOLD grade, n(%)    
Mild 6 (37.5) 6 (37.5) 0.623 
Moderate 4 (25.0) 6 (37.5)  
Severe to very severe 6 (37.5) 4 (25.0)  
Exacerbation risk, n(%)    
A 5 (31.2) 5 (31.2) 0.776 
B 4 (25.0) 6 (37.5)  
C 3 (18.1) 1 (6.2)  
D 4 (25.0) 4 (25.0)  
Data are presented as mean±standard deviation, unless otherwise indicated. Abbreviations: BMI, body mass 
index; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; GOLD, Global Initiative for 
Chronic Obstructive Lung Disease; IQR, interquartile range, M, median; mMRC, modified British Medical 
Research Council dyspnoea scale. 
 
Physical activity 
Figure 2 and Table 2 present the main PA findings. A significant time X group interaction 
was found for time spent in overall MVPA (p=0.030, ƞ2partial=0.21, Power=0.89), 
recommended MVPA (p=0.012, ƞ2partial=0.17, Power=0.78) and total PA (p=0.047, 
ƞ2partial=0.12, Power=0.59) and for the number of steps (P=0.001, ƞ2partial=0.27, 
Power=0.96).  
Patients in the EG spent significantly more time in overall MVPA (three months: 
EG=57.8±32.8 min/day CG=26.7±19.6 min/day, p=0.007; six months: EG=51.6±29.4 
min/day CG=28.0±26.0 min/day, p=0.040), recommended MVPA (three months: 
EG=23.3±28.6 min/day CG=4.3±7.3 min/day, p=0.036; six months: EG=20.3±24.2 
min/day CG=3.8±7.4 min/day, p=0.033) and total PA (three months: EG=279.5±74.0 
min/day CG=212.0±53.9 min/day, p=0.014; six months: EG=269.3±61.5 min/day 
CG=202.9±82.5 min/day, p=0.029). In addition, the EG walked on average more 4010.0 
steps/day at three months (p=0.006) and 3266.7 steps/day at six months (p=0.025) than 
the CG (Figure 2). 
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A time X group interaction was also found for SA (p=0.031, ƞ2partial=0.14, Power=0.66). At 
three months, the EG spent significantly less time in SA (EG=536.4±86.6 min/day 
CG=625.9±93.3 min/day, p=0.018). No between-group differences were found at six 
months (p=0.781). 
 
Figure 2. Physical activity (PA) levels of participants in the EG (●) and CG (▼) at baseline, 3 and 6 months. 
Data are presented as mean and standard error of the mean (SEM). Significant differences between groups in 
each time point are identified with an *. (A) Time in moderate-to-vigorous PA (MVPA); (B) Time in MVPA 
according to the international recommendations (i.e., ≥30min of MVPA either continuous or in blocks of 
≥10min); (C) Time in total PA; (D) Number of daily steps. 
 
Table 2. Daily physical activity (PA) levels of participants in the experimental (EG, n=13) and control (CG, 
n=13) groups at baseline, 3 months and 6 months. 
  
Baseline 3 months 6 months Pa ƞ2partial b 
Observed 
powerc 
Overall  
MVPA (min) 
EG 32.2±15.4 57.8±32.8 51.6±29.4 0.030* 0.21 0.89 
CG 26.6±14.6 26.7±19.6 28.0±26.0    
Recommended 
MVPA (min) 
EG 5.2±7.5 23.3±28.6 20.3±24.2 0.012* 0.17 0.78 
CG 5.3±8.2 4.3±7.3 3.8±7.4    
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(table 2 – continued) 
  
Baseline 3 months 6 months P
a ƞ2partial b 
Observed 
powerc 
Total PA (min) EG 235.4±44.6 279.5±74.0 269.3±61.5 0.047* 0.12 0.59 
CG 208.4±78.9 212.0±53.9 202.9±82.5    
Daily steps 
(number) 
EG 7161.5±1708.1 10440.0±4012.9 9747.9±3511.8 0.001* 0.27 0.96 
CG 6617.1±2914.2 6430.0±2613.1 6481.3±3454.4    
Sedentary 
activities (min) 
EG 600.2±66.1 536.4±86.6 578.8±102.8 0.031* 0.14 0.66 
CG 611.7±77.5 625.9±93.3 566.8±116.5    
Data are presented as mean±standard deviation. Significant differences are identified with an *. aP of Time x 
Group interaction; bPartial eta squared of Time x Group interaction; dObserved power of Time x Group 
interaction. Abbreviations: MVPA, moderate-to-vigorous physical activity; PA, physical activity. 
 
B. Secondary outcomes 
Both EG and CG experienced significant improvements in exercise capacity, muscle 
strength and HRQOL during the study (p≤0.002 – except for SGRQ Symptoms score, 
p=0.051), with no between-group differences (0.148≤p≤0.987). Self-efficacy remained 
constant throughout the study in both groups (p=0.899, Table 3). 
 
Table 3. Outcome measures of patients of the experimental (EG, n=13) and control (CG, n=13) groups. 
  
Baseline 3 months 6 months Pa Pb ƞ2partial c 
Observed 
powerd 
6MWD (m) 
EG 493.8±63.0 547.9±47.9 540.4±31.1 0.962 <0.001* 0.53 0.99 
CG 476.2±54.9 529.7±57.2 519.4±50.8     
Quadriceps 
muscle 
strength (kg) 
EG 37.0±7.4 47.2±11.4 43.7±11.6 0.148 <0.001* 0.68 0.99 
CG 40.7±8.0 51.0±10.8 43.8±8.2     
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(table 3 – continued) 
  
Baseline 3 months 6 months Pa Pb ƞ2partial c 
Observed 
powerd 
SGRQ Global 
score 
EG 31.5±15.7 24.0±13.6 23.1±10.3 0.987 <0.001* 0.41 0.99 
CG 34.9±14.7 26.9±15.2 26.2±15.3     
SGRQ 
Symptoms 
score 
EG 40.2±23.0 32.1±18.4 27.2±16.9 0.773 0.051 0.13 0.58 
CG 41.2±22.7 35.9±21.6 34.0±26.3     
SGRQ 
Activities score 
EG 48.7±20.2 38.2±20.4 41.9±17.3 0.882 0.002* 0.25 0.92 
CG 49.2±16.7 38.8±22.2 40.0±17.3     
SGRQ Impact 
score 
EG 18.4±13.2 13.1±11.6 10.8±7.8 0.833 <0.001* 0.36 0.99 
CG 24.8±13.8 17.5±12.8 15.7±14.0     
Self-efficacy 
EG 77.0±12.0 75.3±12.7 79.5±11.4 0.068 0.899 0.05 0.07 
CG 82.4±10.4 85.7±11.1 79.6±13.0     
Data are presented as mean±standard deviation. Significant differences are identified with an *. ap of Time X 
group interaction; bp of Time; cPartial eta squared of Time; dObserved power of Time. Abbreviations: 6MWD, 
six-minute walking distance; SGRQ, St. George’s Respiratory Questionnaire.  
 
Discussion  
This was the first randomised controlled trial that evaluated the impact of a PA-focused 
behavioural intervention comprising a Health contract and pedometer feedback on PA 
levels of patients with COPD during and after PR. The addition of this novel approach to 
PR was effective in improving patients’ PA levels at three months which remained 
improved after follow-up support. Nevertheless, it did not produce further improvements in 
exercise capacity, muscle strength or HRQOL. 
The addition of the PA-focused behavioural intervention to PR led to significant PA 
improvements in the EG which remained improved after follow-up support. Findings 
suggest that this intervention is feasible and enhances patients’ PA levels. A previous 
study implementing a PA-focused intervention with goal setting and pedometer feedback 
during PR found only modest (non-significant) improvements in patients’ daily steps (de 
Blok et al., 2006). Differences between studies may be explained by the different duration 
of the PR programme (nine weeks vs. 12 weeks) and professional support (five 30min 
individual sessions vs. weekly 20-30min group sessions). When that intervention was 
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implemented in a 3-month period, significant results were observed albeit the 
improvement was less pronounced than in the present study (547 steps/day vs. 3278.6 
steps/day, respectively) (Altenburg et al., 2015). Disease severity and baseline PA levels 
may explain in part these discrepancies. Nevertheless, the type of PA-focused 
intervention may have also played a role, as in the present study a formal commitment 
was encouraged by the use of the Health contract. This technique has been applied with 
varied degrees of success in interventions conducted with other populations and health 
behaviours (Haber and Rhodes, 2004, Speelman et al., 2014, Cupples and Steslow, 
2001). It has advantages over verbal communication alone, since formal commitment 
enhances the individual-clinician relationship and stimulates the active participation of the 
individual in identifying an achievable health goal and creating a behaviour change plan 
(Haber and Looney, 2000). 
The costs associated with the addition of the PA-focused behavioural intervention to PR 
were relatively small and related to the purchase of pedometers and printed material 
(Health contract and calendar), the telephone calls and the time needed by the 
physiotherapist to provide support (~20-30min/session). Thus, this intervention can be 
implemented in various healthcare settings without the need for significant additional costs 
or human resources. Further research is needed to study the cost-effectiveness of this 
PA-focused behavioural intervention. 
Despite the PA improvements found in the EG, there were no significant between-group 
differences in exercise capacity, muscle strength and HRQOL, similarly to a previous 
study (Altenburg et al., 2015). Therefore, the hypothesis that a more active lifestyle after 
the intervention translates into improved health-related measures could not be shown. 
One possible explanation is that PA improvements may not have been enough to promote 
changes in patients’ daily life, as the minimum clinically important difference (MCID) of PA 
has not been established in COPD (Wilson et al., 2014). Other health-related measures 
which were not explored in this study but have been related to patients’ PA (e.g., 
exacerbations (Donaldson et al., 2005, Pitta et al., 2006)) may have improved as a result 
of the intervention. This should be explored in further research. The fact that patients 
receiving the PR programme alone did not improve their PA levels despite having similar 
exercise capacity levels to those in the EG also supports the idea that low PA levels, as 
frequently found in patients with COPD, have a strong behavioural component. This 
means that some patients may opt to limit their PA levels rather than be restricted by their 
symptoms or impairments (Spruit et al., 2013). 
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No significant differences were found for self-efficacy over time in either group. Since self-
efficacy is the main construct of the SCT (Bandura, 1986), it was expected that a SCT-
based behavioural intervention would improve patients’ self-efficacy. However, studies 
conducted in COPD have shown conflicting results regarding the relationship between PA 
and self-efficacy (DePew et al., 2013, Hartman et al., 2013, Steele et al., 2000), which 
may in part explain the non-significant findings obtained in this study. These findings may 
also be attributable to the use of a global self-efficacy scale instead of a specific scale to 
assess PA behaviour, given that self-efficacy is a task-specific domain (Sweet et al., 
2012). Future research should apply a PA self-efficacy scale. 
 
B. Limitations 
Findings from the present study must be interpreted in light of the limitations. First, this 
was a small-scale trial, therefore, the generalisability of the results to clinical practice is 
limited. Nevertheless, the sample size calculation and the large effect sizes found for PA 
levels added strength to the results. Second, patients had high functioning levels at 
baseline (mean baseline step counts 6600-7200 steps/day, mean baseline 6-mintute 
walking distance 493.8–476.2m). Future research is warranted to explore whether 
patients with lower performance levels present similar results after the intervention. Third, 
the PA-focused behavioural intervention comprised asking patients to walk 800 additional 
daily steps; however, not all patients achieved the step target throughout the duration of 
the study (data not shown). Therefore, future research should define the step-count goals 
according to each patient’s performance, e.g. by increasing a percentage of the total steps 
achieved. Fourth, all measures were administrated in a face-to-face interview conducted 
by the same researchers who implemented the intervention. Thus, assessor blinding was 
not possible. Fifth, the short- and long-term effects of the intervention were not studied, 
therefore the sustainability of the results could not be determined. Finally, both groups 
received the PR during the same timeframe and hence seasonal variations were not taken 
into account, although they may influence PA (Demeyer et al., 2014). 
 
Conclusions 
A PA-focused behavioural intervention during and after PR may improve patients’ PA 
levels. Further research with larger samples and follow-up assessments is warranted to 
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support these preliminary findings and assess the short- and long-term impact of this 
intervention in COPD. 
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General discussion 
The main aim of this Thesis was to study whether self-management interventions can 
support patients with Chronic Obstructive Pulmonary Disease (COPD) in their disease 
management and impact significantly on health-related outcomes. The body of evidence 
on home telemonitoring for patients with COPD was updated regarding its effectiveness, 
methodologies and patients’ adherence and satisfaction with the telemonitoring 
technologies. Also, the impact of a physical activity (PA)-focused behaviour intervention 
combined with pulmonary rehabilitation (PR) on PA levels and health-related outcomes of 
patients with COPD was investigated. In this chapter, the results from the studies that 
have supported this Thesis are integrated and discussed in light of the most updated 
literature and a description of the general limitations is provided, hoping to contribute for 
improving knowledge in the field of self-management in COPD.  
 
Effectiveness of home telemonitoring in COPD 
The need for home care is expanding dramatically to reduce health-related costs while 
increasing patient involvement in their own care. Studies presented in Chapter 3 found 
that there are still a limited number of studies of home telemonitoring in COPD, most of 
them published in the last five years which emphasises the novelty of this type of 
intervention. In Study 1 of Chapter 3, it was hypothesised that regular assessment of 
symptoms and/or physiological signs through home telemonitoring could help patients and 
healthcare providers better manage patients’ clinical condition, which would be translated 
in improved health-related outcomes and savings in COPD management. In other chronic 
conditions, such as chronic heart failure, home telemonitoring was found to reduce the 
risk of all-cause mortality and rates of hospitalisation related to the disease (Clarke et al., 
2011, Polisena et al., 2010). However, meta-analyses conducted in Study 1 showed that 
there is still no clear indication that home telemonitoring improves health-related 
outcomes and reduces healthcare utilisation in COPD, as only hospitalisation rates (but 
not mean number of hospitalisations) and health-related quality of life (HRQOL – 
measured using the St. Georges Respiratory Questionnaire) yielded significant (but small) 
results in favour of the home telemonitoring group. Furthermore, samples of the included 
studies were relatively small and the number of studies pooled for analysis was limited for 
each outcome. These limitations highlighted in Study 1 emphasise the idea that the role of 
home telemonitoring in COPD management is yet inconclusive. This study supports the 
current recommendations of the Global Strategy for the Diagnosis Management and 
 
 
 
Chapter 7 
 
148 
 
 
 
 
Prevention of COPD (GOLD, 2016) which refer that, given the current lack of evidence, 
telehealth in any of its current forms (including home telemonitoring) should not be 
routinely recommended in clinical practice at this time. Further research is needed to 
assess the effectiveness of home telemonitoring in COPD. 
Other methodological limitations may also have accounted for the results found in Study 1 
– these are comprehensively described in Study 2 of Chapter 3. One major limitation 
was the telemonitoring technology used across studies. Generally, it included a main 
device (mobile/web phone) where patients answered questions about their symptoms and 
disease management and/or recorded data collected via the peripheral devices. Although 
patients with COPD reported an overall positive attitude towards the telemonitoring 
technology, they also described a number of concerns regarding the user-friendliness of 
the devices (e.g., small screen, sensitivity of the buttons and/or touch-screen, sound 
volume) and the frequency of data collection/transmission (3 times/day was considered 
too demanding). These concerns were related to the high dropouts and low compliance 
rates found in some studies. Findings suggest that, even though technology may facilitate 
the involvement of patients in their clinical management, it may also become a barrier if 
they cannot easily and effectively use it to meet their needs and preferences (Broens et 
al., 2007, Krupinski et al., 2006b, Demiris et al., 2001). For example, older users may 
require larger visual displays, bigger input buttons and more automated steps than 
younger users (Krupinski et al., 2006b). The American Telemedicine Association (ATA) 
clinical guidelines (2003) highlighted the importance of assessing patients’ clinical needs 
and functional ability to use the equipment when developing and implementing home 
telehealth and, specifically, home telemonitoring. None of the studies included in the 
systematic reviews of Chapter 3 addressed this issue prior to the implementation of home 
telemonitoring, although all but one (Dale et al., 2003) were published after the ATA 
guideline. Furthermore, as home telemonitoring requires important changes in healthcare 
professionals’ usual practice, their acceptance of the technology should also be evaluated 
(Paré et al., 2007). Future research should test and tailor telemonitoring technology prior 
to its implementation in order to reduce technophobia among users (i.e., patients with 
COPD and healthcare professionals) and increase the chances of success (ATA, 2003, 
Broens et al., 2007, Krupinski et al., 2006a). 
Another important limitation identified in Study 2 of Chapter 3 was the provision of 
training to use the telemonitoring technology. Typically, patients’ training was only 
conducted in the initial home visit which may not have been enough to allow the easy use 
of technology, as many difficulties were encountered throughout the implementation of 
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home telemonitoring. Previous studies on the topic of telemedicine and web-based 
applications have emphasised the need to provide users with repetitive training and 
support at the technological level (e.g., how to install and sustain the system, how to deal 
with errors and problem situations) (Broens et al., 2007, Demiris et al., 2001). This is 
particularly valuable to users at older ages (Demiris et al., 2001), such as patients with 
COPD included in the studies described in the systematic reviews (Chapter 3). Such 
training/support may improve patients’ ability and motivation to use the telemonitoring 
technology, potentially increasing patients’ adherence to the intervention. This topic has 
not been explored in the COPD population and thus further research is warranted.  
Most patients with COPD reported that home telemonitoring provided them with a better 
understanding of the disease and allowed them to be aware of symptoms and recognise 
the earlier signs of an exacerbation (Study 2 of Chapter 3). These findings support the 
belief that home telemonitoring may hold promise for patients to self-manage their disease 
(Fairbrother et al., 2012). However, the impact of the intervention on behaviour change, 
which is the pivotal objective of self-management interventions, was not properly 
evaluated in studies described in the systematic reviews (Chapter 3). Evaluating the 
benefits of a self-management intervention solely on patients’ health status and 
healthcare utilisation is overly narrow and may not be realistic in the short-term (Bourbeau 
and van der Palen, 2009). It is only after achieving behaviour change that effective self-
management of the disease can be expected, thus resulting in better patient outcomes 
and reduction in utilisation of healthcare services (Bourbeau and van der Palen, 2009). 
Furthermore, details on the incorporation of behaviour change strategies were lacking in 
home telemonitoring interventions (Study 2 of Chapter 3), although these are essential to 
promote behaviour change. Future studies aiming at enhancing patient self-management 
through home telemonitoring should include the measurement of patients’ behaviour 
change and its determinants (e.g., self-efficacy), and provide information on how 
behaviour change will be encouraged. 
The diagnosis of an exacerbation relies exclusively on the clinical presentation of the 
patient complaining of an acute change of respiratory symptoms that is beyond normal 
day-to-day variation (GOLD, 2016). As this clinical presentation may vary among patients, 
currently there is a lack of understanding about which combination of changes in 
symptoms and physiological measurements indicates what is abnormal for a particular 
patient in order to predict exacerbations through home telemonitoring (Hardisty et al., 
2011, McKinstry, 2013). Studies included in the systematic reviews presented in Chapter 
3 collected various clinical parameters (e.g., symptoms, oxygen saturation, heart rate), 
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however, there was no consistency in which parameters should be measured to early 
detect exacerbations. Therefore, the insufficient evidence to support home telemonitoring 
may be in part attributed to the difficulty in establishing the clinical criteria necessary to 
detect and address health deterioration. Further research is needed to develop clinical 
algorithms with the most sensitive parameters to early detect COPD exacerbations. This 
information would be valuable to develop effective home telemonitoring interventions. 
In conclusion, home telemonitoring has the potential to improve patient self-management 
without the need of face-to-face contact with healthcare services, thus leading to less 
costly interventions. This could also promote interactivity between patients, families and 
healthcare professionals and help decentralise healthcare by extending its access to 
regions where healthcare professionals are scarce (e.g., rural areas). However, evidence 
to support this type of intervention is still limited and further work needs to be conducted 
before it can be incorporated into clinical practice.  
 
Behaviour change towards improved physical activity in COPD 
Technology advancements have increased the opportunities for monitoring patients’ daily 
PA at home. Chapter 4 assessed the step-count accuracy of a piezoeletric pedometer 
(Yamax PW/EX-510) when worn at different body parts and identified users’ preferences 
regarding its wearing location. The Yamax PW/EX-510 pedometer was highly accurate in 
quantifying steps at normal and fast walking paces, particularly when worn at the front 
right or left positions of the waist and inside the front pockets of the trousers. The latter 
was also identified as the preferred location to wear the device. Pedometer accuracy was 
lower at slow walking pace, though it was within the maximum error values considered 
acceptable for slower speeds (i.e., 5-10% (Crouter et al., 2003, De Cocker et al., 2012, 
Vincent and Sidman, 2003)). These findings suggest that the Yamax PW/EX-510 
pedometer can be confidently used at the front of the waist or inside the pockets of the 
trousers to assess step counts in individuals who ambulate at slower speeds, such as 
patients with COPD (Ilgin et al., 2011). Chapter 4 also assessed the step-count accuracy 
of a triaxial accelerometer (GT3X+) and compared accuracy between devices (i.e., 
pedometer and accelerometer). The GT3X+ accelerometer underestimated steps when 
compared to manually-counted and pedometer step counts, although differences between 
devices were relatively small at normal and fast paces. Thus, the pedometer may be more 
appropriate than the GT3X+ accelerometer in studies using the number of steps as the 
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main outcome measure. If a more detailed analysis of PA is required, the accelerometer 
should be used instead.  
The GT3X+ accelerometer was used in Chapter 5 to assess the feasibility of providing 
patients with feedback on their PA levels (i.e., number of daily steps; time spent in 
sedentary, light and moderate-to-vigorous (MVPA) intensity activities; time spent standing, 
sitting and lying) during a 12-week PR programme. Patients with COPD used the 
accelerometer during the first, seventh and twelfth weeks and feedback was provided in 
the following weeks. This exploratory study demonstrated that using feedback to improve 
patients’ PA levels during PR was feasible and increased the number of daily steps and 
standing time in the short-term (week 7), although these values declined on week 12. In 
the discussion of Chapter 5, a number of methodological limitations were identified and 
recommendations were provided to enhance the design and implementation of future PA-
focused interventions. Briefly, patients’ experience in using the accelerometer was overall 
positive, however, they described problems related to the usability of the accelerometer 
(monitor placement, pressure exerted by the elastic belt) and monitoring duration (i.e., 7 
days). Patients also suggested that daily feedback would have facilitated comparisons 
between the activities performed on a given day and the results reported by the device. 
These issues were addressed in the randomised controlled trial presented in Chapter 6: 
(1) the accelerometer was used over the right hip and the elastic belt was replaced for 
another with a softer material; (2) monitoring duration was reduced to four consecutive 
weekdays, as recently recommended (Demeyer et al., 2014a); and (3) real-time feedback 
on patients’ PA levels was provided on a daily basis using the Yamax PW/EX-510 
pedometers (experimental group). The GT3X+ accelerometer was used in both 
experimental and control groups to assess patients’ PA levels as it provided information 
about changes in the quantity (i.e., time, number of steps) and intensity (e.g., moderate-
to-vigorous) of PA.  
The feasibility study presented in Chapter 5 also identified the need to explore the value of 
combining feedback with additional strategies to stimulate patients’ behaviour change into 
a more active lifestyle. Chapter 6 addressed this issue by implementing a PA-focused 
behavioural intervention during a 12-week PR programme (3 months) and 3 months after 
its completion. The PA-focused intervention was guided by a sound theoretical framework 
(Social Cognitive Theory (Bandura, 1986)) as advocated in recent literature on the topic 
(Leidy et al., 2014, Spruit et al., 2015). The intervention involved a formal commitment by 
the use of a Health contract (Haber, 2010, Haber and Rhodes, 2004) and objective 
feedback provided by pedometers. This novel approach provided promising results by 
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suggesting that a PA-focused behavioural intervention during PR improves patients’ PA 
levels at 3 months which are sustained with follow-up support (3 months). A recent study 
conducted by Burtin et al. (2015) did not achieve the same results. Burtin et al. (2015) 
investigated the impact of adding an individual activity counselling programme to a 6-
month PR on PA levels of patients with COPD (experimental group). The control group 
received PR and face-to-face attention (sham programme). Notably, the authors found no 
significant differences between groups. Divergences between the results obtained in 
Burtin et al. (2015) and in the study presented in Chapter 6 may be partly explained by 
differences in patients’ disease severity (moderate to very severe COPD vs. all COPD 
grades) and baseline PA levels which were lower in Burtin et al. (2015). In addition, the 
nature of the intervention may have accounted for the differences between studies. In the 
study of Burtin et al. (2015), as well as in the studies of de Block et al. (2006) and 
Altenburg et al. (2015), the intervention consisted of individualised counselling provided to 
patients. In contrast, the intervention described in Chapter 6 was implemented through a 
Health contract which was carried out in a group format, although step-count goals were 
individualised to each patient. The formal commitment encouraged by the use of the 
Health contract may have helped patients in identifying an achievable health goal and 
creating a behaviour change plan (Haber and Looney, 2000). Furthermore, the group may 
have acted as an additional stimulus for patients to fulfil the step-count goals and thus 
increase their PA levels. Previous research has highlighted the importance of groups in 
supporting behaviour change through a sharing of experiences and social learning and by 
discouraging passivity (Bourbeau et al., 2004, Kaptein et al., 2014). This hypothesis 
should be investigated in future research.  
Despite the PA improvements found after the implementation of the PA-focused 
behavioural intervention (Chapter 6), there were no significant between-group differences 
in exercise capacity, muscle strength and HRQOL. Therefore, the hypothesis that a more 
active lifestyle translates into improved health-related measures was not confirmed. A 
number of reasons may have accounted for these results. First, the mean time spent in 
moderate-to-vigorous physical activity was below the internationally recommended (i.e., 
≥30min of daily either continuous or in blocks of ≥10min (Garber et al., 2011)). Currently, 
the classification of whether a patient is sufficiently physically active is based on general 
PA recommendations directed to healthy adults (Garber et al., 2011) and the extent to 
which these recommendations apply to people with varying degrees of COPD is still 
unknown (Watz et al., 2014). This is important to provide patients with an evidence-based 
tailored advice. Other possible explanation is that PA improvements may not have been 
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enough to promote changes in patients’ daily life, as the minimum clinically important 
difference (MCID) has not been extensively investigated in COPD (Wilson et al., 2014). To 
date, there was only one study that determined the MCID for the number of daily steps in 
COPD, which ranged between 576 and 1181 steps depending on the distribution-based 
approach used (Demeyer et al., 2014b). Finally, the lack of significant between-group 
differences in performance-based outcomes, such as exercise capacity, supports the idea 
that low PA levels have a strong behavioural component. It is believed that, as a complex 
behaviour, PA is influenced by a combination of determinants including individual 
characteristics, health beliefs, exercise-associated symptoms, as well as social and 
environmental determinants (Sallis et al., 2006, Spruit et al., 2013). For example, it is 
known that climate may influence the PA levels of patients with COPD (Pitta et al., 2009, 
Sewell et al., 2010). Functional and psychosocial factors have also been associated with 
patients’ PA levels (Altenburg et al., 2013, Gimeno-Santos et al., 2014, Hartman et al., 
2013), although the quality of evidence is low (Gimeno-Santos et al., 2014). Other factors, 
such as the physical environment (e.g., neighbourhood), have been identified as important 
factors in PA levels in adults (Addy et al., 2004, Wendel-Vos et al., 2007), but its influence 
has not been studied in patients with COPD. More insight is necessary on the (modifiable) 
determinants of PA behaviour in patients with COPD to develop effective interventions 
and, ultimately, provide guidance to the international health policies and action. This is a 
challenging new area of research. 
In conclusion, activity monitors (i.e., pedometer, accelerometers) have the potential to 
support patient self-management by reliably tracking, storing and providing feedback 
about an individual’s engagement in PA. A PA-focused behavioural intervention consisting 
of goal setting and objective feedback from pedometers during and after a PR programme 
has the potential to improve patients’ PA levels. Further research with larger samples and 
follow-up assessments is warranted to support these preliminary findings and assess the 
long-term impact of this intervention in COPD. 
 
Limitations 
The present Thesis has some important limitations that should be considered when 
interpreting the results. First, the systematic reviews presented in Chapter 3 were 
restricted to studies published in English, Portuguese and Spanish. Studies published in 
other languages could also be relevant for the scope of these reviews. Second, the 
keywords used in the search strategy did not include terms such as ‘smartphone’, ‘e-
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mobile’ or ‘e-health’, which may have reduced the number of relevant papers found. Third, 
the studies included in the systematic reviews were not exactly the same due to their 
study design (i.e., only randomised and non-randomised controlled trials entered in Study 
1), therefore, a direct relationship between the outcomes and home telemonitoring 
methodologies could not be investigated. In addition, it was not possible to understand 
whether patients’ satisfaction was related to improved outcomes and reduced healthcare 
utilisation found in some studies. Further research should explore the impact of the 
methodologies in the effectiveness of home telemonitoring in COPD. 
In Chapter 4, all tests were performed in healthy adults which may limit the 
generalisability of the findings to patients with COPD. Nevertheless, previous validation 
studies conducted simultaneously in healthy and chronic disease populations concluded 
that pedometer accuracy was similar between samples when walking at different speeds 
(Furlanetto et al., 2010, Turner et al., 2012). Only step counts were considered when 
assessing pedometer accuracy (Chapter 4) and when using pedometers as a feedback 
tool (Chapter 6). The Yamax PW/EX-510 pedometers provide additional PA parameters 
(e.g., energy expenditure, fat burn, distance and activity time) which could also have been 
valuable to motivate patients with COPD increase their PA levels. Further research should 
assess the accuracy of Yamax PW/EX-510 pedometers in measuring these PA 
parameters before their use in interventions aiming to enhance PA levels. The validation 
tests presented in Chapter 4 were performed in controlled conditions and, thus, the 
potential of activity monitors (i.e., pedometers, accelerometer) to detect human activity 
was not fully investigated. Future studies should assess pedometer and accelerometer 
accuracy under free-living conditions. 
Chapters 5 and 6 included small sample sizes and most participants were in mild and 
moderate COPD grades. Therefore, the generalisability of the results is limited. Further 
studies with larger samples and different COPD grades are needed to understand which 
patients are most likely to benefit from the PA-focused behavioural intervention. Another 
limitation of these Chapters concerns the inclusion of patients with relatively high 
functioning levels at baseline (e.g., step counts, 6-minute walking distance). Future 
research is warranted to explore whether patients with lower performance levels at 
baseline present (or not) similar results after the intervention. Outcome assessment was 
not blinded in Chapters 5 and 6, since all measures were administrated by the same 
researchers who implemented the intervention. Nonetheless, there was an attempt to 
standardise the order of the tests to minimise bias. Studies presented in Chapters 5 and 6 
were conducted during the same timeframe and hence seasonal variations were not taken 
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into account, although they may influence PA (Demeyer et al., 2014a). Finally, the 
implementation of the PA-focused behavioural intervention described in Chapter 6 
resulted in increased patients’ PA levels immediately after the intervention. However, it is 
unknown whether these findings were sustained as the short- and long-term effects were 
not assessed. More research on the sustainability of the results is needed.  
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Conclusions 
This Thesis contributes to further understanding of the role of home telemonitoring and 
physical activity (PA)-focused behavioural interventions in self-management of patients 
with Chronic Obstructive Pulmonary Disease (COPD). Findings provide limited evidence 
of the effectiveness of home telemonitoring to improve health-related outcomes and 
reduce healthcare utilisation in patients with COPD (Study 1 of Chapter 3). Home 
telemonitoring still needs to be adjusted to ensure its suitability to the target population. 
Study 2 of Chapter 3 provides important recommendations for the development and 
implementation of future home telemonitoring interventions. It was also concluded that 
activity monitors (Yamax PW/EX-510 pedometers, GT3X+ accelerometers) have the 
potential to support patient self-management by reliably tracking, storing and providing 
feedback about an individual’s PA levels (Chapter 4). A PA-focused behavioural 
intervention consisting of goal setting and objective feedback during and after pulmonary 
rehabilitation (PR) has the potential to improve patients’ PA levels (Chapters 5 and 6). 
Further research with larger samples and follow-up assessments is warranted to support 
these preliminary findings and assess the short- and long-term impact of this intervention 
in COPD. 
 
Recommendations for future research and clinical practice  
This chapter presents the main recommendations for future research as well as 
implications for clinical practice.  
Findings from Chapter 3 showed that there is still no robust evidence to support home 
telemonitoring interventions in COPD and further work needs to be conducted before it 
can be incorporated into clinical practice. Recommendations for future research are the 
following: 
 Studies should be conducted with larger samples, higher methodological quality (e.g., 
multicentre randomised controlled trials) and longer observation periods; 
 There is a need to identify clinical indicators of exacerbations and develop algorithms 
to help recognise deterioration of patients’ health condition. This information would be 
valuable to develop effective home telemonitoring interventions; 
 Telemonitoring technology should be tested and tailored to users (i.e., patients with 
COPD and healthcare professionals) prior to its implementation and more training 
sessions should be provided to patients in order to improve their adherence. In 
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addition, there is an urgent need to identify the type of patients most likely to benefit 
from these interventions; 
 Home telemonitoring interventions should provide information on how behaviour 
change is encouraged; 
 Assessment of patients’ behaviour change and its determinants (e.g., self-efficacy) 
should be conducted along with the measurement of health-related and healthcare 
outcomes; 
 Outcome measures should be similar across studies and reported in a format that can 
be further pooled into meta-analysis. 
 
Self-management of PA was addressed in Chapters 4-6. Findings suggest that a PA-
focused behavioural intervention during and after PR can be used to support patients in 
achieving a more active lifestyle, by helping them self-monitor their daily PA. 
Nevertheless, more research is needed before it can be routinely used in clinical practice, 
specifically: 
 The intervention should be implemented in larger samples with follow-up 
assessments to assess its short- and long-term impact in COPD; 
 It should also be explored whether patients with lower performance at baseline 
present (or not) PA improvements after the intervention similar to those with higher 
performance; 
 The role of the group as an additional stimulus for patients’ behaviour change should 
be investigated; 
 It seems worthwhile to investigate whether general guidelines for the recommended 
minimum amount of PA for adults are also suitable for patients with COPD and lead 
to health-related benefits; 
 The minimum clinically important difference (MCID) of PA in patients with COPD 
should be established; 
 Finally, the (modifiable) determinants of PA behaviour in patients with COPD should 
be identified in order to develop more effective interventions and, ultimately, provide 
guidance to the international health policies and action. 
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Physical activity estimates in COPD rehabilitation: self-report vs. objective 
measures  
 
Joana Cruz 
Dina Brooks 
Alda Marques 
 
Introduction: Self-report physical activity (PA) measures are often used to assess changes 
before/after chronic obstructive pulmonary disease (COPD) rehabilitation, as they are easy to 
employ and more feasible than objective measures. However, the ability of self-report measures to 
detect intervention-related changes in PA should be determined.  
Objective: To examine the sensitivity of the International Physical Activity Questionnaire short-
form (IPAQ-sf) to detect intervention-related changes in PA compared to accelerometry in patients 
with COPD.  
Methods: Eleven patients with COPD (67.5±9.2yrs) participated in a 12-week pulmonary 
rehabilitation program. Participants wore an accelerometer (Actigraph GT3X+) for 7 consecutive 
days on the 1st and 12th weeks of the program and completed the IPAQ-sf. Spearman’s correlation 
coefficients (ρ) were used to assess relationships between the results of the IPAQ-sf and the 
accelerometer.  
Results: Both the IPAQ-sf and the accelerometer showed non-significant differences in time spent 
in sedentary activities [median(IQR): IPAQ=60.0(240.0) min/day; accelerometer=1.1(128.0) 
min/day), moderate-to-vigorous physical activities (MVPA: IPAQ=-150.0(1080.0) min/week; 
accelerometer=12.0(60.0)min/week) and total PA (IPAQ=-495.0(1060.0) min/week; 
accelerometer=-9.0(559.0) min/week) as a result of the intervention (p>0.05). Changes in 
sedentary activities obtained by self-report were significantly correlated to those obtained by 
accelerometry (ρ=0.714, p=0.014). Changes in self-reported and accelerometer-based MVPA were 
moderately yet non-significantly correlated (ρ=0.588, p=0.057). No significant correlations were 
found for total PA measured by self-report and accelerometry.  
Conclusions: The IPAQ-sf showed limited correlations with accelerometer-based PA. Patients 
with COPD tend to under-report their PA levels. Thus, objective measures should be preferred 
when assessing the impact of rehabilitation interventions in patients with COPD, as these have 
greater potential to detect PA changes. 
 
Keywords: accelerometer; COPD; physical activity; pulmonary rehabilitation; self-report measures 
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Does family support affect physical activity of patients with COPD? An 
exploratory study 
Joana Cruz 
Dina Brooks 
Alda Marques 
 
Introduction: Despite the well-recognised benefits of regular physical activity (PA) in COPD, a 
large number of patients are inactive. Previous research has highlighted that family support may 
affect PA levels of healthy people. However, the influence of family members on PA levels of 
patients with COPD has never been explored. Objective: To assess PA levels of patients with 
COPD and explore the influence of family members on this health behaviour.  
Methods: Eighteen patients (66.2±11.7 years, FEV1 67.2±20.7pp) and their respective family 
members (57.7±12.4 years) completed the Portuguese version of the International Physical Activity 
Questionnaire short-form (IPAQ-sf), which provides information about the amount of PA performed 
in the last 7 days. This was reported as Metabolic Equivalents-minutes spent per week (MET-
min/wk) and sitting time per day. Descriptive statistics were conducted and a stepwise multiple 
linear regression analysis was used to evaluate whether family members’ PA variables were 
associated with patients’ PA.  
Results: Patients spent a median of 1386.0 (interquartile range [IQR]=2255.5) MET-min/wk and 
family members spent 862.5 (IQR=1533.0) MET-min/wk. Self-reported sitting time was 4.0 
(IQR=2.3) h/day for patients and 3.0 (IQR=3.25) h/day for family members. Family members’ MET-
min/wk (B=0.957, p=0.021) and sitting time (B=-10.319, p=0.015) were significant predictors of 
patients’ MET-min/wk (F(2,15)=6.438, p=0.010; r2adjusted=0.39).  
Conclusion: Findings suggest that family members influence the PA levels of patients with COPD. 
Therefore, the inclusion of the family in rehabilitation interventions might facilitate the increase of 
patients’ PA. 
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Self-report vs. pedometer steps in COPD: are they similar?  
 
Joana Cruz 
Dina Brooks 
Alda Marques 
 
Background: Pedometers have been used as an objective measure to assess physical activity 
(PA) in COPD. However, in most studies, pedometer results rely on users’ ability to provide 
accurate information using daily logs. It is important to understand if self-report steps correspond to 
actual steps recorded by pedometers, in order to use more confidently self-report data.  
Aims: This study aimed to compare self-report steps and steps recorded by a pedometer with a 
memory function in patients with COPD.  
Methods: Patients (n=15, 75.4±26.6yrs, FEV1=69.9±27.6pp) were asked to use a pedometer and 
register their daily steps, as part of a rehabilitation programme with step goals. Patients were 
unaware of pedometer memory. A researcher recorded the steps stored in pedometers. A mixed-
model ANOVA was used to investigate if self-report and pedometer steps differed among patients 
(method X patient, P<0.05), using 7 random days. 
Results: Self-report and pedometer steps were significantly different among patients (P<0.001). 
Nevertheless, Fig. 1 shows that self-report steps were over-reported in only 3 patients (out of 15). 
Conclusions: Most patients with COPD provide an accurate estimation of their PA, although 
differences between self-report and pedometer steps may occur. Patients’ failure to recall steps or 
technological problems with pedometer memory may explain these differences. 
 
 
Fig 1. Comparison between self-report and pedometer steps among patients (n=15). 
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Accuracy of piezoelectric pedometer step counts in different wearing 
locations 
 
Joana Cruz 
Dina Brooks 
Alda Marques 
 
Background: Pedometers are simple and inexpensive devices used as a motivational tool or in 
rehabilitation interventions for chronic respiratory diseases. Piezoelectric pedometers may be worn 
at different body locations; however, their impact on pedometer accuracy has been scarcely 
explored. In addition, it is unknown which locations are preferred by patients, despite its importance 
to improve user’s acceptance. 
Aims: To assess the accuracy of a piezoeletric pedometer (Yamax EX-510) in counting steps, 
when worn at different body locations, and identify users’ preferred location(s). 
Methods: Sixty-three healthy adults (45.8±20.6yrs) wore 7 pedometers (neck, lateral/front right/left 
of the waist, pockets of the trousers), while walking 120m at slow, self-preferred (normal) and fast 
paces. Steps were manually counted (criterion measure) and pedometer steps were recorded. 
Tests were repeated twice. Participants indicated their preferred location(s) to wear a pedometer. 
Absolute percent error (APE) and the Bland and Altman method were used to examine device 
accuracy and consistency. 
Results: APE was, on average, <3% at normal and fast paces despite wearing location, but higher 
at slow pace (4.5-9.1%). Accuracy was improved in pedometers located at the front of the waist 
and inside the pockets. Results were consistent (p>0.05). Most patients preferred to wear the 
pedometer inside the right (n=25) and left (n=20) pockets. 
Conclusions: Yamax EX-510 pedometers can be used to monitor walking activity, as they provide 
accurate results even at slower speeds (considering a 10% error1). They should be worn at the 
front of the waist or inside the pockets. 
1Crouter SE, et al. Med Sci Sports Exerc 2003;35(8):1455-60 
 
 
 
 
 
 
European Respiratory Journal, 46: Suppl. 59 (2015) 
 
 
 
Appendix 2 
177 
 
 
 
Outcome changes in COPD rehabilitation: exploring the relationship 
between physical activity and health-related outcomes 
 
Joana Cruz 
Dina Brooks 
Alda Marques 
 
Introduction: Reduced physical activity(PA) levels are associated with poor health-related 
outcomes in patients with Chronic Obstructive Pulmonary Disease(COPD). PA-focused 
interventions complementary to pulmonary rehabilitation(PR) have been developed to increase 
patients’ PA. However, it is unknown whether PA changes are related to health-related outcomes 
improvement. This study explored the relationship between changes in PA and health-related 
outcomes in patients with COPD. 
Methods: Thirteen patients with COPD (65.6±10.6yrs) participated in a 12-week PR programme 
plus a PA-focused intervention. Daily PA was measured using accelerometers on weeks (W) 1, 7 
and 12 and feedback was given to participants in the following weeks regarding: daily steps; time 
spent in sedentary, light and moderate-to-vigorous (MVPA) intensity activities. Exercise capacity 
(6-minute walk test), functional balance (Timed Up-and-Go (TUG) test) and health-related quality of 
life (St George’s Respiratory Questionnaire (SGRQ) – Symptoms, Activities, Impact) were 
assessed at W1/W12. Correlations between PA data and health-related outcomes were performed 
at W1 and using the change scores (W12-W1). 
Results: At W1, time spent in MVPA was correlated with exercise capacity (r=0.817, p=0.001) and 
TUG (r=-0.692, p=0.009). Changes in MVPA time were correlated with changes in TUG (r=-0.653, 
p=0.016) and SGRQ Symptoms (r=-0.588, p=0.035). The latter was also correlated with changes in 
sedentary time (r=0.760, p=0.003). No other significant correlations were found. 
Conclusions: Patients with better exercise capacity and functional balance were also more 
physically active at W1. Nevertheless, findings suggest that intervention-related improvements in 
symptoms and functional balance may contribute to PA changes in a greater extent than exercise 
capacity. More research is needed. 
 
Keywords: active lifestyle; activity monitoring; chronic respiratory disease; COPD 
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Walk2Bactive: Patients’ perspectives of a physical activity-focused 
intervention beyond pulmonary rehabilitation in COPD 
 
Joana Cruz 
Dina Brooks 
Alda Marques 
 
In the last decade, several physical activity (PA)-focused interventions complementary to 
pulmonary rehabilitation (PR) have been developed in Chronic Obstructive Pulmonary Disease 
(COPD). A randomised controlled trial including self-monitoring with pedometers and goal setting 
showed promising results.1 Before implementing this intervention in a larger scale, patients’ 
perspectives should be considered as they may provide important findings for future research. This 
study explored patients’ perspectives of a PA-focused intervention beyond PR in COPD. 
13 patients with COPD completed a PA-focused intervention during PR (3 months) and follow-up 
support (3 months).1 The intervention included a Health contract and calendar where patients 
registered step-count goals and objective feedback provided by pedometers. Two focus groups 
were conducted after the intervention to assess patients’ perspectives of their participation (n=11, 
69.2±6.9yrs, FEV1=69.4±32.9pp). 
Patients’ perspectives were largely positive (n=10), except for one patient which was in the most 
severe COPD grade. Patients emphasised the importance of step-count goals (n=6), professional 
support (n=4) and social support (n=2) to motivate PA behaviour change. They reported a positive 
impact on their health (n=5) and lifestyle (n=4). Nevertheless, they underlined the need for on-
going support (n=7) and regular PR sessions to optimise benefits (n=5). 
The PA-focused intervention was valuable to patients with COPD, although regular support and PR 
sessions may be needed to sustain the benefits. Disease severity may be a factor of non-
adherence. Future research is needed. 
1Cruz J. et al. Chron Respir Dis 2016;13:57-66. 
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Termo de Consentimento Livre e Esclarecido 
 
Título do Projeto: Reabilitar pessoas com Doença Pulmonar Obstrutiva Crónica  
 
Nome do investigador principal: Alda Marques 
 
Por favor leia e assinale com uma cruz (X) os quadrados seguintes. 
1. Eu confirmo que percebi a informação que me foi dada e tive a oportunidade de 
questionar e de me esclarecer. 
 
2. Eu percebo que a minha participação no programa de reabilitação respiratória é 
voluntária e que sou livre de desistir, em qualquer altura, sem dar nenhuma explicação, 
sem que isso afete qualquer serviço de saúde que me é prestado. 
 
3. Eu concordo que as sessões do programa de reabilitação respiratória sejam filmadas 
com o objetivo de ajudar no planeamento de futuros programas de reabilitação 
respiratória. 
 
4. Eu compreendo que os dados recolhidos durante a investigação são confidenciais e 
que só os investigadores do projeto da Universidade de Aveiro têm acesso a eles. 
Portanto, dou autorização para que os mesmos tenham acesso a esses dados. 
 
5. Eu compreendo que os resultados do estudo podem ser publicados em Revistas 
Científicas e usados noutras investigações, sem que haja qualquer quebra de 
confidencialidade. Portanto, dou autorização para a utilização dos dados para esses 
fins. 
 
6. Eu concordo então em participar no estudo. 
 
 
 
________________________ 
Nome da pessoa 
                     
 
 
 
_________ 
Data 
 
 
___________________________ 
Assinatura 
 
 
________________________ 
Nome do Investigador(a) 
 
 
_________ 
Data 
 
 
___________________________ 
Assinatura 
 
